Document:

Exhibit 10.3

 

FOUNDER/EXECUTIVE VICE-CHAIRMAN COMPENSATION
AGREEMENT

 

This FOUNDER/EXECUTIVE VICE-CHAIRMAN
COMPENSATION AGREEMENT (this “Agreement”) is made and entered into as of August 26, 2021 (the “Effective Date”),
by and between CUENTAS, INC., a Florida Corporation (the “Company”) and MICHAEL DE PRADO (the “Executive”)
(each a “Party” and collectively the “Parties”).

 

WHEREAS, the Company and the
Executive have previously entered into employment agreements, dated November 5, 2019 and July 24, 2020, each of which has expired and
is no longer in effect (the “Prior Employment Agreements”);

 

WHEREAS, the Company desires
to continue to obtain the benefit of the experience and services of the Executive in connection with the operation of the Company and
desires to cause the Executive to be employed under the terms and conditions hereinafter set forth, and the Executive is willing and able
to accept such employment on such terms and conditions; and

 

WHEREAS, the Company wishes,
as part of the mutual rights and duties described in this Agreement, to assure that the Executive will be subject to certain restrictive
covenants, including a covenant not to compete against the Company and its Affiliates.

 

NOW, THEREFORE, for and in
consideration of the premises and the mutual covenants and agreements herein contained, and for other valuable consideration, the receipt
and sufficiency of which are hereby acknowledged, and intending to be legally and ethically bound hereby, the Parties agree with each
other as follows:

 

1. Term.

 

(a) The
Company agrees to employ the Executive, and the Executive agrees to be so employed by the Company, for a continuous twelve-month term
beginning on the Effective Date and ending on August 25, 2022 (the “Initial Term”). The Initial Term will be extended
automatically for additional one-year periods (each a “Renewal Term”), on the same terms and conditions as set forth
in this Agreement (as modified from time to time in writing by the Parties), unless either Party gives the other Party written notice
of its or his decision not to renew the term of this Agreement at least ninety (90) prior to the end of the Initial Term or any Renewal
Term. The Initial Term, together with all Renewal Terms, if any, are collectively referred to in this Agreement as the “Term.”
If this Agreement is not renewed as provided in this Section 1(a), neither Party shall have any further rights under this Agreement, except
as specifically provided herein.

 

(b) Notwithstanding
the foregoing, either Party may terminate this Agreement prior to the expiration of the Term pursuant to Section 6 below and with the
effect set forth in Section 7 below. Employment hereunder is “at will” and either Party may terminate the Executive’s
employment at any time with or without notice, except as provided herein or required by applicable law. This Agreement does not guarantee
continuation of employment for any period after the date it is executed.

 

    1

    

    

 

2. Position,
Duties, and Responsibilities. 

 

(a) The
Executive will serve as the Executive Vice-Chairman of the Company, reporting directly to the Company’s Board of Directors (the
“Board”).

 

(b) The
Company agrees that the Executive will be nominated for election to the Board and re-nominated when his Board term ends for so long as
he remains employed as the Company’s Executive Chairman.

 

(c) The
Executive will perform the duties and responsibilities and have the authorities customarily associated with his position and any other
duties commensurate with the Executive’s position that may be reasonably assigned to him from time to time by the Board.

 

3. Standard
of Performance.

 

(a) The
Executive will be employed on a full-time basis and will devote his full business time, efforts, and attention (except for permitted vacation
periods and periods of illness or other incapacity) to the business and affairs of the Company and its Affiliates.

 

(b) Without
limiting the generality of the foregoing, the Executive will not, without the prior written approval of the Board, during the Term, render
services of a business, professional, or commercial nature for compensation or otherwise (including as a director) to any entity other
than the Company and its Affiliates; provided, however, that the Executive may (i) serve on association and corporate boards
of non-profit educational, professional, civic, or charitable organizations, and (ii) manage his (including his immediate family’s)
passive personal investments, in each case so long as such activities, service, and management do not materially detract from or materially
adversely affect the performance of his duties and responsibilities to the Company and its Affiliates or conflict with his obligations
under this Agreement.

 

(c) The
Executive will primarily perform his duties at the Company’s headquarters in Miami Beach, Florida, but will work remotely and travel
from time to time to such other places as reasonably required to perform his obligations hereunder.

 

(d) The
Executive acknowledges and agrees that the hours of work involved in the performance of his duties and exercise of his responsibilities
may vary and be irregular and are those hours required to meet the objectives of his position. The Executive acknowledges that this subsection
constitutes an agreement to work such hours if such agreement is required by any applicable legislation and confirms that the remuneration
set forth in this Agreement is intended to compensate the Executive for all such hours worked.

 

(e) The
Executive agrees that, while employed by the Company, he will comply with all Company policies, practices and procedures, and all codes
of ethics or business conduct applicable to his position, as in effect from time to time.

 

4. Compensation
and Benefits. As full compensation for the covenants provided by the Executive relating to confidentiality, non-competition, and non-solicitation
(as more particularly described in Section 5 below) and for the services to be rendered during the Term to or on behalf of the Company
and its Affiliates and the other obligations undertaken by the Executive, the Company will pay the Executive the following compensation
and benefits:

 

(a) Base
Salary. The Company will pay the Executive an annual base salary of Two Hundred Seventy-Five Thousand Dollars ($275,000) (the “Base
Salary”), payable in monthly installments in accordance with the regular payroll practices of the Company.

 

    2

    

    

 

(b) Annual
Incentive. The Executive will be eligible for an annual incentive payment of up to one hundred percent (100%) of his Base Salary,
based on the Company’s performance against goals established by the Board in consultation with the Executive (the “Annual
Incentive”). The Executive’s entitlement to the Annual Incentive and the amount of such award, if any, will be determined
in the good faith discretion of the Board. The Annual Incentive will have a 12-month performance period, based on the January 1 through
December 31 calendar year. Any earned Annual Incentive payments will be payable by the end of the second quarter following the calendar
year to which the performance relates. The Executive must be employed by the Company on the payment date to receive any earned Annual
Incentive payment. The Executive shall have the option to have any earned Annual Incentive paid in fully vested shares of Common Stock,
provided such option is elected by the end of the first quarter following the performance period, and the number of shares of Common Stock
shall be determined by dividing the earned Annual Incentive by the closing price of the Company’s Common Stock on the applicable
payment date. The Annual Incentive will be pro-rated for partial years of employment.

 

(c) Participation
in Employee Benefit Plans. The Executive will be entitled to participate in all employee benefit plans from time to time in effect
for senior executives of the Company generally, except to the extent such plans are duplicative of benefits otherwise provided to the
Executive under this Agreement (e.g., a severance pay plan). The Executive’s participation will be subject to the terms of the applicable
plan documents and generally applicable Company policies, as the same may be in effect from time to time, which plan documents may be
amended or terminated in the Company’s sole discretion.

 

(d) Cost
of Group Health Coverage. If the Executive makes a timely election to participate in any group health coverage offered by the Company
(coverage for medical, hospitalization, prescription drug, dental, and vision expenses, to the extent offered by the Company) with benefits
for himself, his eligible spouse, and any eligible dependents, the Company agrees to pay for the cost of such coverage during the Term.
The Executive acknowledges that the Company may be required to impute the cost of such coverage as taxable income to the Executive, to
the extent required by applicable law or as needed for the Company’s plans to satisfy relevant non-discrimination rules.

 

(e) Vacation.
The Executive will be entitled to accrue twenty (20) days of vacation per year (pro-rated for any partial calendar year of employment),
in addition to holidays observed by the Company. Vacation may be taken at such times and intervals as the Executive shall determine, subject
to the business needs of the Company. Vacation shall otherwise be subject to the policies of the Company, as in effect from time to time.

 

(f) Business
Expenses. The Company will pay or reimburse the Executive for all reasonable business expenses incurred or paid by the Executive in
the performance of his duties and responsibilities for the Company, provided that any expense in excess of $10,000 must be preapproved
by the Board and subject to any maximum annual limit and other restrictions on such expenses set by the Company and to such reasonable
substantiation and documentation as may be specified by the Company from time to time. The Executive’s right to payment or reimbursement
hereunder shall be subject to the following additional rules: (i) the amount of expenses eligible for payment or reimbursement during
any calendar year shall not affect the expenses eligible for payment or reimbursement in any other calendar year, (ii) payment or reimbursement
shall be made not later than December 31 of the calendar year following the calendar year in which the expense or payment was incurred,
and (iii) the right to payment or reimbursement shall not be subject to liquidation or exchange for any other benefit.

 

    3

    

    

 

(g) Change
in Control Bonus.

 

(i) During
the Term, the Executive shall be entitled to a bonus payment in connection with the Change in Control of the Company (as defined below)
(the “Change in Control Bonus”). The Change in Control Bonus for the Executive will be equal to two and one-half percent
(2.5%) of the cash consideration received by the shareholders of the Company in the Change in Control transaction (minus any expenses,
holdback provisions or other deductions from the purchase price), as determined in the sole discretion of the Board.

 

(ii) The
Change in Control Bonus will be paid as soon as practicable following the receipt by the shareholders of the cash consideration in the
Change in Control as described above (the “CIC Funding Date”), but in all events will be paid prior to the date that
is two and one-half months following the calendar year in which the Change in Control occurs (the “Short-Term Deferral Period”),
provided that the Executive must be an employee or director of the Company on the date of the closing of the Change in Control to be entitled
to payment. In the event that the CIC Funding Date does not occur within the Short-Term Deferral Period, the Change in Control Bonus will
not be paid.

 

(iii) For
purposes of this Section 4(g), “Change in Control” shall mean the occurrence of any of the following events:

 

(A) any
“person” (as such term is used in Section 13(d) and 14(d) of the Securities Exchange Act of 1934, as amended) that is an un-affiliated
third party becomes the “beneficial owner” (as defined in Rule 13d-3 under said Act), directly or in directly, of securities
of the Company representing more than fifty percent (50%) of the total combined voting power represented by the Company’s then outstanding
voting securities; provided, however, that for purposes of this subsection, (I) the acquisition of additional stock by any
one Person, who is considered to own more than fifty percent (50%) of the total voting power of the stock of the Company will not be considered
a Change in Control, and (II) if the shareholders of the Company immediately before the change in ownership continue to retain, immediately
after the change in ownership, in substantially the same proportions as their ownership of shares of the Company’s voting stock
immediately prior to the change in ownership, the direct or indirect beneficial ownership of fifty percent (50%) or more of the total
voting power of the shares of the Company or of the ultimate parent entity of the Company, such event will not be considered a Change
in Control;

 

(B) the
Company is party to a merger or consolidation which results in the holders of the voting securities of the Company outstanding immediately
prior thereto failing to retain immediately after such merger or consolidation direct or indirect beneficial ownership of more than fifty
percent (50%) of the total combined voting power of the securities entitled to vote generally in the election of directors of the Company
or the surviving entity outstanding immediately after such merger of consolidation; or

 

    4

    

    

 

(C) the
sale of all or substantially all of the Company’s assets in a single transaction.

 

(iv) For
the avoidance of doubt, a Change in Control shall not include any related party transfers or an incremental increase in shares by an existing
shareholder that does not result in more than fifty percent (50%) of the then-current shareholders of the Company to change ownership
from one person to another un-affiliated person.

 

5. Confidential
Information and Restrictive Covenants.

 

(a) Acknowledgments.
In consideration of employment and this Agreement, together with all other good, sufficient, and valuable consideration, the receipt of
which is hereby acknowledged, the Executive hereby acknowledges and agrees that the Company and its Affiliates have generated, and will
continue to generate, significant goodwill with its vendors, suppliers, customers, borrowers, and business partners. Further, the Executive
acknowledges that during the course of employment with the Company, he has and will continue to be privy to trade secrets and other confidential
information of substantial value to the Company and its Affiliates. The Executive acknowledges that, in light of these considerations,
the Company has a legitimate interest in protecting its business and property interests and its investment in human capital. The Executive
agrees and acknowledges that reasonable limits on his ability to engage in activities competitive with the Company and its Affiliates
are warranted to protect its substantial investment in developing and maintaining its status in the marketplace, reputation, and goodwill
and that the Company will suffer substantial damage which will be difficult to compute if, during the Term or thereafter, the Executive
should violate the restrictions contained in this Section 5.

 

(b) Confidential
Information. During the course of the Executive’s employment with the Company, the Executive has and will continue to learn
of Confidential Information, and has and will continue to develop Confidential Information on behalf of the Company and its Affiliates.
The Executive agrees that he will not use or disclose to any Person (except as required by applicable law or for the proper performance
of his regular duties and responsibilities for the Company) any Confidential Information obtained by the Executive incident to his employment
or any other association with the Company or any of its Affiliates; provided, however,
that the provisions of this Section 5(b) will not prohibit (A) disclosure to the Executive’s legal or financial advisors to
the extent reasonably required in connection with their services to the Executive, provided such advisers agree not to further disclose
such information; (B) retention of any documents relating to the Executive’s compensation, benefits, or ongoing obligations to the
Company or any of its Affiliates and any information reasonably required for tax preparation purposes; or (C) any disclosure made
in connection with the enforcement of any right or remedy relating to this Agreement. The Executive agrees that this restriction
will continue to apply after his employment terminates, regardless of the reason for such termination.

 

    5

    

    

 

(c) Protection
of Documents. All documents, records, and files, in any media of whatever kind and description, relating to the business, present
or otherwise, of the Company or any of its Affiliates, and any copies, in whole or in part, thereof (the “Documents”),
whether or not prepared by the Executive, shall be the sole and exclusive property of the Company. The Executive agrees to safeguard all
Documents and to surrender to the Company, at the time his employment terminates or at such earlier time or times as the Board or its
designee may specify, all Documents then in his possession or control. The Executive also agrees to disclose to the Company, at the time
his employment terminates or at such earlier time or times as the Board or its designee may specify, all passwords necessary or desirable
to obtain access to, or that would assist in obtaining access to, any Confidential Information which the Executive has password-protected
on any computer equipment, network, or system of the Company or any of its Affiliates.

 

(d) Subpoena
or Other Legal Process. Nothing contained herein shall prevent the Executive from making any disclosures required by applicable law
or in response to any validly issued subpoena or request by any state, federal, or local agency having jurisdiction. If the Executive
is required, under applicable law or by interrogatories, subpoena, or regulatory or other legally binding process, to disclose any Confidential
Information, it is agreed that the Executive (if legally permitted to do so) will provide the Company with prompt notice of any such request
or requirement (written, to the extent practicable) and otherwise provide reasonable cooperation to the Company in order to enable the
Company or its Affiliates to seek an appropriate protective order or other appropriate remedy or to waive compliance with the provisions
of this Agreement. In the event that such protective order or other remedy is not obtained, or that the Company grants a waiver hereunder,
the Executive may furnish that portion (and only that portion) of the Confidential Information which the Company determines, with the
advice of its counsel, the Executive is legally compelled to disclose. In any event, the Executive will not oppose action by the Company
or its Affiliates to obtain an appropriate protective order or other reliable assurance that confidential treatment will be accorded to
the Confidential Information.

 

(e) Protected
Activity. The Executive understands that nothing in this Agreement shall in any way limit or prohibit the Executive from engaging
for a lawful purpose in any Protected Activity; provided, however, that the Executive agrees not to seek or accept any monetary
award from such a proceeding (except with respect to proceedings before the Securities and Exchange Commission). For purposes of this
Agreement, “Protected Activity” shall mean filing a charge, complaint, or report with, or otherwise communicating with,
cooperating with or participating in any investigation or proceeding that may be conducted by, any federal, state, or local government
agency or commission, including the Securities and Exchange Commission, the Equal Employment Opportunity Commission, the Occupational
Safety and Health Administration, and the National Labor Relations Board (“Government Agencies”), or discussing the
terms and conditions of Executive’s employment with others to the extent expressly permitted by Section 7 of the National Labor
Relations Act. The Executive understands that in connection with such Protected Activity, the Executive is permitted to disclose documents
or other information to Government Agencies as permitted by law, and without giving notice to, or receiving authorization from, the Company.
Notwithstanding the foregoing, the Executive agrees to take all reasonable precautions to prevent any unauthorized use or disclosure of
Confidential Information to any parties other than the relevant Government Agencies. The Executive further understands that “Protected
Activity” does not include the disclosure of any Company attorney-client privileged communications. In addition, pursuant to the
Defend Trade Secrets Act of 2016, the Executive is notified that an individual will not be held criminally or civilly liable under any
federal or state trade secret law for the disclosure of a trade secret that (i) is made in confidence to a federal, state, or local government
official (directly or indirectly) or to an attorney solely for the purpose of reporting or investigating a suspected violation of law,
or (ii) is made in a complaint or other document filed in a lawsuit or other proceeding, if (and only if) such filing is made under seal.
In addition, an individual who files a lawsuit for retaliation by an employer for reporting a suspected violation of law may disclose
the trade secret to the individual’s attorney and use the trade secret information in the court proceeding, if the individual files
any document containing the trade secret under seal and does not disclose the trade secret, except pursuant to court order.

 

    6

    

    

 

(f) Assignment
of Rights to Intellectual Property. The Executive shall promptly and fully disclose all Intellectual Property to the Company. The
Executive hereby assigns and agrees to assign to the Company (or as otherwise directed by the Company) his full right, title, and interest
in and to all Intellectual Property. The Executive agrees to execute any and all applications for domestic and foreign patents, copyrights,
or other proprietary rights and to do such other acts (including without limitation the execution and delivery of instruments of further
assurance or confirmation) requested by the Company to assign the Intellectual Property to the Company (or as otherwise directed by the
Company) and to permit the Company to enforce any patents, copyrights, or other proprietary rights to the Intellectual Property. The Executive
will not charge the Company or any of its Affiliates for time spent in complying with these obligations but will be entitled to reimbursement
for reasonable expenses incurred or paid by the Executive in connection with the same. All copyrightable Intellectual Property that the
Executive creates during his employment shall be considered “work made for hire” and shall, upon creation, be owned exclusively
by the Company.

 

(g) Non-Competition.
While the Executive is employed by the Company and during the twelve (12)-month period immediately following termination of employment,
regardless of the reason thereof (in the aggregate, the “Restricted Period”), the Executive will not, in any way directly
or indirectly, whether as owner, partner, investor, consultant, agent, employee, co-venturer or otherwise, engage in or compete with,
or undertake any planning to engage in or compete with, any Competing Business in the Restricted Area. Notwithstanding the provisions
of the foregoing sentence to the contrary, the Executive shall be permitted to own securities of five percent (5%) or less of any class
of securities of a public company.

 

(h) Customer
Non-Solicitation. During the Restricted Period, the Executive will not, directly or indirectly, (i) solicit or attempt to solicit
any Customer for the purpose of providing or selling the Customer any product similar to the Company Products; or (ii) encourage or seek
to persuade the Customer to terminate or diminish its relationship with the Company or its Affiliates. Such restriction shall only apply
to Customers with whom Executive had material contact in the twelve (12) month period immediately preceding the activity restricted by
this Section.

 

(i) Supplier
Non-Solicitation. During the Restricted Period, the Executive will not, directly or indirectly, (i) solicit or attempt to solicit
any Supplier to provide labor and materials for the purpose of creating or selling any product similar to the Company Products; or (ii)
encourage or seek to persuade the Supplier to terminate or diminish its relationship with the Company of its Affiliates. Such restriction
shall only apply to Suppliers with whom Executive had material contact in the twelve (12) month period immediately preceding the activity
restricted by this Section.

 

    7

    

    

 

(j) Employee
Non-Solicitation. During the Restricted Period, the Executive will not, directly or indirectly, (i) hire or engage, or solicit for
hiring or engagement, any employee of the Company or any of its Affiliates or seek to persuade any such employee to discontinue employment
or (ii) solicit or encourage any independent contractor providing services to the Company or any of its Affiliates to terminate or diminish
his, her or its relationship with any of them. For the purposes of this Section 5(j), an “employee” or an “independent
contractor” of the Company or any of its Affiliates is any Person who was such at any time during the twelve (12)-month period
immediately preceding the activity restricted by this Section 5(j). Notwithstanding the foregoing,
nothing contained herein shall prohibit or restrict the Executive from (A) engaging in any general solicitation not targeted at any employee
of the Company or any of its Affiliates, including non-directed executive searches or placing general advertisements for employees in
newspapers or other media of general circulation, or (B) hiring such Persons who have not been employees of the Company or any of its
Affiliates for at least six (6) months prior to the time of hiring.

 

(k) Non-Disparagement.
The Executive agrees that at no time during or after the Term shall the Executive, directly or indirectly, engage in any form of written,
verbal, electronic, or other communication that is or reasonably would be interpreted as being disparaging of the Company or its Affiliates
or any of their officers, managers, employees, agents, successors, or assigns (including any such individuals who were associated with
the Company or its Affiliates during the Term). Nothing in this Section shall prevent the Executive from offering truthful and accurate
testimony or statements as a part of any government investigation, any legal proceedings, or as otherwise required under applicable law,
regardless of whether such testimony or statements may be considered disparaging.

 

(l) Cooperation.
During the Restricted Period, the Executive agrees to provide reasonable assistance to the Company (including assistance with litigation
matters), upon the Company’s request, concerning the Executive’s previous employment responsibilities and functions with the
Company. In consideration for such cooperation, but only if the Executive is not receiving a Severance Benefit pursuant to Section 7(b)
below, the Company will compensate the Executive for the time the Executive spends on such cooperative efforts (at an hourly rate based
on the Executive’s Base Salary during the year preceding the date of termination) and the Company will reimburse the Executive for
his reasonable out-of-pocket expenses incurred in connection with such cooperative efforts.

 

(m) Modification.
The Parties each agree that the restrictive covenants contained in this Agreement are severable and separate, and the unenforceability
of any specific covenant herein shall not affect the validity of any other covenant set forth herein. The Parties acknowledge and agree
that the duration, scope, and geographic area of the covenants described above are fair, reasonable, and necessary in order to protect
the goodwill and other legitimate interests of the Company and its Affiliates, regardless of the reason for or circumstances giving rise
to such termination, and that adequate consideration has been received for such obligations. The Executive agrees that given the scope
of the Company’s business and the sophistication of the information highway, any further geographic limitation on such remedies and restrictions
would deny the Company the protection to which it is entitled hereunder. If, however, for any reason any court of competent jurisdiction
or arbitrator determines that the restrictions in this Agreement are not reasonable, such restrictions shall be interpreted, modified,
or rewritten to include as much of the duration, scope, and geographic area identified as will render such restrictions valid and enforceable.
No claimed breach of this Agreement or other violation of law attributed to the Company or any of its Affiliates, or change in the nature
or scope of the Executive’s employment or other relationship with the Company or any of its Affiliates, shall operate to excuse
the Executive from the performance of his obligations under this Section 5. It is understood by the Parties that the Executive’s
obligations and the restrictions and remedies set forth in this Section 5 are essential elements of this Agreement and that but for his
agreement to comply with and/or agree to such obligations, restrictions, and remedies, the Company would not have entered into this Agreement
or employed (or continued to employ) him.

 

    8

    

    

 

(n) Remedies
for Breach.

 

(i) The
Executive acknowledges and agrees that the Company and its Affiliates will suffer irreparable harm as a result of a breach of the restrictive
covenants or any of the representations, warranties, or covenants made by the Executive in this Agreement, for which an adequate monetary
remedy does not exist and a remedy at law may prove to be inadequate. Accordingly, in the event of any actual or threatened breach by
the Executive of any provision of this Agreement, the Company shall, in addition to any other limitation, be permitted to seek specific
performance, injunctive relief, a temporary restraining order, and/or a permanent injunction in any court of competent jurisdiction, to
prevent or otherwise restrain a breach hereof, without the necessity of proving damages, posting a bond or other security, and seek to
recover any and all costs, expenses, and liabilities, including reasonable attorneys’ fees, incurred in enforcing this Agreement
against the Executive or incurred if any representation, warranty, or covenant made by the Executive in the Agreement is false or otherwise
breached.

 

(ii) Such
relief shall be in addition to, and not in substitution of, any other remedies available to the Company and its Affiliates. The existence
of any claim or cause of action, whether predicated on this Agreement or otherwise, shall not constitute a defense to the enforcement
by the Company of said covenants. The Parties agree not to defend on the basis that there is an adequate remedy at law. In the event any
court of competent jurisdiction finds a violation of the restrictive covenants has occurred, the Executive acknowledges and agrees that
the post-termination restrictions shall be extended by a period of time equal to the period of such violation, it being the intention
of the Parties hereto that the running of the applicable post-termination restriction period shall be tolled during any period of such
violation.

 

(o) Survival
of Terms; Representations. The Executive’s obligations under this Section 5 shall remain in full force and effect notwithstanding
the termination of his employment. The Executive acknowledges that he is sophisticated in business, and that the restrictions and remedies
set forth in this Section 5 do not create an undue hardship on him and will not prevent him from earning a livelihood. He further acknowledges
that he has had a sufficient period of time within which to review this Agreement, including, without limitation, this Section 5, with
counsel of his choice and he has done so to the extent he desired. In signing this Agreement, the Executive gives the Company assurance
that the Executive has carefully read and considered all the terms and conditions of this Agreement, including the restraints imposed
on the Executive under this Section 5.

 

    9

    

    

 

6. Termination
of Employment. This Agreement may be terminated prior to the expiration of the Term as follows:

 

(a) By
the Company For Cause. The Company may terminate the Executive’s employment for Cause upon notice to the Executive setting forth
in reasonable detail the nature of the Cause. Such termination must be approved by the Board to be effective.

 

(b) By
the Company Without Cause. The Company may terminate the Executive’s employment at any time other than for Cause upon notice
to the Executive. Such termination must be approved by the Board to be effective.

 

(c) By
the Executive for Good Reason. The Executive may terminate his employment for Good Reason, provided that (i) the Executive provides
written notice to the Company, setting forth in reasonable detail the nature of the condition giving rise to Good Reason, within sixty
(60) days of the initial existence of such condition, (ii) the condition remains uncured by the Company for a period of sixty (60) days
following such notice, and (iii) the Executive terminates his employment, if at all, not later than sixty (60) days after the expiration
of such cure period. For purposes of this Agreement, “Good Reason” shall mean the occurrence of any of the following
without the Executive’s consent: (A) a material reduction in the Executive’s Base Salary; (B) a material diminution in the
Executive’s authority, duties, or responsibilities; (C) a change in the geographic location at which the Executive must perform
services of more than thirty-five (35) miles in radius from Miami Beach, Florida; or (D) a material breach by the Company of this Agreement
or any other material agreement between the Executive and the Company. Notwithstanding anything to the contrary contained herein, any
isolated, insubstantial, and inadvertent action not taken in bad faith and that is remedied by the Company promptly after receipt of notice
thereof given by the Executive shall not be or constitute Good Reason.

 

(d) By
the Executive Without Good Reason. The Executive may terminate his employment without Good Reason at any time upon sixty (60) days’
notice to the Company. The Board may elect to waive such notice period or any portion thereof but, in such event, will pay to the Executive
the Base Salary for the period so waived.

 

(e) Death
and Disability. The Executive’s employment hereunder shall automatically terminate in the event of the Executive’s death
during employment. The Company may terminate the Executive’s employment, upon notice to the Executive, in the event that the Executive
becomes disabled during his employment hereunder through any illness, injury, accident or condition of either a physical or psychological
nature and, as a result, is unable to perform substantially all of his duties and responsibilities hereunder (notwithstanding the provision
of any reasonable accommodation) for a period of one hundred and eighty (180) days during any period of three hundred sixty-five (365)
consecutive days. If any question shall arise as to whether the Executive is disabled to the extent that he is unable to perform substantially
all of his duties and responsibilities for the Company and its Affiliates, the Executive shall, at the Company’s request, submit
to a medical examination by a physician selected by the Company to whom the Executive or the Executive’s guardian, if any, has no
reasonable objection to determine whether the Executive is so disabled, and such determination shall for purposes of this Agreement be
conclusive of the issue.

 

    10

    

    

 

7. Other
Matters Related to Termination.

 

(a) Final
Compensation. In the event of termination of the Executive’s employment with the Company, howsoever occurring, the Company shall
pay the Executive (i) the Base Salary for the final payroll period of his employment, through the date his employment terminates; (ii)
compensation at the rate of the Base Salary for any vacation time earned but not used as of the date his employment terminates; and (iii)
reimbursement, in accordance with Section 4(f) above, for business expenses incurred by the Executive but not yet paid to the Executive
as of the date his employment terminates, provided that the Executive submits all expenses and supporting documentation required within
sixty (60) days of the date his employment terminates, and provided further that such business expenses are reimbursable under Company
policies then in effect (all of the foregoing, “Final Compensation”). Except as otherwise provided in Section 7(a)(iii),
Final Compensation will be paid to the Executive within thirty (30) days following the date of termination or such shorter period required
by law.

 

(b) Severance
Benefits. In the event the Company terminates the Executive’s employment without Cause pursuant to Section 6(b) above or the
Executive terminates his employment for Good Reason pursuant to Section 6(c) above, the Executive will be eligible to receive the following
severance benefits in addition to the Final Compensation:

 

(i) the
Company will pay the Executive a single, lump-sum payment equal to one (1) times the Base Salary; and

 

(ii) any
outstanding unvested portion of any stock option to purchase Common Stock shall become fully vested and exercisable, with the other terms
of such stock option grant otherwise continuing to be applicable (together, the “Severance Benefits”).

 

(c) Conditions
To And Timing Of Severance Benefits. Any obligation of the Company to provide the Severance Benefits is conditioned on his signing
and returning, without revoking, to the Company a timely and effective general release of claims in the form attached hereto as Exhibit
A (as updated for any future change in law). Any such Severance Benefits will be made no later than fifteen (15) days following the
expiration of the release’s revocation period, provided that the Executive has returned an enforceable release within the period
stated in his severance letter, but in no case later than sixty (60) days following his termination date.

 

(d) Benefits
Termination. Except for any right the Executive may have under the federal law known as “COBRA” or other applicable law
to continue participation in the Company’s group health plans at his cost, the Executive’s participation in all employee benefit
plans shall terminate in accordance with the terms of the applicable benefit plans based on the date of termination of his employment,
without regard to any Severance Benefits or other payment to the Executive following termination of his employment, and the Executive
shall not be eligible to earn vacation or other paid time off following the termination of his employment.

 

    11

    

    

 

(e) Officer
Resignation. On termination of employment, the Executive acknowledges and agrees that he will resign all offices held in the Company
and its Affiliates, without any further action required.

 

(f) Change
in Control Bonus. Following the expiration of the Term, the Executive shall be deemed actively employed for purposes of satisfying
the requirements for the Change in Control Bonus under Section 4(g) above, if the closing of such Change in Control occurs within twenty-four
(24) months of the Effective Date, but Executive shall not be deemed actively employed under this section if Executive’s employment
was terminated for Cause or the Executive resigned his employment without Good Reason.

 

8. Timing
of Payments and Section 409A. 

 

(a) Notwithstanding
anything to the contrary in this Agreement, if at the time the Executive’s employment terminates, the Executive is a “specified
employee,” as defined below, any and all amounts payable under this Agreement on account of such separation from service that would
(but for this provision) be payable within six (6) months following the date of termination, shall instead be paid on the next business
day following the expiration of such six (6)-month period or, if earlier, upon the Executive’s death; except (i) to the extent of
amounts that do not constitute a deferral of compensation within the meaning of Treasury Regulation Section 1.409A-1(b) (including without
limitation by reason of the safe harbor set forth in Section 1.409A-1(b)(9)(iii), as determined by the Company in its reasonable good
faith discretion); (ii) benefits which qualify as excepted welfare benefits pursuant to Treasury Regulation Section 1.409A-1(a)(5); or
(iii) other amounts or benefits that are not subject to the requirements of Section 409A of the Code (“Section 409A”).

 

(b) For
purposes of this Agreement, all references to “termination of employment” and correlative phrases shall be construed to require
a “separation from service” (as defined in Treasury Regulation Section 1.409A-1(h) after giving effect to the presumptions
contained therein), and the term “specified employee” means an individual determined by the Company to be a specified employee
under Treasury Regulation Section 1.409A-1(i).

 

(c) Each
payment made under this Agreement shall be treated as a separate payment, and the right to a series of installment payments under this
Agreement is to be treated as a right to a series of separate payments.

 

(d) In
no event shall the Company have any liability relating to the failure or alleged failure of any payment or benefit under this Agreement
to comply with, or be exempt from, the requirements of Section 409A.

 

9. Section
280G Modified Cutback.

 

(a) Notwithstanding
any other provision of this Agreement, if any payment distribution or provision of a benefit by the Company or its Affiliates to or for
the benefit of the Executive, whether paid or payable, distributed or distributable or provided or to be provided pursuant to the terms
of this Agreement or otherwise (a “Payment”), (i) would be subject to the excise tax imposed by Section 4999 of the
Code or any interest or penalties with respect to such excise tax (such excise tax, together with any such interest or penalties, are
hereinafter collectively referred to as the “Excise Tax”) and (ii) the net after-tax amount of such Payments, after
the Executive has paid all taxes due thereon (including, without limitation, the Excise Tax), would be less than the net after-tax amount
of all such Payments otherwise due to the Executive in the aggregate if such Payments were reduced to an amount equal to 2.99 times the
Executive’s “base amount” (as defined in Section 280G(b)(3) of the Code), then the aggregate amount of such Payments
payable to the Executive shall be reduced to an amount that will equal 2.99 times the Executive’s base amount.

 

    12

    

    

 

(b) To the
extent any Payments are required to be so reduced, the Payments due to the Executive shall be reduced in the following order, unless otherwise
agreed and such agreement is in compliance with Section 409A: (i) Payments that are payable in cash, with amounts that are payable last
reduced first; (ii) Payments due in respect of any equity or equity derivatives included at their full value under Section 280G of the
Code (rather than their accelerated value); (iii) Payments due in respect of any equity or equity derivatives valued at accelerated value
under Section 280G of the Code, with the highest values reduced first (as such values are determined under Treasury Regulation Section
1 280G-I, Q&A 24); and (iv) all other non-cash benefits.

 

(c) The
determination of any reduction in Payments in accordance with this Section 9 shall be made by the Company’s independent public accountants
or another firm designated by the Company.

 

10. Definitions.
For purposes of this Agreement, the following definitions apply:

 

“Affiliates”
means all persons and entities directly or indirectly controlling, controlled by or under common control with the Company, where control
may be by management authority, equity interest or otherwise.

 

“Cause”
shall mean the occurrence of any of the following:

 

		(1)	the Executive’s material failure to perform (other than by reason of disability), or gross negligence in the performance of,
the Executive’s duties and responsibilities to the Company or any of its Affiliates, which material failure or gross negligence,
if capable of cure, is not cured by the Executive within thirty (30) days following the Board’s notice to the Executive of such
material failure or gross negligence;

 

		(2)	the Executive’s material breach of any provision of this Agreement or any other written agreement by and between the Executive
and the Company or any of its Affiliates, which material breach, if capable of cure, is not cured by the Executive within thirty (30)
days following the Board’s notice to the Executive of such material breach;

 

		(3)	the Executive’s indictment for, or plea of nolo contendere to, a felony or other crime involving embezzlement, misappropriation,
fraud, or moral turpitude;

 

    13

    

    

 

		(4)	other willful misconduct by the Executive with respect to his duties and responsibilities to the Company or any of its Affiliates
that is or could reasonably be expected to be materially harmful to the business interests or reputation of the Company or any of its
Affiliates;

 

		(5)	the Executive’s violation of or disregard for any rule, procedure or policy of the Company or any of its Affiliates; or

 

		(6)	the Executive’s violation of the restrictive covenants contained in Section 5 above.

 

“Code”
means the Internal Revenue Code of 1986, as amended.

 

“Common
Stock” means the Company’s common stock, par value $0.001 per share.

 

“Company
Business” means the administration, marketing, and sale of proprietary technology to provide e-banking and e-commerce services
delivering mobile banking, online banking, prepaid debit and general purpose reloadable cards, and digital content services that are specifically
targeted to the Latino community.

 

“Company
Products” means prepaid debit and general purpose reloadable cards targeted to the Latino community.

 

“Competing
Business” means any Person engaged in the Company Business or actively planning to become engaged in the Company Business.

 

“Confidential
Information” means any and all information of the Company and its Affiliates that is not generally available to the public.
Confidential Information also includes any information received by the Company or any of its Affiliates from any Person with any understanding,
express or implied, that it will not be disclosed. Confidential Information does not include information that enters the public domain,
other than through the Executive’s breach of his obligations under this Agreement or any other agreement between the Executive and
the Company or any of its Affiliates.

 

“Customer”
means any Person who purchased Company Products or who the Company actively solicited to purchase Company Products. This definition also
includes any Person who the Company provided Company Products to for distribution or sale or that Company actively solicited for the purpose
of providing Company Products to for distribution or sale.

 

“Intellectual
Property” means inventions, discoveries, developments, methods, processes, compositions, works, concepts and ideas (whether
or not patentable or copyrightable or constituting trade secrets) (collectively, “Inventions”) conceived, made, created,
developed or reduced to practice by the Executive (whether alone or with others, whether or not during normal business hours or on or
off Company premises) during the Executive’s employment that relate either to the business of the Company or any of its Affiliates
or to any prospective activity of the Company or any of its Affiliates or that result from any work performed by the Executive for the
Company or any of its Affiliates or that make use of Confidential Information or any of the equipment or facilities of the Company or
any of its Affiliates. For the avoidance of doubt, Intellectual Property shall not include those Inventions set forth on Exhibit B
hereto.

 

    14

    

    

 

“Restricted
Area” means any geographic area in which the Company or any of its Affiliates does business or is actively planning to do business
during the Executive’s employment or, with respect to the portion of the Restricted Period that follows the termination of the Executive’s
employment, any geographic area in which the Executive, at any time within the last two (2) years of the Executive’s employment
with the Company, provided services or had a material presence or influence.

 

“Person”
means an individual, a corporation, a limited liability company, an association, a partnership, an estate, a trust or any other entity
or organization, other than the Company or any of its Affiliates.

 

“Supplier”
means any Person who has provided the Company goods or services material to the performance of the Company Business.

 

11. Withholding.
All payments made by the Company under this Agreement shall be reduced by any tax or other amounts required to be withheld by the
Company to the extent required by applicable law.

 

12. Assignment.
Neither the Executive nor the Company may make any assignment of this Agreement or any interest in it, by operation of law or otherwise,
without the prior written consent of the other; provided, however, the Company may assign its rights and obligations under
this Agreement without the Executive’s consent to one of its Affiliates or to any Person with whom the Company shall hereafter effect
a reorganization, consolidate or merge, or to whom the Company shall hereafter transfer all or substantially all of its assets. This Agreement
shall inure to the benefit of and be binding upon the Executive and the Company, and each of their respective successors, executors, administrators,
heirs and permitted assigns.

 

13. Severability.
If any portion or provision of this Agreement shall to any extent be declared illegal or unenforceable by a court of competent jurisdiction,
then the remainder of this Agreement, or the application of such portion or provision in circumstances other than those as to which it
is so declared illegal or unenforceable, shall not be affected thereby, and each portion and provision of this Agreement shall be valid
and enforceable to the fullest extent permitted by law.

 

14. Miscellaneous.
This Agreement sets forth the entire agreement between the Executive and the Company, and replaces all prior and contemporaneous communications,
agreements and understandings, written or oral, with respect to the terms and conditions of the Executive’s employment, including,
but not limited to, the Prior Employment Agreements; provided, however that this Agreement shall not supersede any prior
assignment of intellectual property to the Company or any of its Affiliates. This Agreement may not be modified or amended, and no breach
shall be deemed to be waived, unless agreed to in writing by the Executive and an expressly authorized representative of the Board. The
headings and captions in this Agreement are for convenience only and in no way define or describe the scope or content of any provision
of this Agreement. This Agreement will be construed fairly as to both Parties and not in favor of, or against, either Party. This Agreement
may be executed in any number of counterparts (including by means of facsimile or electronically transmitted portable document format
(PDF) signature pages), each of which when so executed and delivered shall be taken to be an original; but such counterparts shall together
constitute one and the same document.

 

    15

    

    

 

15. Governing
Law, Venue, and Waiver of Jury Trial.

 

(a) This
Agreement shall be governed by the laws of the State of Florida, without regard to any conflicts of laws principles thereof that would
call for application of the laws of any other jurisdiction.

 

(b) Any
action or proceeding seeking to enforce any provision of, or based on any right arising out of, this Agreement shall be brought against
either of the Parties in the appropriate courts in the State of Florida, and each Party hereby consents to the jurisdiction of such courts
(and of the appropriate appellate courts) in any such action or proceeding and waives any objection to venue laid therein.

 

(c) Process
in any action or proceeding referred to in the preceding section may be served on any Party anywhere in the world, whether within or without
the State of Florida, in any manner permitted by the laws of the State of Florida.

 

(d) Any
dispute shall be heard only by a judge and the Parties hereby waive any right to a trial by jury.

 

THE PARTIES WAIVE ANY AND ALL RIGHTS TO TRIAL BY
JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT.

 

16. Notices.
Any notices provided for in this Agreement shall be in writing and shall be effective when delivered in person or deposited with a
nationally recognized overnight courier, postage prepaid, and addressed to the Executive at his last known address on the books of the
Company or, in the case of the Company, to it at its principal place of business, attention of the Chairman of the Board, or to such other
address as either party may specify by notice to the other actually received.

 

17. Indemnification
and D&O Insurance. To the fullest extent permitted by law, the Company shall indemnify, defend, and hold harmless the Executive
against and in respect of any and all actions, suits, proceedings, claims, demands, judgments, costs, expenses (including reasonable attorneys’
fees), losses, and damages arising out of or relating to Executive’s performance of duties and obligations for the Company. The
Company agrees to maintain and name Executive as an insured on a directors’ and officers’ liability insurance policy both
during the Term and while potential liability exits at the same level and coverage as its other directors and officers.

 

18. Ownership
of Outside Entities. Employee represents and warrants he has disclosed all entities in which he has an ownership or pecuniary interest
on Schedule 1 hereto.

 

    16

    

    

 

19. Executive’s
Representations. The Executive represents and warrants that:

 

(a) There
are no unpaid amounts due to him from the Company as of the Effective Date, whether under the Prior Employment Agreements or otherwise;

 

(b) He is
not an employee, consultant, or advisor to any other business;

 

(c) He is
not subject to any restrictive covenants or other agreements or legal restriction in favor of any person or entity which would in any
way preclude, inhibit, or limit his employment or the performance of his duties and responsibilities to the Company and its Affiliates
and such performance of employment duties will not create a default or event of default or the right to terminate any other agreement
to which the Executive (or any entity under his control) is a party or otherwise bound;

 

(d) He has
provided the Company with copies of any non-competition, confidentiality, non-solicitation, or non-hire contracts or provisions currently
applicable to him;

 

(e) He has
been advised of, and has agreed to abide by, the Company’s policy not to obtain or use any confidential information, proprietary
information, or trade secrets of its competitors or others, unless such information is properly obtained from sources permitted to disclose
such information;

 

(f) He can
perform the essential functions of his job with or without a reasonable accommodation, and he shall provide notice to the Company regarding
any required accommodation; and

 

(g) He has
not dealt with any employment agency or broker in connection with his employment by the Company.

 

[REMAINDER OF PAGE INTENTIONALLY
LEFT BLANK]

[SIGNATURE PAGE FOLLOWS]

 

    17

    

    

 

The Executive acknowledges
that (1) the Company provided the Executive with this Agreement at least ten (10) business days before its effective date, (2) the Executive
has been and is hereby advised of the Executive’s right to consult an attorney before signing this Agreement, and (3) the Executive
has carefully read this Agreement and understands and agrees to all of the provisions in this Agreement.

 

IN WITNESS WHEREOF, this Agreement
has been executed by the Company, by its duly authorized representative, and by the Executive, as of the date first above written.

 

	THE EXECUTIVE:	 	THE COMPANY:
	 	 	CUENTAS, INC.
	 	 	 	 
	/s/ Michael De Prado	 	By:	/s/ Jeff Johnson
	Michael De Prado	 	Name: 	Jeff Johnson
	 	 	Title:	CEO

 

    18

    

    

 

Exhibit A

 

FORM OF GENERAL WAIVER AND RELEASE OF CLAIMS

 

1. General Release.

 

(a) In exchange
for the payments and benefits set forth in Annex 1 attached hereto, other than payment of any Final Compensation, as defined in
the Founder/Executive Vice-Chairman Compensation Agreement, dated as of August 26, 2021, by and between CUENTAS, INC., a Florida Corporation
(the “Company”) and MICHAEL DE PRADO (the “Executive”) (the “Agreement”), Executive,
for himself and Executive’s heirs, family members, executors, estates, agents and assigns, or any controlled affiliate and any trust
or other entity of which Executive or said heirs, estates or family directly or indirectly hold a majority beneficial interest (together,
the “Executive Releasors”), releases and discharges each member of the Company Group (defined below), and each of such
member’s current or former owners, agents, officers, executives, shareholders, agents, employees, directors, attorneys or representatives,
and all persons acting by, through, under or in concert with any member of the Company Group (collectively referred to as the “Released
Parties”), from any and all causes of action, claims, liabilities, obligations, promises, agreements, controversies, damages
and expenses, known or unknown, which Executive ever had, or now has, against the Released Parties to the date Executive signs this general
waiver and release of claims (the “Waiver and Release”), including, without limitation, those that arise out of or
in connection with Executive’s employment with the Company. The Released Parties are intended to be express third-party beneficiaries
of this Waiver and Release, and this Waiver and Release may be enforced by each of them in accordance with the terms hereof in respect
of the rights granted to such Released Parties hereunder. “Company Group” means, collectively, the Company and each
of its subsidiaries and affiliates, and each of their respective predecessors, successors and assigns.

 

(b) The
claims Executive releases include, but are not limited to, any and all claims, suits, controversies, actions, causes of action, cross-claims,
counter-claims, demands, debts, damages (whether compensatory, punitive, direct, special, liquidated, exemplary or otherwise), claims
for costs (including, without limitation, enforcement costs and expenses, and attorneys’ fees), or liabilities of any nature whatsoever
in law and in equity, both past and present (through the date that this Waiver and Release becomes effective and enforceable), and whether
known or unknown, suspected, or claimed against the Company or any of the Released Parties, which Executive and each other Executive Releasors,
may have, by reason of any matter, cause, or thing whatsoever, until the date Executive signs this Waiver and Release, and particularly,
but without limitation of the foregoing general terms, any claims arising from or relating in any way to Executive’s employment
relationship with the Company, the terms and conditions of that employment relationship, and the termination of that employment relationship
(including, but not limited to, any allegation, claim or violation, arising under: Title VII of the Civil Rights Act of 1964; the Civil
Rights Act of 1991; the Age Discrimination in Employment Act of 1967 (including the Older Workers Benefit Protection Act) (“ADEA”);
the Equal Pay Act of 1963; the Americans with Disabilities Act of 1990; the Family and Medical Leave Act of 1993; the Worker Adjustment
Retraining and Notification (“WARN”) Act; the Employee Retirement Income Security Act of 1974; any applicable Executive
Order Programs; the Fair Labor Standards Act; the Genetic Information Nondiscrimination Act of 2008, or their state or local counterparts;
the Florida Constitution (including wage claims to the extent permitted by law), the Florida Civil Rights Act of 1992, as amended, Florida’s
general labor regulations (including but not limited to wage and retaliation, private whistleblower, and any other claims set out in Chapter
448, Part 1, Fla. Stat. claims) (Chapter 448, Part 1, Fla. Stat.), retaliation prohibitions under Florida Workers’ Compensation Act, as
amended (Fla. Stat. §440.205), Florida’s Wage Discrimination Law (Fla. Stat. §448.07), Florida’s Equal Pay Law (Fla. Stat. §725.07
and Fla. Stat. §448.07), Florida’s Minimum Wage Act (Fla. Stat. §448.110), the Florida State and Miami-Dade County Human Rights
Laws, and any other Florida and Miami-Dade labor laws; or any other Federal, state or local civil or human rights law (whether U.S. or
non-U.S.); all of the foregoing including their amendments and respective implementing regulations, or under any public policy, contract
or tort, or under common law; or any other claim arising under any policies, practices or procedures of the Company; or any claim for
wrongful discharge, breach of contract, infliction of emotional distress, defamation; or any claim for costs, fees, or other expenses
or amounts, including attorneys’ fees incurred in these matters) (all of the foregoing collectively referred to herein as the “Claims”).

 

    A-1

     

    

 

(c) For
the purpose of giving a full and complete release, Executive understands and agrees that this Waiver and Release includes all Claims that
Executive may now have but does not know or suspect to exist in Executive’s favor against the Released Parties, and that, except
as set forth in Section 2 below, this Waiver and Release extinguishes those Claims.

 

(d) If
Executive was employed by the Company at any time in California, or if Executive resided in California at any time while employed by the
Company, Executive waives all rights under California Civil Code Section 1542, which states:

 

A general release does not extend to claims which the creditor
or releasing party does not know or suspect to exist in his or her favor at the time of executing the release, which if known by him or
her would have materially affected his or her settlement with the debtor or released party.

 

2. Protected Rights.

 

(a) Executive
and the Company acknowledge that nothing in this Waiver and Release shall be deemed to be a waiver or release by Executive of (i) any
claim or right under state workers’ compensation or unemployment laws; (ii) any rights of Executive arising under, or preserved
by, this Waiver and Release; (iii) rights of Executive to the payments and benefits set forth in Annex 1; (iv) any benefit vested
as of the date of Executive’s termination of employment to which Executive is entitled under any employee benefit plan or arrangement
of the Company; (v) any claim or right which by law cannot be waived, including, but not limited to, Executive’s rights to file
a charge with an administrative agency or to participate in an agency investigation (including, but not limited to, the right to file
a charge or participate in an investigation or proceeding conducted by the Equal Employment Opportunity Commission (“EEOC”));
(vi) any rights of Executive as a holder of equity in the Company, any direct or indirect parent of the Company, or any of their respective
subsidiaries or affiliates; or (vii) any rights of Executive to indemnification as a director or officer of the Company or claims under
any directors’ and officers’ liability insurance policy (or similar policy). Executive waives, however, the right to recover
money if any U.S. Federal, state or local government agency, including, but not limited to, the EEOC, pursues a claim on Executive’s
behalf or on behalf of a class to which Executive may belong that arises out of or relates to Executive’s employment or severance
from employment.

 

    A-2

     

    

 

(b) Nothing
in or about this Waiver and Release prohibits Executive from: (i) filing and, as provided for under Section 21F of the Securities Exchange
Act of 1934 (the “Exchange Act”), maintaining the confidentiality of a claim with the Securities and Exchange Commission
(the “SEC”); (ii) providing Confidential Information, as defined in the Agreement, to the SEC, or providing the SEC
with information that would otherwise violate any provision of the Agreement, to the extent permitted by Section 21F of the Exchange Act;
(iii) cooperating, participating, or assisting in an SEC investigation or proceeding without notifying the Company; or (iv) receiving
a monetary award as set forth in Section 21F of the Exchange Act. Furthermore, Executive is advised that Executive shall not be held criminally
or civilly liable under any U.S. Federal or state trade secret law for the disclosure of any Confidential Information that constitutes
a trade secret to which the Defend Trade Secrets Act (18 U.S.C. § 1833(b)) applies that is made (A) in confidence to a U.S. Federal,
state, or local government official, either directly or indirectly, or to an attorney, in each case, solely for the purpose of reporting
or investigating a suspected violation of law; or (B) in a complaint or other document filed in a lawsuit or proceeding, if such filings
are made under seal.

 

3. Covenant Not to Sue.

 

(a) Executive
(i) affirms that Executive has not filed, has not caused to be filed, and is not presently party to, any lawsuit or arbitration against
any Released Party in any forum and (ii) agrees not to sue any of the Released Parties or become a party to a lawsuit on the basis of
any claims of any type to date that arise out of any aspect of Executive’s employment or severance from employment other than, in
each case, in order to enforce rights under (A) the Agreement with respect to Final Compensation, (B) Annex 1, or (C) Section 2
above. Executive understands that this is an affirmative promise by Executive not to sue any of the Released Parties, which is in addition
to Executive’s general release of Claims in Section 1 above. However, nothing in this Waiver and Release affects Executive’s
right to challenge the validity of this Waiver and Release under ADEA.

 

(b) If
Executive breaches this Waiver and Release by suing any of the Released Parties in violation of this covenant not to sue, or if Executive
breaches any covenant referenced in Section 6, (i) the Company shall have no obligation to pay any amounts set forth in Annex 1
(other than payment of any Final Compensation) and (ii) Executive understands that the Released Parties will be entitled to apply for
and receive an injunction to restrain any violation of this Section 3 or Section 6.

 

4. Acknowledgments.

 

(a) Executive
affirms that Executive has fully reviewed the terms of this Waiver and Release, affirms that Executive understands its terms, and states
that Executive is entering into this Waiver and Release knowingly, voluntarily and in full settlement of all Claims which existed in the
past or which currently exist, that arise out of Executive’s employment with the Company or Executive’s severance from employment.

 

    A-3

     

    

 

(b) Executive
acknowledges that Executive has had at least 21 days to consider this Waiver and Release thoroughly, and has been specifically advised
to consult with an attorney, if Executive wishes, before Executive signs below.

 

(c) If
Executive signs and return this Waiver and Release before the end of the 21-day period, Executive certifies that Executive’s acceptance
of a shortened time period is knowing and voluntary, and the Company did not improperly encourage Executive to sign through fraud, misrepresentation,
a threat to withdraw or alter the offer before the 21-day period expires, or by providing different terms to other employees who sign
the release before such time period expires.

 

(d) Executive
understands that Executive may revoke this Waiver and Release within seven (7) days after Executive signs it. Executive revocation must
be in writing and submitted within the seven-day period to [name], [title], [company], [address]. If Executive does not revoke this Waiver
and Release within the seven-day period, it becomes effective and irrevocable. Executive further understands that if Executive revokes
this Waiver and Release, Executive will not be eligible to receive the payments and benefits set forth in Annex 1 (other than payment
of any Final Compensation). Payments and benefits set forth in Annex 1 shall commence after the end of the seven-day period, or
later, in accordance with the terms of Annex 1 and applicable law. Executive acknowledges that, before signing this Waiver and
Release, Executive (i) received certain information about eligibility for the payments and benefits available under this Waiver and Release
and (ii) had at least 21 days to consider this information before signing this Waiver and Release.

 

5. Assignment; Binding
Effect. This Waiver and Release is assignable only by the Company (provided that no such assignment shall relieve the Company
of its obligations under this Waiver and Release to Executive), shall inure to the benefit of the Company’s assigns, successors,
affiliates, and Released Parties, and is binding on the parties, their representatives, agents and assigns, and as to Executive, Executive’s
spouse, dependents, heirs, executors, administrators, representatives, and assigns.

 

6. Restrictive Covenants.
Notwithstanding anything to the contrary in this Waiver and Release, the restrictive covenants in Section 5 of the Agreement shall continue
to apply to Executive following the date of Executive’s termination of employment, as specified and in accordance with the terms
of such restrictive covenants.

 

7. Complete Agreement;
Severability. This Waiver and Release is the exclusive and complete agreement between Executive and the Company relating to the subject
matter of this Waiver and Release. No amendment or update of this Waiver and Release will be binding unless in writing and signed by Executive
and the Company. The parties acknowledge and agree that if any provision of this Waiver and Release is found, held, or deemed by a court
of competent jurisdiction to be void, unlawful, or unenforceable under any controlling law, the rest of this Waiver and Release will continue
in full force and effect. Additionally, a court of competent jurisdiction is authorized to modify any portion of this Waiver and Release
which is overbroad to make such portion enforceable.

 

    A-4

     

    

 

8. Governing Law. THIS
WAIVER AND RELEASE SHALL BE DEEMED TO BE MADE IN THE STATE OF FLORIDA, AND, TO THE EXTENT NOT PREEMPTED BY ERISA OR OTHER U.S. FEDERAL
LAW, THE VALIDITY, INTERPRETATION, AND PERFORMANCE OF THIS WAIVER AND RELEASE IN ALL RESPECTS SHALL BE GOVERNED BY THE LAWS OF THE STATE
OF FLORIDA WITHOUT REGARD TO ITS PRINCIPLES OF CONFLICTS OF LAW.

 

9. This Waiver and Release
shall be irrevocable on the 8th day following the date on which Executive signs and dates this Waiver and Release below. Executive’s
right to revoke this Waiver and Release is described in Section 4 of this Waiver and Release.

 

10. Executive is hereby advised
by the Company to consult with an attorney prior to signing this Waiver and Release.

 

11. This Waiver and Release
may be executed in any number of counterparts (including by means of facsimile or electronically transmitted portable document format
(PDF) signature pages), each of which when so executed and delivered shall be taken to be an original; but such counterparts shall together
constitute one and the same document.

 

[REMAINDER OF PAGE INTENTIONALLY
LEFT BLANK]

[SIGNATURE PAGE FOLLOWS]

 

    A-5

     

    

 

IN WITNESS WHEREOF, this Waiver and Release has been signed by the
parties as of the dates indicated below.

 

	 	 
	Michael De Prado	 

 

	Date signed:	 	

 

	Acknowledged and agreed: 	 

 

	CUENTAS, INC.	 
	 	 	 
	By:  	         	 
	Name: 	 	 
	Title: 	 	 

 

	Date signed: 	 	 

 

    A-6

     

    

 

ANNEX 1

SEVERANCE PAYMENTS AND BENEFITS

 

[To be completed at the time of separation.
Annex to include full list of any severance payments on any other benefits (including treatment of equity awards) to be provided in connection
with Executive’s separation.]

 

    A-7

     

    

 

Exhibit B

 

PRIOR INVENTIONS

 

	TO:	Cuentas, Inc. 
	 	 
	FROM:	Michael De Prado
	 	 
	DATE:	August 26, 2021
	 	 
	SUBJECT:	Prior Inventions 

 

1. Except
as listed in Section 2 below, the following is a complete list of all inventions or improvements relevant to the subject matter
of my employment by Cuentas, Inc. (the “Company”) that have been made or conceived or first reduced to practice by
me alone or jointly with others prior to my engagement by Company:

 

		☐	No inventions or improvements.

 

		☐	See below:

 

		☐	Additional sheets attached.

 

2. Due
to a prior confidentiality agreement, I cannot complete the disclosure under Section 1 above with respect to inventions or improvements
generally listed below, the proprietary rights and duty of confidentiality with respect to which I owe to the following party(ies):

 

	 	Invention or Improvement	 	Party(ies)	 	Relationship
	 	 	 	 	 	 
	1.	 	 	 	 	 
	 	 	 	 	 	 
	2.	 	 	 	 	 
	 	 	 	 	 	 
	3.	 	 	 	 	 

 

		☐	Additional sheets attached.

 

	/s/ Michael De Prado	 
	Michael De Prado	 

 

    B-1

     

    

 

Schedule 1

 

Ownership
of Outside Entities

 

		 	1.

 

		 	2.meso-ex427_593.htm

 

Exhibit 4.27

 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED

 

30 June 2021

 

 

 

Mesoblast Limited and Mesoblast International Sàrl

and

Grünenthal GmbH

 

	
	
 

DEED AMENDING AND RESTATING THE DEVELOPMENT AND COMMERCIALIZATION AGREEMENT

 

 

 

 

This DEED (the “Deed”) is made as of 30 June 2021 by and between, on the one hand, Mesoblast Limited with a place of business at 55 Collins Street, Level 38, Melbourne 3000, Victoria Australia (“Mesoblast Limited”) and Mesoblast International Sàrl, a Swiss societé a responsibilité limitée, with its principal place of business located at Route de Pre-Bois 20, c/o Accounting & Management Service SA, 1217 Meyrin, Switzerland (“Mesoblast Sàrl,” and together with Mesoblast Limited, “MSB”) and, on the other hand, Grünenthal GmbH, with a place of business at Zieglerstraße 6, 52078 Aachen, Germany (“Grünenthal” or “GRT”).  MSB and Grünenthal are each referred to herein by name or, individually, as a “Party” or, collectively, as the “Parties.” (together the “Parties”, and each a “Party”).

WHEREAS

	
(A)
	
The Parties entered into a Development and Commercialization Agreement dated 9 September 2019, as amended from time to time prior to the date hereof (the “Original DCA”).

	
(B)
	
The Parties have agreed to amend and restate the Original DCA in the form set out in the Schedule (Amended and Restated DCA) to this Deed.

	
1.
	
Definitions and Interpretation

Save as otherwise expressly provided herein, terms defined in the Original DCA shall be attributed the same meaning in this Deed.

	
2.
	
Amendment and Restatement of the Original DCA

	
 
	
2.1
	
The Parties hereby agree that with effect from (and including) the date of this Deed the Original DCA shall be amended and restated (the “Amended and Restated DCA”) to be in the form of the Schedule (Amended and Restated DCA) to this Deed, which shall supersede the Original DCA and all previous amendments to the Original DCA in their entirety.

	
 
	
2.2
	
Grünenthal hereby waives any and all rights:

	
 
	
(a)
	
to terminate the Original DCA pursuant to Section [***]of the Original DCA; and

	
 
	
(b)
	
to receive any re-payment of the $2,500,000 (two million five hundred thousand) CMC Milestone paid by Grünenthal to MSB prior to the date of this Deed (the “Paid CMC Milestone Amount”),

in each case, which may have accrued on or prior to the date of this Deed.  For the avoidance of doubt, clause 2.2(b) above shall be without prejudice to any right to receive re-payment of the Paid CMC Milestone Amount that may arise after the date of this Deed in accordance with Section [***] of the Amended and Restated DCA.

 

 

 

 

	
3.
	
MISCELLANEOUS

Sections 11.1, 11.2, 14.4, 15.1, 15.3 through 15.15 (inclusive) of the Amended and Restated DCA shall apply mutatis mutandis to this Deed.  For clarity, this Deed is indivisible from the Amended and Restated DCA and may only be assigned as part thereof.

IN WITNESS whereof the Parties hereto have duly executed and delivered this document as a deed on the day, month and year first written before.

 

[The remainder of this page left blank intentionally; signature pages attached behind.]

 

 

 

 

 

	
Signed, sealed and delivered as a deed
	
)
	
 

	
by MESOBLAST LIMITED
	
)
)

)
	
 

/s/ Silviu Itescu.........................................................

(By)

	
 
	
)
	
 

	
 

 

 

 

 
	
)

)

)
	
 

Silviu Itescu, ........Director.................................................

(Name, Title)

 

 

			
	
 
	
)
	
 

	
 
	
)
)

)
	
 

/s/ Niva Sivakumar.........................................................

Signature of witness

	
 
	
)
	
 

	
 

 

 

 

 
	
)

)

)
	
 

Niva Sivakumar, Company Secretary.........................................................

Name of witness

 

 

-4-

 

 

 

 

			
	
Signed, sealed and delivered as a 
	
)
	
 

	
deed by MESOBLAST International SÀRL
	
)
)
	
 

	
 
	
)

)
)
)
)
)
	
/s/ Ralph Challancin.........................................................

(By)

 

 

Ralph Challancin, Director.........................................................

(Name, Title)

 

 

 

			
	
 
	
)
	
 

	
 
	
)
)

)
	
 

.........................................................

Signature of witness

	
 
	
)
	
 

	
 

 

 

 

 
	
)

)

)
	
 

.........................................................

Name of witness

 

 

 

-5-

 

 

 

 

			
	
Signed, sealed and delivered as a 
	
)
	
 

	
deed by GRÜNENTHAL GMBH
	
)
)
	
 

	
acting by two directors.
	
)

)
)
)
)
)
	
./s/ Gabriel Baertschi........................................................

Gabriel Baertschi (Director)

 

 

.............../s/ Dr. Jan Adams..........................................

Dr. Jan Adams (Director)

 

			
	

	
)
	
 

	
 
	
)
)

)
	
 

/s/ Ralf Radermacher.........................................................

Signature of witness

	
 
	
)
	
 

	
 

 

 

 

 
	
)

)

)
	
 

Ralf Radermacher, Senior Vice President, Corporate Development and Licensing.........................................................

Name of witness

 

 

-6-

 

 

 

 

 

Schedule

(Amended and Restated DCA)

 

 

-7-

 

 

 

 

AMENDED AND RESTATED

DEVELOPMENT AND COMMERCIALIZATION AGREEMENT

 

Between

Mesoblast Limited and Mesoblast International Sàrl

and

Grünenthal GmbH

Executed: 30 June 2021

Effective:  9 September 2019

 

 

 

 

 

 

 

 

Table of Contents

 

	
Article 1 DEFINITIONS
	
6

	
Article 2 GOVERNANCE
	
21

	
2.1.
	
Joint Steering Committee
	
21

	
2.2.
	
Membership
	
22

	
2.3.
	
Meetings
	
23

	
2.4.
	
Initial Period
	
23

	
2.5.
	
Governance following Continuation Date.
	
23

	
2.6.
	
Committee Authority
	
24

	
2.7.
	
Alliance Managers
	
24

	
2.8.
	
Day-to-Day Responsibilities
	
24

	
2.9.
	
Expert Determination
	
25

	
2.10.
	
MSB Personnel.
	
25

	
Article 3 RIGHTS AND EXCLUSIVITY
	
26

	
3.1.
	
Rights of Grünenthal
	
26

	
3.2.
	
Rights of MSB
	
27

	
3.3.
	
No Contravention
	
28

	
3.4.
	
No Other Rights
	
28

	
3.5.
	
Exclusivity of Efforts
	
29

	
[***]
	
 
	
30

	
[***]
	
 
	
30

	
Article 4 Initial DEVELOPMENT
	
31

	
4.1.
	
General
	
31

	
4.2.
	
MSB Development.
	
31

	
4.3.
	
Initial Development Plan
	
31

	
4.4.
	
Inclusion of European Patients.
	
32

	
4.5.
	
Grünenthal Assistance.
	
32

	
4.6.
	
Development Data, Regulatory Materials and Other Reporting Obligations
	
33

	
4.7.
	
Conduct
	
33

	
4.8.
	
Development Costs
	
34

	
4.9.
	
Continuation.
	
34

	
Article 5 CONTINUATION DEVELOPMENT
	
35

	
5.1.
	
Continuation Development
	
35

	
5.2.
	
Grünenthal Development
	
35

	
5.3.
	
Continuation Development Plan.
	
36

	
5.4.
	
Regulatory Meetings and HTA Meetings
	
36

	
5.5.
	
Label Extensions and Lifecycle Management.
	
37

	
5.6.
	
Regulatory Meetings Outside the Territory
	
37

	
5.7.
	
European Clinical Trials
	
37

	
5.8.
	
Development Data, Regulatory Materials and Other Reporting Obligations
	
38

	
5.9.
	
Conduct
	
39

	
5.10.
	
Development Costs
	
39

 

 

 

	
Article 6 COMMERCIALIZATION AND MEDICAL AFFAIRS
	
39

	
6.1.
	
General
	
39

	
6.2.
	
Commercialization Plan
	
39

	
6.3.
	
Pricing
	
40

	
6.4.
	
Diligence Obligations
	
40

	
6.5.
	
Conflicts of Interest
	
40

	
6.6.
	
Medical Affairs Activities
	
40

	
6.7.
	
Reporting
	
41

	
6.8.
	
Commercialization Review Board.
	
41

	
6.9.
	
Commercialization Costs
	
42

	
6.10.
	
Territorial Considerations.
	
42

	
Article 7 MANUFACTURE / SUPPLY
	
42

	
7.1.
	
Development Supply
	
42

	
7.2.
	
Specifications
	
42

	
7.3.
	
Regulatory Approvals for Manufacture.
	
43

	
7.4.
	
Direct Supply From Third Party Manufacturers
	
43

	
7.5.
	
Maintenance of Master Cell Banks.
	
44

	
7.6.
	
Manufacturing Technology Transfer.
	
44

	
Article 8 REGULATORY AND RELATED MATTERS
	
44

	
8.1.
	
Regulatory Matters
	
44

	
8.2.
	
Regulatory Cooperation
	
46

	
8.3.
	
Exchange of Data
	
46

	
8.4.
	
Audit Rights.
	
47

	
8.5.
	
Safety Data Exchange Agreement
	
48

	
Article 9 PAYMENTS
	
48

	
9.1.
	
Fees and Royalty
	
48

	
9.2.
	
Payment Method
	
50

	
9.3.
	
Taxes
	
51

	
9.4.
	
Inspection of Records
	
51

	
9.5.
	
Late Payment
	
52

	
9.6.
	
Currency Conversion
	
52

	
9.7.
	
Acknowledgement
	
52

	
Article 10 INTELLECTUAL PROPERTY
	
53

	
10.1.
	
Ownership of Inventions
	
53

	
10.2.
	
Patent Prosecution
	
53

	
10.3.
	
Defense of Third Party Infringement Claims
	
54

	
10.4.
	
Enforcement
	
55

	
10.5.
	
Regulatory Exclusivity
	
56

	
10.6.
	
Patent Marking
	
57

	
10.7.
	
Data
	
57

	
10.8.
	
Trademarks
	
57

	
10.9.
	
Recordal of Licence
	
57

 

 

	
Article 11 CONFIDENTIALITY
	
57

	
11.1.
	
Confidentiality; Exceptions
	
57

	
11.2.
	
Authorized Use and Disclosure
	
58

	
11.3.
	
Prior Agreements
	
59

	
11.4.
	
Scientific Publications
	
59

	
11.5.
	
Publicity
	
60

	
11.6.
	
Common Interest
	
61

	
Article 12 REPRESENTATIONS, WARRANTIES AND COVENANTS; INDEMNIFICATION
	
62

	
12.1.
	
Grünenthal Representations and Warranties
	
62

	
12.2.
	
MSB’s Warranties
	
62

	
12.3.
	
MSB Product Technology Warranties and Covenants
	
64

	
12.4.
	
Disclaimer of Warranties
	
65

	
12.5.
	
Indemnification
	
65

	
12.6.
	
Limitation of Liability
	
66

	
12.7.
	
Insurance
	
67

	
Article 13 TERM AND TERMINATION
	
67

	
13.1.
	
Term
	
67

	
13.2.
	
Grünenthal Termination Rights
	
67

	
13.3.
	
Termination for Failure to Provide Continuation Notice.
	
69

	
13.4.
	
Termination for Breach
	
69

	
13.5.
	
Termination for Patent Challenge
	
70

	
13.6.
	
Termination for Insolvency
	
70

	
13.7.
	
[***].
	
71

	
13.8.
	
General Effects of Expiration or Termination
	
71

	
13.9.
	
Additional Effects of Certain Terminations
	
71

	
13.10.
	
Termination Press Releases
	
73

	
13.11.
	
No Prejudice
	
74

	
Article 14 DISPUTE RESOLUTION
	
74

	
14.1.
	
Dispute Resolution
	
74

	
14.2.
	
Committee Disputes
	
74

	
14.3.
	
Other Disputes
	
74

	
14.4.
	
Binding Arbitration.
	
75

	
14.5.
	
Patent Dispute Resolution
	
76

	
14.6.
	
Interim Relief
	
76

	
Article 15 MISCELLANEOUS
	
76

	
15.1.
	
Governing Law
	
76

	
15.2.
	
Assignment
	
76

	
15.3.
	
Notices
	
77

	
15.4.
	
English Language
	
78

	
15.5.
	
Waiver
	
78

	
15.6.
	
Severability
	
78

 

 

	
15.7.
	
Joint and Several Liability
	
78

	
15.8.
	
No Third Party Beneficiaries
	
79

	
15.9.
	
Entire Agreement/Modification
	
79

	
15.10.
	
Relationship of the Parties
	
79

	
15.11.
	
Force Majeure
	
79

	
15.12.
	
Compliance with Applicable Law; Anti-Corruption; Grünenthal Business Partner Code of Conduct
	
80

	
15.13.
	
Further Assurance
	
80

	
15.14.
	
Costs
	
81

	
15.15.
	
Counterparts
	
81

 

 

 

 

 

CONFIDENTIAL

AMENDED AND RESTATED DEVELOPMENT AND COMMERCIALIZATION AGREEMENT

This AMENDED AND RESTATED DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (the “Agreement”) is made effective as of September 9, 2019 (the “Effective Date”) by and between, on the one hand, Mesoblast Limited with a place of business at 55 Collins Street, Level 38, Melbourne 3000, Victoria Australia (“Mesoblast Limited”) and Mesoblast International Sàrl, a Swiss societé a responsibilité limitée, with its principal place of business located at Route de Pre-Bois 20, c/o Accounting & Management Service SA, 1217 Meyrin, Switzerland (“Mesoblast Sàrl,” and together with Mesoblast Limited, “MSB”) and, on the other hand, Grünenthal GmbH, with a place of business at Zieglerstraße 6, 52078 Aachen, Germany (“Grünenthal” or “GRT”).  MSB and Grünenthal are each referred to herein by name or, individually, as a “Party” or, collectively, as the “Parties.”

 

BACKGROUND

A.Mesoblast Limited or its Affiliates own and control (clinical) data, intellectual property, the right to manufacture and other rights in and to that certain proprietary mesenchymal precursor cell product (including the Product, as defined below).

B.The Parties will collaborate to complete the Development of Product and Grünenthal will obtain the right to Commercialize Product within the Field throughout the Territory (each capitalized term as defined below), all on the terms and conditions set forth herein below.

NOW, THEREFORE, in consideration of the mutual covenants and agreements provided herein below and other consideration, the receipt and sufficiency of which is hereby acknowledged, Grünenthal and MSB hereby agree as follows:

Article 1
DEFINITIONS

The following capitalized terms have the meanings given in this Article 1 when used in this Agreement: 

1.1.“Accounting Standards” means, with respect to a Person, then current generally accepted accounting principles consistently applied by such Person across its operations, including International Financial Reporting Standards (IFRS) and/or German Generally Accepted Accounting Principles.

1.2.“Affiliate” means with respect to a Person, any other Person controlling, controlled by or under common control with such first Person, for so long as such control exists.  For purposes of this Section 1.2 only, “control” means (a) direct or indirect ownership of fifty per cent (50%) or more (or, if less than fifty per cent (50%), the maximum ownership interest permitted by 

-6-

 

 

Applicable Law) of the stock or shares having the right to vote for the election of directors of such Person, or (b) the possession, directly or indirectly, of the power to direct, or cause the direction of, the management or policies of such Person, whether through the ownership of voting securities, by contract or otherwise.

1.3. “Amendment and Restatement Date” means 30 June 2021.

1.4.“Annual Net Sales” means, subject to Section 9.1.4, with respect to a particular Annual Period, aggregate Net Sales of Product during such Annual Period in each country in the Territory.

1.5.“Annual Period” means (a) for the calendar year during which the First Commercial Sale of Product in the Territory occurs, the period commencing on the date of such First Commercial Sale and ending on December 31st of such year (or the date this Agreement is terminated if such termination is effective prior to December 31), (b) for each successive calendar year thereafter during the Term (other than the calendar year in which this Agreement is terminated) the period beginning on January 1st of such year and ending on December 31st of such year, and (c) for the calendar year in which this Agreement is terminated, the period beginning on January 1st of such calendar year and ending on the effective date of the termination of this Agreement.

1.6.“Anti-Corruption Laws” means any and all applicable anti-corruption laws and regulations, including those laws and regulations for combatting bribery of foreign public officials in the United States, Australia, Switzerland and Germany including the United States Foreign Corrupt Practices Act, the UK Bribery Act 2010, and the Organization for Economic Co-operation and Development (OECD) Convention, each in its then current version.

1.7.“Applicable Law” means any and all laws, ordinances, orders, rules, rulings, directives and regulations of any kind whatsoever of any Regulatory Authority or other governmental authority within any jurisdiction that are applicable to a Party’s activities under this Agreement.

1.8. “Assignee” means any Third Party that is assigned or transferred, or succeeds to, the rights and obligations of a Party under this Agreement.

1.9.“Business Day” means any day except a Saturday, Sunday or any other day on which commercial banks in Düsseldorf, Germany or Melbourne, Australia are authorized or required by law to remain closed.

1.10.“cGxP” means then-current good manufacturing, clinical, pharmacovigilance or laboratory practices and quality system regulations, as applicable, promulgated by any applicable Regulatory Authority.

-7-

 

 

1.11.“CMO” means each Third Party contract manufacturer with whom MSB or Grünenthal may from time to time enter into an agreement for the Manufacture of the Product for the Territory.  As of the Amendment and Restatement Date, CMO shall mean those entities listed in Exhibit 1.11.

1.12.“COGS” means, with respect to any Product Manufactured by or on behalf of a Party, the [***]cost of that Party incurred in the Manufacture of the relevant Product ready for delivery at the relevant delivery location as calculated in accordance with that Party’s internal accounting policies in a manner consistent with Accounting Standards and the methodology employed by that Party for other products applied on a consistent basis [***] 

1.13.“Commercialization” means, with respect to a [***]product (including the Product), any and all processes and activities conducted to establish and maintain sales for such product, including obtaining and maintaining Pricing Approvals, market access activities, coding and patient access, offering for sale, detailing, selling (including launching), marketing (including pre-launch and launch, as well as advertising activities), promoting, storing, transporting, distributing, and importing such product, but shall exclude Development and Manufacture of such product.  For clarity, Commercialization includes activities traditionally conducted by sales representatives (including field sales, institutional sales, pharmacy/trade sales and managed care sales representatives) and other individuals having similar functions.  “Commercialize”, “Commercialized” and “Commercializing” shall have their correlative meanings.

1.14.“Commercially Reasonable Efforts” means, with respect to a Person, [***]and other relevant factors applicable to the pharmaceutical/biotech industry. As appropriate consistent with the foregoing, Commercially Reasonable Efforts shall require the applicable Party to:[***]  When determining its Commercially Reasonable Efforts, neither Party shall [***]

1.15.“Competing Product” means any similar [***]intended for use within the Field, other than the Product.

1.16.“Control” means, with respect to any particular Know-How or a particular Patent, possession by the Party granting the applicable right, license, access or release to the other Party as provided herein of the power and authority, whether arising by ownership, license, or other authorization, to disclose and deliver the particular Know-How to the other Party, and to grant and authorize under such Know-How or Patent the right, license, access or release, as applicable, of the scope granted to such other Party in this Agreement without giving rise to any violation of the terms of any written agreement with any Third Party existing at the time such disclosure is first made or such right, license, access or release first comes into effect hereunder.  “Controlled” and “Controlling” have their correlative meanings.  Notwithstanding anything to the 

-8-

 

 

contrary in this Agreement, in the event that a Third Party merges or consolidates with or acquires a Party or an Affiliate of a Party, or a Party or an Affiliate of a Party transfers to a Third Party all or substantially all of its assets to which this Agreement relates (such Third Party and its Affiliates immediately prior to such merger, consolidation or transfer (the “Acquisition Transaction”), collectively, the “Acquiring Entities”), the following shall not be deemed to be Controlled by such Party or its Affiliates for purposes of this Agreement: (a) any subject matter controlled (whether by ownership, license or otherwise) by any Acquiring Entity immediately prior to the effective date of such Acquisition Transaction, and (b) any subject matter independently developed or acquired by or on behalf of any Acquiring Entity after an Acquisition Transaction, without accessing or practicing subject matter within the Product Technology or any other technology or information made available to such Party by the other Party under this Agreement.

1.17.“CTA” means the application for a clinical trial authorization as required from the competent Regulatory Authority for the performance of clinical trials as regards investigational medicinal products.

1.18.“CTA Approval” means any Regulatory Approval necessary for the initiation of recruitment at clinical trial sites (including those required from any Regulatory Authority, EC, IRB or additional relevant committee) or any import certificate necessary for the import of the investigational medicinal product to which a clinical trial relates;

1.19.“Data” means any and all data of any kind including, preclinical data, non-clinical data, pharmacology data, biological, pharmaceutical and quality related data (including analytical, product characterization, manufacturing, and stability data), toxicology data, clinical data (including investigator reports (both preliminary and final), statistical analyses, expert opinions and reports, safety data and other electronic databases), analytical, process and quality assurance/control data and stability data, in each case together with supporting data.

1.20.“Data Package” means a copy of the Biologics License Application (as provided for in 42 U.S.C. § 262 and 21 C.F.R. Part 601) or equivalent (“BLA”) submitted to the FDA for the Product within the Field in electronic format.

1.21.“Debarred Entity” means a Person (other than an individual) that has been debarred by the FDA pursuant to 21 U.S.C. § 335a (a) or (b), or by another Regulatory Authority pursuant to a comparable statute, from submitting or assisting in the submission of any application for any abbreviated or other drug application/registration or generation or preparation of any data with respect thereto, or any affiliate of such Person.

-9-

 

 

1.22.“Debarred Individual” means an individual who has been debarred by the FDA pursuant to 21 U.S.C. § 335a (a) or (b), or by another Regulatory Authority pursuant to a comparable statute, from providing services in any capacity (including generation or preparation of data) to a Person that has an approved or pending drug application/registration.

1.23.“Development” means, with respect to a [***]product (including the Product), any and all processes and activities, including research, development (non-clinical and clinical) and regulatory affairs activities and interface conducted to obtain, maintain or expand Regulatory Approvals for such product, including preclinical testing, test method development and stability testing, toxicology, formulation, process development, quality assurance/control development, statistical analysis, clinical trials, quality of life assessments, pharmacoeconomics, health outcomes, post-marketing studies, patient registries, label expansion studies, and further activities relating to development or preparation of such product for Commercialization.  “Develop”, “Developed” and “Developing” have their correlative meanings.

1.24.  “Development Plan” means, individually, each of the Initial Development Plan or the Continuation Development Plan (as applicable). 

1.25.“Dollar” means a United States dollar, and “$” shall be interpreted accordingly.

1.26.“Dossier” means the complete regulatory dossier or any preliminary versions thereof, in common electronic technical document (“eCTD”) format, containing a core set of Product information submitted in the U.S.A. as part of the BLA for the Product including quality and clinical data.

1.27.“EMA” means the European Medicines Agency, or any successor agency(ies) thereto.

1.28.“Euro” means the single currency of participating member states of the European Union, and “€” shall be interpreted accordingly.

1.29.“Ex-Field Product” means any [***]product (or combination product incorporating a [***]product) Developed or Commercialized during the Term by or under authority of MSB or its Affiliates for applications outside of the Field (as shown by its Development or labeling); provided, however, that an Ex-Field Product excludes any Competing Product in the Territory.

1.30.“FDA” means the United States Food and Drug Administration, or any successor agency(ies) thereto.

-10-

 

 

1.31.“Field” means treatment of discogenic chronic back pain, disc degeneration and/or functional disability, in each case by local delivery into or close to the intervertebral disc space in humans.  

1.32.“First Commercial Sale” means, with respect to a country in the Territory, the first sale for use or application by an end user of the Product with a patient after Marketing Approval and Pricing Approval in such country, but excluding sales of Product (a) for clinical study purposes, (b) for compassionate, named patient or similar purposes and (c) to private payers. 

1.33.“First Phase III Clinical Trial” means that certain clinical trial program for the Product ongoing as of the Effective Date [***]conducted pursuant to the clinical trial protocol therefor, as may be required to be modified by the relevant institution review board (“IRB”), ethics committee (“EC”)  or Regulatory Authority. 

1.34.“Gross Margin” means, with respect to Product sold in any country in Europe in any Quarter, (a) Net Sales of such Product minus COGS of such Product (calculated by considering a central warehouse of Grünenthal or one of its Affiliates in Europe as the delivery location) divided by (b) Net Sales of such Product (expressed as a percentage).

1.35.“GRT Improvement Patent” means any GRT Sole Patent that claims or discloses a GRT Sole Invention [***]

1.36.“GRT Know-How” means any Know-How that (a) is generated by or on behalf of the Grünenthal or its Affiliates from the activities conducted hereunder or (b) is used by or on behalf of Grünenthal or its Affiliates in the course of such activities.

1.37.“GRT Patents” means the GRT Sole Patents and Grünenthal’s interest in the Joint Patents.

1.38.“Grünenthal Business Partner Code of Conduct” means the principles and requirements stipulated in Exhibit 15.12.3, as may be amended by Grünenthal from time to time.

1.39.“ICH” means the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, or any successor association(s) thereto.

1.40.“Initial Period” means the period beginning on the Amendment and Restatement Date and ending on the Continuation Date.

1.41.“Key Person” means any employee, director or consultant of MSB identified as key personnel in Exhibit 2.10.1 and any replacement to any such individual appointed in accordance with Section 2.10.3.

-11-

 

 

1.42.“Know-How” means any and all information and materials comprising (a) ideas, discoveries, inventions (whether or not patentable), patent disclosures, improvements or trade secrets, (b) Data, (c) databases, practices, methods (including analytical methods), techniques, processes (including manufacturing and production process), specifications, formulations, formulae or knowledge, or (d) research materials, reagents or compositions of matter.

1.43.“Knowledge” means, with respect to a Party, the actual knowledge of the Party.  For clarity, any representation or warranty to a Party’s Knowledge regarding any Patents (including the non-existence or non-infringement thereof) shall not imply an obligation for such Party to conduct, or be construed that such Party has conducted, a search for Patents or other freedom to operate analysis.

1.44.“MAA” (Marketing Approval Application) means an application (including a BLA) or submission for Marketing Approval filed with a Regulatory Authority to obtain marketing clearance or approval for a [***] product (including the Product) in the applicable jurisdiction.

1.45.“Major European Market” means each of Germany, France and the United Kingdom.

1.46.“Manufacture” means, with respect to any [***] product (including the Product) or any component of any such product, any and all processes and activities conducted for the manufacture, production or processing of such product including the active biological ingredient(s) therein, including activities performed in support of CMC (chemistry, manufacturing and controls), formulating active biologic ingredients into the final dosage form for incorporation into such product, packaging, physical and regulatory labeling and other finishing activities, quality control testing and quality assurance, in each case with respect to such product, and further including the storing and processing of data related to the foregoing activities.  For clarity, Manufacturing shall include the manufacture of preclinical, non-clinical, engineering, validation, clinical and commercial batches of such Product.  “Manufacturing” and “Manufactured” have correlative meanings.

1.47.“Manufacturing Technology Transfer Plan” means a plan prepared by the [***]for the Manufacture of the Product from MSB or its CMO to a Third Party Manufacturer designated by Grünenthal.

1.48.“Marketing Approval” means, with respect to a [***]product (including the Product) in a particular jurisdiction, approval (whether accelerated, conditional or unconditional, including supplements, amendments, variations and pre-post-approvals) or other permission (excluding Pricing Approvals) by the applicable Regulatory Authorities sufficient to initiate marketing and sales of such product in such jurisdiction.

-12-

 

 

1.49.“Medical Affairs Activities” means devising, planning and executing medical affairs strategies and activities, including articulation of scientific and clinical value, data generation (including generation of real world evidence), publication strategy, medical education activities, congress activities, defining medical and science liaison (“MSL”) deployment strategies and scientific story flows, conducting other activities traditionally conducted by MSLs, health economics and outcomes researchers and other individuals having similar functions, including gathering and maintaining user feedback, medical and pharmacovigilance information and establishing and maintaining one or more call centers in connection therewith, and developing and maintaining partnerships with key opinion leaders.

1.50.“MPCs” (mesenchymal precursor cells) means a population of cells that [***]

1.51.“MSB Improvements” means any and all improvements, modifications or enhancements of Product, any component of Product, or the use, Manufacture, delivery, or formulation of Product Controlled by MSB.  For clarity, Know-How comprising and Patents claiming MSB Improvements shall be included within Product Technology.

1.52.“MSB Loan Agreement” means the loan and security agreement between [***]. 

1.53.“MSB MPC Platform” means MSB’s and/or its Affiliates’ proprietary regenerative medicine platform comprising the use of a population of cells [***].

1.54.“Net Sales” means gross amounts invoiced by Grünenthal, its Affiliates or any Third Party sublicensee acting under the authority of Grünenthal (each, a “Selling Party”) for sales of Product (in final labeled and packaged form, together with any component, agent, delivery device, or dispensing device required by the applicable Marketing Approval) less the following:  [***]in each case as determined from books and records of the Selling Party maintained in accordance with Accounting Standards.  Sales of Product between or among any Selling Parties shall be excluded from the computation of Net Sales except where such sales are solely intended for end use by that Selling Party who is purchasing, but Net Sales shall include the subsequent final sales to Third Party customers by a Selling Party.  If a sale, transfer or other disposition with respect to Product involves consideration other than cash or is not at arm’s length then the Net Sales from such sale, transfer or other disposition shall be the arm’s length fair market value that would have been invoiced by the Selling Party, which generally will mean the Selling Party’s average sales price in the relevant country for the Relevant Period.  Any amount described in clauses (a) through (e), inclusive, shall only be deducted once regardless of whether such amount is described in more than one (1) clause under this Section 1.54.

-13-

 

 

All of the foregoing shall be calculated in accordance with the local Accounting Standards.  With respect to each Annual Period for which Net Sales are calculated, there shall be included appropriate accruals for all of the items listed in clauses (a) through (e) of the immediately preceding paragraph, calculated in accordance with the Accounting Standards, as increased or decreased (as applicable) by the difference between actuals and accruals for all such items in the prior Annual Period.  A sale of a Product is deemed to occur in accordance with the Accounting Standards.

1.55.“New Phase III Clinical Trial” means the second phase 3 clinical trial program for the Product conducted and controlled by MSB for the purpose of generating data intended to enable (a) Marketing Approval by the FDA and (b) potentially (i) Marketing Approval by the EMA and (ii) Pricing Approval in the Territory, in each case ((a) and (b)) for the Product within the Field, and conducted by or on behalf of MSB pursuant to a clinical trial protocol and statistical analysis plan consistent with the parameters of the clinical TPP (set forth in Part A of Exhibit 1.86 hereto) as may be modified to address input received by MSB from any relevant IRB, EC or Regulatory Authority. 

1.56.“Non-Product-Specific Patent” means any Product Patent that is not a Product-Specific Patent.

1.57.“Other MSB MPC [***]Product” means a [***].

1.58.“Other MSB [***]Product” means a [***]

1.59.“Patent” means any of the following, whether existing now or in the future anywhere in the Territory: (a) any issued patent, including inventor’s certificates, substitutions, extensions, confirmations, reissues, re-examination, renewal, supplemental protection certificates, any counterparts claiming priority therefrom, or any like governmental grant for protection of inventions, and any patents resulting from any post-grant proceeding involving any of the foregoing; and (b) any pending patent application (or application for any of the foregoing), including any continuation, divisional, substitution, continuation-in-part, provisional and converted provisional applications.

1.60.“Person” means any individual, corporation, partnership, association, joint-stock company, trust, unincorporated organization or government or political subdivision thereof. 

1.61.“Pricing Approval” means the approval, agreement, or determination by the competent (quasi-) governmental authority (including national health technology assessment bodies (“HTA”)) establishing the commercial reimbursed price for the Product for the applicable country(ies) within the Territory for the complete patient population in line with the inclusion criteria of the New Phase III Clinical Trial and, if applicable, any additional Europe-specific Phase III Clinical Trial.

-14-

 

 

1.62.“Product” means that certain formulation of rexlemestrocel-L (USAN), known as MPC-06-ID (“MPC-06-ID”), in all presentations, together with such modifications, or lifecycle updates and label extensions to such formulation as may be Developed under this Agreement ([***]

1.63.“Product Asset” means (i) any Product-Specific Patent in the Territory and (ii) any other intellectual property right, material (including donor cell banks), information, data or other asset owned or Controlled by MSB or any of its Affiliates and necessary for or used primarily in the Development of the Product for the Field for the Territory. 

1.64.“Product Know-How” means any and all Know-How Controlled by MSB or its Affiliates during the Term that is necessary or useful for the Development, Manufacture or Commercialization of, or conduct of Medical Affairs Activities for, Product [***]within the Field for the Territory in accordance with this Agreement.  For clarity, Product Know-How shall include Know-How comprising (a) MSB Sole Inventions, (b) MSB’s interest in Joint Inventions and (c) MSB Improvements.

1.65.“Product Patents” means any and all Patents in the Territory Controlled by MSB or its Affiliates during the Term claiming [***]  As at the Amendment and Restatement Date, the Product Patents are as set out at Exhibit 1.65 and Exhibit 1.67, and MSB will periodically (and, in any event, at least once every six (6) months) update the lists to reflect changes thereto during the Term.

1.66.“Product Technology” means Product Patents and Product Know-How.

1.67.“Product-Specific Patent” means any Product Patent that (a) is listed on Exhibit 1.67, (b) is created (via claim amendments, continuing application or otherwise) pursuant to Section 10.2.4 or (c) contains only Product-Specific Claims. “Product-Specific Claim” means any claim within a Patent with only one or more of the following within its scope and no other material subject matter:[***]  A list of Product-Specific Patents is set out at Exhibit 1.67, and MSB will periodically (and, in any event, at least once every six (6) months) update the list to reflect updates thereto during the Term; provided, however, that MSB shall not remove any Patents from the list, unless and until such Patent has expired. 

1.68.“Prosecution and Maintenance” means, with respect to a Patent, (a) the preparing, filing, prosecuting and maintenance of such Patent (including conducting all correspondence and interactions with any government office or court having jurisdiction over the same), including the right to apply for Patents pursuant to The Agreement on Trade-Related Aspects of Intellectual Property Rights or pursuant to any other convention, treaty, agreement or 

-15-

 

 

understanding and (b) seeking, conducting or defending re‐examinations, reissues, requests for Patent term extensions and the like with respect to such Patent, together with the conduct of interferences, inter partes reviews, post-grant reviews, the defense of oppositions and other similar proceedings with respect to the particular Patent (whether before or after issuance); and “Prosecute and Maintain” and “Prosecuting and Maintaining” have their correlative meanings.

1.69.“Quarter” means a three (3) month period of each calendar year ending on March 31, June 30, September 30 or December 31, as applicable.  “Quarterly” has a correlative meaning.

1.70.“Regulatory Approval” means, with respect to a [***]product (including the Product) in a particular jurisdiction, any Marketing Approval, Pricing Approval and all clearances, approvals, licenses, registrations or authorizations necessary for the Development, Manufacture and Commercialization of such product in such jurisdiction, including any tissue bank licenses for the Manufacture of such product by the competent Regulatory Authority.  Regulatory Approvals include approvals (or other clearance) of applications or submissions filed with or submitted to any Regulatory Authority necessary to initiate or conduct any clinical trial in conformance with the requirements of such Regulatory Authority, but exclude any Pricing Approvals that are not required to be obtained prior to selling Product.

1.71.“Regulatory Authority” means any federal, national, multinational, state, provincial or local regulatory agency, department, bureau or other governmental entity with authority over the Development, Manufacture or Commercialization or other use or exploitation (including the granting of Regulatory Approvals) of Product in any jurisdiction, including (a) the EMA, ANVISA and Cofepris and (b) any relevant HTA in the Territory.

1.72.“Regulatory Materials” means regulatory applications (including MAAs), submissions, notifications, communications, correspondence, registrations, Regulatory Approvals or other filings made to, received from or otherwise conducted with a Regulatory Authority (including minutes of meeting with any Regulatory Authority) that are necessary or relate to the Development, Manufacture or Commercialization of, or conduct of the Medical Affairs Activities for, Product within the Field for the Territory.

1.73.“Reimbursement Net Price” means the [***](the “Net Price Determination Date”).

1.74.“Relevant Date” means (a) with respect to any representation, warranty or covenant given pursuant to Article 11 as of the Effective Date, the Effective Date and (b) with respect to any representation, warranty or covenant given pursuant to Article 11 as of the Amendment and Restatement Date, the Amendment and Restatement Date.

-16-

 

 

1.75. “Relevant Period” means a six (6) month period of each calendar year ending on June 30 or December 31, as applicable.

1.76.“Results Package” means a package of the complete data and results from [***]

1.77.“Royalty Period” means: [***]

1.78.“Royalty Start Date” means [***]

1.79.“Specifications” means, with respect to the Product, those written specifications for the Product appended at Exhibit 1.79, as may be amended as set forth herein. 

1.80.“Tax” or “Taxes” means any and all taxes, duties, imposts, charges, withholdings, rates, levies and other governmental impositions and other taxes of any kind whatsoever imposed, assessed or charged.

1.81.“Taxing Authority” means any governmental authority responsible for the imposition, assessment or collection of any Tax.

1.82.“Territory” means (a) Argentina, Belize, Bolivia, Brazil, Chile, Colombia, Costa Rica, Cuba, Dominican Republic, Ecuador, El Salvador, French Guiana, Guatemala, Guyana, Haiti, Honduras, Mexico, Nicaragua, Panama, Paraguay, Peru, Suriname, Uruguay and Venezuela (including in each case, any and all territories thereof, individually and collectively, “Latin America”); (b) Aruba, Anguilla, Antigua and Barbuda, Barbados, Bermuda, British Virgin Islands, Cayman Islands, Co-operative Republic of Guyana, Collectivity of Saint Martin, Commonwealth of the Bahamas, Commonwealth of Dominica, Curaçao, Dominican Republic, Federation of Saint Christopher and Nevis (Saint Kitts and Nevis), Grenada, Guadeloupe, Jamaica, Martinique, Montserrat, Republic of Suriname, Republic of Trinidad and Tobago, Saint Barthélemy, Saint Lucia, Sint Maarten, Saint Martin, Saint Vincent and the Grenadines and Turks and Caicos Islands (including in each case, any and all territories thereof, individually and collectively, the “Caribbean”) and (c) the member states of the European Union, the member states of the European Economic Area, the United Kingdom and Switzerland (including in each case, any and all territories thereof, individually and collectively, “Europe”). For avoidance of doubt, a country will be considered a part of Europe even if it ceases to be a member state of the European Union or the European Economic Area during the Term.

1.83.“Third Party” means any Person other than MSB, Grünenthal or their respective Affiliates.

1.84.“Third Party Competitive Product” means any Competing Product sold by a [***].

-17-

 

 

1.85.“Third Party Manufacturer” means any CMO and any other Third Party that (i) Manufactures the Product (in whole or in part), (ii) Manufactures any materials used in the Manufacture of the Product or (iii) supplies materials used in the Manufacture of the Product.

1.86.“TPP” means the target product profiles set out at Exhibit 1.86, as may be amended in accordance with Section 15.9.  

1.87.“Trademark” means any trademark, trade name, service mark, service name, brand, domain name, trade dress, logo, slogan or other indicia of origin or ownership in or available in the Territory, including registrations and applications therefor as well as any unregistered rights therein and the goodwill and activities associated with each of the foregoing.

1.88.“Valid Claim” means in relation to a Product-Specific Patent in the Territory, [***]

1.89.“Xeno-Free Product” means any formulation of the Product that is [***]

1.90.Additional Definitions.  Each of the following definitions shall have the meanings defined in the corresponding sections of this Agreement indicated below:

 

-18-

 

 

 

 

 

	
Defined Term
	
 
	
Section

	
Acquiring Entities
	
 
	
1.16

	
[***]Intent Notice
	
 
	
3.8.2

	
[***]Negotiation Period
	
 
	
3.8.3

	
[***]Acquisition Transaction
	
 
	
1.16

	
Actual Supply Price
	
 
	
Exhibit 7.4.1

	
Additional LE/LCM Activities
	
 
	
5.5

	
Agreement
	
 
	
Preamble

	
Alliance Manager
	
 
	
2.7

	
Announcing Party
	
 
	
11.5.1(c)

	
BLA
	
 
	
1.20

	
Caribbean
	
 
	
1.82

	
CCDS
	
 
	
8.1.3(a)

	
Challenge
	
 
	
13.5

	
CMC
	
 
	
4.2.3

	
Co‐Chair
	
 
	
2.2

	
Commercialization Plan
	
 
	
6.2

	
Committee
	
 
	
2.2

	
Competing Activities
	
 
	
3.5.1

	
Confidential Information
	
 
	
11.1

	
Continuation
	
 
	
4.9.2

	
Continuation Date
	
 
	
4.9.4(a)

	
Continuation Development Plan
	
 
	
5.3.1

	
Continuation Notice
	
 
	
4.9.2

	
Continuation Trigger Fee
	
 
	
4.9.4(b)

	
Control Affiliate
	
 
	
3.5.2(a)

	
Control Transaction
	
 
	
3.5.2(a)

	
Controlled Party
	
 
	
3.5.2(a)

	
CRB
	
 
	
6.8

	
Defending Party
	
 
	
10.3

	
Direct Supply Agreement
	
 
	
7.4

	
Discounts
	
 
	
6.5

	
Dispute
	
 
	
14.1

	
Divest
	
 
	
3.5.2(c)

	
Divestiture
	
 
	
3.5.2(c)

	
EC
	
 
	
1.33

	
eCTD
	
 
	
1.26

	
Effective Date
	
 
	
Preamble

	
Enforcement Action
	
 
	
10.4.2

	
Defined Term
	
 
	
Section

	
Enforcing Party
	
 
	
10.4.4

	
Europe
	
 
	
1.82

	
Fair Economic Terms
	
 
	
3.2.3

	
Gain Share Price
	
 
	
Exhibit 7.4.1

	
GRT
	
 
	
Preamble

	
GRT Sole Inventions
	
 
	
10.1

	
GRT Sole Patents
	
 
	
10.1

	
Grünenthal
	
 
	
Preamble

	
Grünenthal Indemnitees
	
 
	
12.5.1

	
Grünenthal Intent Notice
	
 
	
3.7.2

	
Grünenthal Rights
	
 
	
3.1.1(a)

	
Guaranteed Supply Price
	
 
	
Exhibit 7.4.1

	
HTA
	
 
	
1.61

	
HTA Meeting
	
 
	
5.4.2

	
ICC Rules
	
 
	
14.4.2

	
ICD Expert
	
 
	
Exhibit 2.9

	
ICD Proposal
	
 
	
Exhibit 2.9

	
Improvement Compensation Dispute
	
 
	
3.2.3

	
IMS
	
 
	
9.1.6(c)

	
Indemnify
	
 
	
12.5.1

	
Initial Development Plan
	
 
	
4.3

	
Initial European Marketing Approval
	
 
	
Exhibit 9.1.2

	
Initial Regulatory Meeting
	
 
	
5.4

	
IRB
	
 
	
1.33

	
Joint Inventions
	
 
	
10.1

	
Joint Patents
	
 
	
10.1

	
JSC
	
 
	
2.1.1

	
Latin America
	
 
	
1.82

	
LIBOR
	
 
	
9.5

	
Lonza
	
 
	
Exhibit 7.4.1

	
Losses
	
 
	
12.5.1

	
Manufacturing Change
	
 
	
Exhibit 7.4.1

	
Marking Date
	
 
	
Exhibit 7.4.1

	
Mesoblast Limited
	
 
	
Preamble

	
Mesoblast Sàrl
	
 
	
Preamble

	
MD Proposal
	
 
	
Exhibit 2.9

	
Milestone Dispute
	
 
	
2.9

	
Milestone Event
	
 
	
9.1.2

	
Milestone Payment
	
 
	
9.1.2

 

-19-

 

 

 

 

 

	
Defined Term
	
 
	
Section

	
MD Expert
	
 
	
Exhibit 2.9

	
MD Proposal
	
 
	
Exhibit 2.9

	
MPC-06-ID
	
 
	
1.62

	
MSB
	
 
	
Preamble

	
MSB Indemnitees
	
 
	
12.5.2

	
MSB Insolvency Event
	
 
	
13.6.2

	
MSB Rights
	
 
	
3.2.1

	
MSB Sole Inventions
	
 
	
10.1

	
MSB Sole Patents
	
 
	
10.1

	
MSB/GRT[***] 
	
 
	
3.7.3

	
Net Price Determination Date
	
 
	
1.73

	
Other Dispute
	
 
	
14.3

	
Other MSB [***]Notice
	
 
	
3.7.1

	
[***]Period
	
 
	
3.7.3

	
Party, or Parties
	
 
	
Preamble

	
Paying Party
	
 
	
13.4.2

	
Prior Understandings
	
 
	
11.3

	
Process Improvement
	
 
	
7.4.2

	
[***]Notice
	
 
	
3.8.1

	
Product Marks 
	
 
	
10.8

	
Product-Specific Claim
	
 
	
1.67

	
Public Announcement
	
 
	
11.5.1(b)

	
Receiving Party
	
 
	
13.4.2

	
Regulatory Manufacturing Change
	
 
	
Exhibit 7.4.1

	
Defined Term
	
 
	
Section

	
Reminder Notice
	
 
	
13.4.2

	
Required European Patients
	
 
	
4.4

	
Royalty
	
 
	
9.1.3

	
Royalty Tier 1
	
 
	
Exhibit 9.1.3

	
Royalty Tier 2
	
 
	
Exhibit 9.1.3

	
Royalty Tier 3
	
 
	
Exhibit 9.1.3

	
Royalty Tier 4
	
 
	
Exhibit 9.1.3

	
Agreement
	
 
	
3.8.3

	
SDE Agreement
	
 
	
8.5

	
Selling Party
	
 
	
1.54

	
Signature Fee
	
 
	
9.1.1

	
Subject Affiliate
	
 
	
3.5.2(b)

	
Subject Party
	
 
	
3.5.2(b)

	
Subject Transaction
	
 
	
3.5.2(b)

	
Supply Price Offset
	
 
	
Exhibit 7.4.1

	
Term
	
 
	
13.1

	
Third Party Claim
	
 
	
12.5.1

	
Third Party[***] Transaction
	
 
	
3.7.4

	
Third Party Project Technology Agreements
	
 
	
12.3.1

	
Third Party [***] Agreement
	
 
	
3.8.4

	
Treatment
	
 
	
Exhibit 7.4.1

 

 

 

 

 

 

-20-

 

 

 

1.91.Interpretation. The captions and headings to this Agreement are for convenience only and are of no force or effect in construing or interpreting any of the provisions of this Agreement.  Unless specified to the contrary, references to Articles, Sections or Exhibits mean the particular Articles, Sections or Exhibits to this Agreement and references to this Agreement include all Exhibits hereto.  Unless expressly determined otherwise, whenever used in this Agreement:  (a) the words “include” or “including” shall be construed as incorporating, also, “but not limited to” or “without limitation;” (b) the word “day” or “year” means a calendar day or year unless otherwise specified; (c) the word “notice” means notice in writing (whether or not specifically stated) and shall include notices, consents, approvals and other communications contemplated under this Agreement; (d) the words “hereof,” “herein,” “hereby” and derivative or similar words refer to this Agreement (including any Exhibits); (e) provisions that require that a Party, the Parties or a Committee hereunder “agree,” “consent” or “approve” or the like shall require that such agreement, consent or approval be specific and in writing, whether by written agreement, letter, approved minutes or otherwise; (f) words of any gender include the other gender; (g) words using the singular or plural number also include the plural or singular number, respectively; (h) references to any specific law, rule or regulation, or article, section or other division thereof, shall be deemed to include the then-current amendments thereto or any replacement law, rule or regulation thereof; (i) each accounting term not otherwise defined in this Agreement has the meaning assigned to it in accordance with Accounting Standards and any particular cost or expense shall be accounted for only once; and (j) neither Party or its Affiliates shall be deemed to be acting “on behalf of” or “under authority of” the other Party.

1.92.Conflicts. If there is any conflict or inconsistency between (a) any terms of this Agreement and (b) any terms of the SDE Agreement, unless expressly stated otherwise the terms of this Agreement shall take precedence, provided that the terms of the SDE Agreement shall take precedence in relation to any drug safety or pharmacovigilance matter relating to the Product supplied hereunder.

Article 2
GOVERNANCE

2.1.Joint Steering Committee.

2.1.1Establishment.  Promptly after the Effective Date, Grünenthal and MSB shall establish a joint steering committee (the “JSC”) to oversee the following activities of each Party under this Agreement: (i) the Development of Product, (ii) the clinical Manufacture of Product and (iii) such other activities as are described in Section 2.1.2, in each case within the Field for the Territory and as described below.

-21-

 

 

2.1.2Responsibilities.  The JSC shall be responsible for:

(a)Providing high-level strategic direction to and coordinating the Parties’ respective activities with respect to matters pertaining to (i) the Development and Manufacture for Product within the Field for the Territory, and (ii) the filing for, obtaining and maintaining of Regulatory Approvals for Product within the Field for the Territory;

(b)Performing such other duties as are specifically assigned to the JSC in this Agreement; and

(c)Resolve any disputes that arise in any Sub-Committees.

2.2.Membership.  The JSC and each Sub-Committee created pursuant to Section 2.5.1(b) (each a “Committee”) shall consist of an equal number of representatives from each of MSB and Grünenthal, and unless otherwise agreed on such number, with respect to the JSC,[***]  Each Party shall ensure that its representatives of any committee shall be of suitable seniority, have suitable experience and have appropriate authority having regard to the activities and responsibilities of the relevant committee.  Either Party may replace its respective representative(s) to any Committee at any time with prior notice to the other Party, provided that such replacement is of comparable authority and scope of responsibility within that Party’s organization as the individual he or she is replacing, but may represent a different discipline (e.g., clinical vs. manufacturing).  Unless otherwise agreed by the Parties,[***]  Without limiting the foregoing, each Party shall appoint one of its representatives to the JSC to co‐chair the meetings of the JSC (each, a “Co‐Chair”).  The Co‐Chairs, working together, shall (a) coordinate and prepare the agenda (which agenda shall include all matters requested by a JSC representative from either Party) and ensure the orderly conduct of the JSC’s meetings, (b) each attend (subject to the below) each meeting of the JSC, and (c) alternating between the Co-Chairs, prepare and issue minutes of each meeting within [***]thereafter accurately reflecting the discussions and decisions of the JSC at such meeting.  Such minutes from each JSC meeting shall be finalized only when the Co‐Chair from each Party has reviewed and confirmed the accuracy of such minutes in writing, which each Party shall endeavor to complete within ten (10) Business Days of the issuance thereof.  The Co‐Chairs shall solicit agenda items from the other JSC representatives and provide an agenda along with appropriate information for such agenda reasonably but not less than [***]in advance (to the extent possible) of any meeting.  The Parties agree that unless the Co-Chair from each Party agrees otherwise, at each meeting of the JSC, the JSC shall review the progress of the activities, if any, under the Development Plan (until completed).  In the event the Co‐Chair or another representative of the JSC from either Party is unable to attend or participate in any meeting of the JSC, the Party who appointed such Co‐Chair or representative may appoint a substitute Co‐Chair or other representative for the meeting.

-22-

 

 

2.3.Meetings.  Each Committee shall hold meetings (either in person or by teleconference) at such times and places as the Parties may mutually agree as necessary for such Committee to conduct its responsibilities, provided that, unless the Parties otherwise agree, the JSC shall meet at least [***]until such time as all Development and Manufacturing activities to be conducted under this Agreement are complete.  Each Party shall bear its own costs associated with attending such meetings.  As appropriate, a reasonable number of other employees or consultants of a Party or its Affiliate may attend Committee meetings as nonvoting observers, but no Third Party personnel may attend unless expressly agreed by the Parties (such agreement not to be unreasonably withheld, conditioned or delayed).  Each Party may also call for special meetings to address matters requiring prompt attention with at least [***](or such shorter period as necessary to address exigent or other time-critical matters) to resolve particular matters identified by such Party in such notice.

2.4.Initial Period.  During the Initial Period, the JSC shall have no decision-making authority and shall act solely as the forum for the Parties to discuss the Initial Development Plan and the progress of MSB’s Development activities in relation to the Initial Development Plan, in accordance with Sections 4.3 and 4.6.

2.5.Governance Following the Continuation Date.

2.5.1Agreement of Governance Structure.  As soon as reasonably practicable after the Continuation Date, and in any event within ninety (90) days after the Continuation Date, the Parties shall discuss and agree the governance structure that shall be applicable to the Parties’ relationship under this Agreement for the remainder of the Term.  The details of such governance structure shall (subject to the Parties’ agreement) include:

(a)details of the JSC’s roles and responsibilities for the remainder of the Term;

(b)details of any sub-committees or working groups that will operate under, and report to, the JSC (each a “Sub-Committee”), including the scope of each Sub-Committee’s responsibilities; and

(c)details of any matters for which one Party shall have final decision making authority.

2.5.2Post Continuation Date Decision Making.  Following the Continuation Date, decisions of each Committee shall be made by consensus, with each Party having one (1) vote.  Each Party shall work in good faith to reach consensus on matters and act in the general spirit of cooperation (taking into consideration the scope of such Committee’s authority and the principles set forth in Section 2.6.2) and in no event shall either Party unreasonably withhold, condition or delay any approval or other decision of a Committee hereunder.  In the event a Sub-Committee fails to reach consensus with respect to a particular matter within [***]

2.5.3[***]

-23-

 

 

2.6.Committee Authority.

2.6.1General.  Notwithstanding the creation of the JSC and any Sub-Committee, each Party retains the rights, powers and discretion granted to it hereunder, and no Committee shall be delegated or vested with rights, powers or discretion unless such delegation or vesting is expressly provided herein, or the Parties expressly so agree.  No Committee has the power to (a) amend, modify or waive compliance with this Agreement or act in a manner which is otherwise inconsistent with the express terms of this Agreement, (b) to determine whether or not a Party has met its diligence or other obligations under the Agreement, or (c) to determine whether or not a breach of this Agreement has occurred, and no decision of any Committee shall be in contravention of any terms and conditions of this Agreement.  It is understood and agreed that issues to be formally decided by the JSC and any Sub-Committee, as applicable, are only those specific issues that are expressly provided in this Agreement or agreed pursuant to Section 2.5 to be decided by the JSC and any such Sub-Committee, as applicable.  Subject to the foregoing, decisions of the JSC shall be binding on the Parties.

2.6.2Guiding Principles.  Each Committee shall perform its responsibilities under this Agreement, including with respect to Development and Manufacture of Product within the Field for the Territory, in a manner which (i) is consistent with good pharmaceutical practices (including applicable cGxP) and (ii) is for the benefit of the Product franchise.

2.6.3Commercialization Considerations.  The Parties acknowledge and agree that, although the JSC shall have no decision-making authority with respect to Commercialization of the Product in the Field in the Territory, the JSC shall have due regard to relevant Commercialization considerations when discussing and agreeing any matter that does fall within its responsibility.  In accordance with Section 2.3, each Party may invite representatives from its commercial function to attend JSC meetings as nonvoting observers in order to make representations about Commercialization considerations relevant to any matter falling within the JSC’s responsibility.

2.7.Alliance Managers.  Promptly after the Effective Date, each Party shall appoint an individual to act as alliance manager for that Party (each, an “Alliance Manager”).  The Alliance Managers shall be the primary point of contact for the Parties with respect to the activities to be conducted under this Agreement.  The name and contact information for the Alliance Managers, as well as any replacement(s) chosen by either Party in their sole discretion from time to time, shall be promptly provided to the other Party in writing.

2.8.Day-to-Day Responsibilities.  Each Party shall: (a) be responsible for day-to-day implementation and operation of the activities hereunder for which it has or is otherwise assigned responsibility under this Agreement, provided that such implementation is not inconsistent with the express terms of this Agreement or the decisions of a Committee within the scope of its authority specified herein; and (b) keep the other Party informed as to the progress of such activities as reasonably requested by the other Party and as otherwise determined by this Agreement and/or the JSC.

-24-

 

 

2.9.Expert Determination. If, within [***]of the date on which the matter is referred to the Senior Executives in accordance with Section 14.3, the Parties are unable to resolve any dispute as to whether a Milestone Event has occurred (a “Milestone Dispute”), the Parties shall refer the matter to binding expert determination in accordance with the procedure in Part A of Exhibit 2.9.

2.10.Key Persons.

2.10.1MSB shall ensure that each Key Person (for so long as she or he remains in the employ or a consultant of MSB) devotes such portion of his or her time to activities under the Development Plan as is reasonably necessary to satisfy MSB’s Development obligations with respect thereto under this Agreement.  

2.10.2MSB shall ensure that each Key Person remains engaged on activities under the Development Plan (as required by Section 2.10.1) unless:

(a)the relevant Key Person is unable to perform such activities due to (i) serious illness, death or any analogous circumstance, (ii) the relevant Key Person is absent due to maternity or paternity leave (or leave for any other legal right which he or she may have) or (iii) the relevant Key Person leaves MSB’s employment for any reason (provided that MSB shall act reasonably and have due regard to the relevant Key Person’s role in the Development activities hereunder as a key consideration when considering whether to terminate that Key Person’s employment); 

(b)the Development activities for which that Key Person is responsible are completed; or

(c)Grünenthal gives its prior written consent (not to be unreasonably withheld, conditioned or delayed) that the Key Person can be removed or changed. 

2.10.3MSB shall use all reasonable endeavours to ensure that: 

(a)where, in accordance with Section 2.10.2, any Key Person ceases to be engaged on activities under the Development Plan, a replacement for that Key Person is appointed as soon as reasonably practicable and the role of that Key Person is not vacant for any longer than thirty (30) days; 

(b)any replacement Key Person is qualified and experienced in all material respects as the Key Person he or she is replacing, and is fully competent to carry out the tasks assigned to the Key Person under the Development Plan; and 

(c)there is a sufficient period of handover to allow for effective knowledge transfer from the former Key Person to the replacement Key Person, to the extent practicable under the circumstances.  

2.10.4Without limiting the foregoing, MSB shall ensure that the role of any Key Person being replaced is reasonably covered by a suitable, appropriately qualified and experienced 

-25-

 

 

temporary replacement during any period when the relevant role is vacant.  Any replacement Key Person shall be added by the Parties to the list in Exhibit 2.10.1.

2.10.5MSB shall ensure that it allocates sufficient personnel (in terms of (i) numbers of employees and consultants, (ii) expertise and experience of personnel and (iii) seniority of personnel) to the Development activities for which it is responsible hereunder in order to adequately conduct those activities in accordance with the Development Plan and the other requirements of this Agreement. Without prejudice to the generality of the foregoing, if the Development Plan specifies a number of employees and/or consultants to be allocated to any Development activity, MSB shall ensure that, as a minimum, it allocates at least that number of employees and/or consultants to the relevant activity.

2.10.6Any material breach of this Section 2.10 by MSB shall be a material breach of this Agreement.

 

Article 3
RIGHTS AND EXCLUSIVITY

3.1.Rights of Grünenthal.

3.1.1General.

(a)Subject to the terms and conditions of this Agreement, MSB hereby grants Grünenthal the following rights under the Product Technology: (i) the exclusive (subject to MSB’s reservation of rights as expressly set forth herein) right to conduct Development activities anywhere in the world for the purpose of Developing Product within the Field for the Territory; (ii) the exclusive right to Commercialize (including to use, sell, have sold, offer for sale, have offered for sale, export and import) solely within the Field in the Territory and conduct Medical Affairs Activities for Product solely within the Field for the Territory; (iii) the exclusive (subject to MSB’s reservation of rights as expressly set forth herein) right to conduct regulatory activities (including filing for MAAs and obtaining and maintaining Marketing Approvals) in support of Grünenthal’s activities described in (i) and (ii) of this Section 3.1.1(a) and Article 7, including the right to use the Data Package and Dossier (and, to the extent disclosed to Grünenthal by MSB, equivalents of the Data Package and Dossier submitted to any Regulatory Authority outside the Territory) for any such regulatory activities; and (iv) the exclusive right to conduct any market access activities for the Territory, including obtaining Pricing Approvals and interacting with HTAs with respect to the Product solely within the Field in the Territory; and (v) the non-exclusive right to Manufacture Product anywhere in the world in support of Grünenthal’s activities described in (i) to (iv) (such rights collectively, the “Grünenthal Rights”).  

(b)The licences granted pursuant to Section 3.1.1(a) shall (i) [***]and (ii) be sub-licensable in accordance with Section 3.1.2.

(c)Grünenthal’s exercise of the Grünenthal Rights (i) to conduct Development shall be in accordance with the Continuation Development Plan and Article 5; (ii) to conduct Commercialization and Medical Affairs Activities shall be in accordance with the 

-26-

 

 

Article 6; (iii) to conduct regulatory activities shall be in accordance with Article 8; and (iv) to conduct Manufacturing activities shall be in accordance with Article 7.  

(d)Notwithstanding the exclusivity of the rights granted to Grünenthal:  (A) MSB shall continue to have the right to practice Grünenthal Rights for purposes of performing the Development activities assigned to MSB under the Development Plan and the regulatory activities for which MSB is expressly responsible for or assigned to conduct under this Agreement and (B) MSB shall continue to have the right to Develop and Manufacture Product in the Territory to support the Development and Commercialization of Product outside the Territory as set forth in Section 3.2.1.

3.1.2Use of Affiliates and Third Parties.

(a)Grünenthal may exercise the Grünenthal Rights through its Affiliates, and may grant to its Affiliates such Grünenthal Rights under the Product Technology in connection therewith, provided that any failure by such Affiliate to comply with the terms of this Agreement shall be treated as a breach of this Agreement by Grünenthal. 

(b)Neither Grünenthal nor any of its Affiliates may exercise the Grünenthal Rights, or discharge its obligations under this Agreement, with respect to Development activities under the Development Plan through any Third Party without the prior written consent of MSB (such consent not to be unreasonably withheld, conditioned or delayed); provided that no such consent shall be necessary for use of the Third Parties described in the Development Plan (including the contract research organizations named therein). 

(c)Grünenthal may exercise the Grünenthal Rights, or discharge its obligations under this Agreement, through any Third Party, and may grant to such Third Parties such Grünenthal Rights under the Product Technology in connection therewith provided that (i) any such appointment of, and sublicensing to, a Third Party shall not result in Grünenthal no longer maintaining material control of and responsibility for the activities for which Grünenthal is responsible hereunder, and (ii) any failure by such Third Party to comply with the terms of this Agreement shall be treated as a breach of this Agreement by Grünenthal.

3.2.Rights of MSB.

3.2.1General.  Subject to the terms and conditions of this Agreement, MSB has the following rights (collectively, the “MSB Rights”): (a) the right to conduct those activities assigned to it under the Development Plan as described in this Section 3.2 and Articles 4 and 5; (b) the right to conduct regulatory activities in support of MSB’s activities described in (a) of this Section 3.2.1 pursuant to Article 8; and (c) the right to access and use (and grant Third Parties the right to access and use) Regulatory Materials and Data generated with respect to Product for purposes of Developing, Manufacturing and Commercializing and conducting Medical Affairs Activities for Ex-Field Products in or outside the Territory or the Product outside the Territory. For clarity, MSB reserves the right to, itself or through its Affiliates or Third Parties, Develop, Manufacture, Commercialize and conduct Medical Affairs Activities for Product within the Field for sale and use outside of the Territory.

-27-

 

 

3.2.2Use of Affiliates and Third Parties.

(a)MSB may exercise the MSB Rights or discharge its obligations under this Agreement through its Affiliates, provided that any failure by such Affiliate to comply with the terms of this Agreement shall be treated as a breach of this Agreement by MSB.  Upon Grünenthal’s request, MSB shall identify those of its Affiliates that are exercising the MSB Rights.

(b)Neither MSB nor any of its Affiliates may exercise the MSB Rights described in Section 3.2.1(a) or (b), or discharge any related obligations under this Agreement, through any Third Party without the prior written consent of Grünenthal, such consent not to be unreasonably withheld, conditioned or delayed; provided that no such consent shall be necessary for use of (i) the Third Parties described in the Development Plan (including the contract research organizations named therein) or (ii) the CMOs listed in Exhibit 1.11.  For clarity, neither MSB nor any of its Affiliates shall be required to obtain any consent for use of Third Parties in exercising its or their rights under Section 3.2.1(c).  Where any Third Party is used by MSB or its Affiliates in accordance with this Section 3.2.2(b), any failure by such Third Party to comply with the terms of this Agreement shall be treated as a breach of this Agreement by MSB.

3.2.3License to Grünenthal Improvements.  Subject to the terms and conditions of this Agreement, Grünenthal hereby grants to MSB a worldwide, non-exclusive license, with the right to grant and authorize sublicenses (except as provided below), under the GRT Improvement Patents to make, have made, use, sell, offer for sale and/or import products and services and otherwise exploit the GRT Improvement Patents (a) outside the Field in the Territory and (b) for all applications outside the Territory.  Such license shall be fully paid-up and royalty-free with respect to GRT Improvement Patents comprising improvements, modifications, or enhancements to the Manufacturing process. Otherwise, if MSB intends to commercially exploit any such GRT Improvement Patent, then MSB shall notify Grünenthal and the Parties shall negotiate in good faith commercially reasonable economic terms to compensate Grünenthal for the value attributable to the licence of such GRT Improvement Patent (“Fair Economic Terms”). If the Parties are unable to agree on such Fair Economic Terms within [***]of such notice (such failure to agree being an “Improvement Compensation Dispute”), the Parties shall refer the matter to binding expert determination in accordance with the procedure in Part B of Exhibit 2.9.

3.3.No Contravention.  MSB hereby covenants not to grant to any Third Party any right, authorization or license that is in contravention with the Grünenthal Rights including any license under the Product Technology with respect to Product within the Field for the Territory.  Similarly, Grünenthal hereby covenants not to grant to any Third Party any right, authorization or license that is in contravention or interferes with MSB’s license under the GRT Improvement Patents pursuant to Section 3.2.3.

3.4.No Other Rights.  Each Party acknowledges that the rights under this Article 3 and elsewhere in this Agreement are limited to the express scope thereof.  Accordingly, except for the rights expressly granted under this Agreement, no right, title, or interest of any nature whatsoever is granted, whether by implication, estoppel, reliance, or otherwise, by either Party to the other Party.  All rights with respect to Know-How, Patents or other intellectual 

-28-

 

 

property rights that are not specifically granted herein are reserved to the owner thereof.

3.5.Exclusivity of Efforts.

3.5.1Competing Activities. [***]and subject to Section 3.5.2, each Party agrees, on its behalf and on behalf of its Affiliates, not to (i) conduct, participate in or directly sponsor the Commercialization of a Competing Product in the Territory (collectively, such activities “Competing Activities”) or (ii) appoint, license or otherwise authorize any Third Party, whether pursuant to license, appointment or authorization or otherwise to perform any Competing Activities. For the avoidance of doubt, this Section 3.5.1 shall not survive termination of this Agreement for any reason.

3.5.2Post-Execution Transactions.

(a)In the event a Party (the “Controlled Party”) enters into any transaction (a “Control Transaction”) whereby a Third Party that is Commercializing a Competing Product acquires all or substantially all the assets or stock of the Controlled Party (such Third Party, a “Control Affiliate”), then the Controlled Party shall provide notice to the other Party within [***]after the closing of the Control Transaction, specifying the identity of the Control Affiliate and describing in reasonable detail, to the extent permitted by Applicable Law and without disclosing any proprietary information, the Competing Product and a description of the Competing Activities such Control Affiliate is currently engaged in with respect to such Competing Product.  Such notice shall also state whether the Controlled Party shall either: (i) Divest itself of the Competing Product for the Field in the Territory; or (ii) isolate any Competing Activities associated with the Competing Product to ensure that such activities are kept separate and independent of the Development, Manufacture and Commercialization of Product, including using reasonable efforts to ensure that no personnel involved in such Competing Activities have access to Know-How relating to Product (in the case of this clause (ii), any Know-How, Patent or other intellectual property right resulting from such Competing Activities shall not be included as Product Technology or GRT Know-How or GRT Patents under this Agreement, and nothing in this Agreement shall be construed to grant any rights or licenses to the other Party under such Know-How, Patent or other intellectual property right).  Thereafter, the Controlled Party (itself or through the Control Affiliate) shall use diligent efforts to promptly implement (and in the case of isolation, maintain) such election.  For clarity, neither the Controlled Party nor any Control Affiliate shall use, reference or practice any Product Technology or GRT Know-How or GRT Patents for the purpose of Developing or Commercializing any Competing Product.

(b)In the event a Party (the “Subject Party”) enters into any transaction during the Term (a “Subject Transaction”) whereby the Subject Party acquires an interest in, access to, or rights to a Competing Product that is being Commercialized in the Territory through the acquisition of the assets or stock of a Third Party or other transaction (other than a Control Transaction) with a Third Party (such Third Party, a “Subject Affiliate”), then the Subject Party shall (i) provide notice to the other Party within [***]after the closing of the Subject Transaction, specifying the identity of the Subject Affiliate and describing in reasonable detail, to the extent permitted by Applicable Law and without disclosing any proprietary information, the Competing Product and a description of the Competing Activities such Subject Affiliate is currently engaged 

-29-

 

 

in with respect to such Competing Product; and (ii) Divest itself of the Competing Product for the Field in the Territory.  Thereafter, the Subject Party (itself or through the Subject Affiliate) shall use diligent efforts to promptly implement such Divestiture.  For clarity, neither the Subject Party nor any Subject Affiliate shall use, reference or practice any Product Technology or GRT Know-How or GRT Patents for the purpose of Developing or Commercializing any Competing Product.  

(c)For purposes of this Section 3.5.2, “Divest” or “Divestiture” means, with respect to any Competing Product, (i) the sale, license or other transfer of all of the right, title and interest in and to such Competing Product within the Field in the Territory, including all technology, intellectual property and other assets relating solely thereto, to an independent Third Party (other than the Control Affiliate or Subject Affiliate), without the retention or reservation of any rights, license or interest (other than solely an economic interest and other customary reversionary rights) by the Controlled Party/Control Affiliate or Subject Party/Subject Affiliate (as applicable) in such Competing Product within the Field in the Territory and (ii) the complete shutdown of all development and commercialization activities with respect to such Competing Product so that no technology, intellectual property or other asset relating thereto is used by the Controlled Party/Subject Party or its Affiliates and delivery of written confirmation from the Controlled Party or Subject Party, as applicable, that it and its Affiliates covenant not to use any technology, intellectual property and assets solely relating to such Competing Product during the Term.

3.5.3Product.  During the Term, Grünenthal agrees, on its behalf and on behalf of its Affiliates, not to (i) Develop or Commercialize the Product for any applications outside the Field in the Territory or (ii) appoint, license or otherwise authorize any Third Party to Develop or Commercialize the Product for any application outside the Field in the Territory.  Accordingly, Grünenthal agrees that neither it, nor any of its Affiliates, will sell or provide Product to any Third Party if Grünenthal or its relevant Affiliate knows, or has reason to believe, that Product, sold or provided to such Third Party, would be sold or transferred, directly or indirectly, for use outside the Field or for use outside the Territory.  Grünenthal and its Affiliates shall promptly notify MSB in the event it or its Affiliate has reason to believe that any Product sold or otherwise distributed has been or will be used outside the Field or outside the Territory.  Grünenthal shall promptly cease selling or providing the Product to any Third Party that Grünenthal or its relevant Affiliate knows, or has reason to believe, sells or provides the Product for use outside the Field or for use outside the Territory.

3.5.4[***]

3.6.[***]

3.6.1[***]

3.7[***]

-30-

 

 

 

Article 4
DEVELOPMENT DURING INITIAL PERIOD

4.1.General.  Subject to Sections 4.4 and 4.5, during the Initial Period, MSB shall have the exclusive right and be solely responsible for the Development of the Product within the Field (including, for the avoidance of doubt,[***]) and shall use Commercially Reasonable Efforts to conduct the Development of Product within the Field for the Territory in accordance with this Article 4 and the Initial Development Plan.

4.2.MSB Development.  During the Initial Period, MSB will (itself or through its Affiliates or Third Parties) use Commercially Reasonable Efforts to conduct all Development activities with respect to the Product (including, for the avoidance of doubt,[***]) reasonably required or recommendable to perform the Initial Development Plan for the Product in the Field for the Territory save to the extent expressly stated otherwise in Section 4.5. Without limiting the foregoing, the Development activities for which MSB shall be responsible in accordance with this Section 4.2 shall include:

4.2.1the conduct of the [***]

4.2.2the conduct of[***]; and

4.2.3the conduct of the [***],

each as set forth in the Initial Development Plan. 

All the activities under this Section 4.2 shall be conducted in accordance with the Initial Development Plan as provided by MSB to Grünenthal from time to time in accordance with Section 4.3.  All Development activities under this Section 4.2 shall be conducted in accordance, to the extent applicable, with the applicable TPPs (including (i) the conduct of the New Phase III Clinical Trial in accordance with a clinical trial protocol and statistical analysis plan consistent with and including the parameters of the clinical TPPs set forth in Part A of Exhibit 1.86 and (ii) the conduct of all CMC activities in accordance with the CMC TPPs set forth in Part B of Exhibit 1.86).

4.3.Initial Development Plan.  Within [***]of the Amendment and Restatement Date, MSB shall provide Grünenthal with a copy of a plan for the Development of the Product within the Field during the Initial Period (including the conduct of the New Phase III Clinical Trial) (“Initial Development Plan”).  During the Initial Period, MSB shall have the right to update the Initial Development Plan in its sole discretion, provided that (i) such updates are consistent with its Development obligations under this Article 4, (ii) MSB shall make such updates as are reasonably required to implement any requirements or recommendations of any relevant Regulatory Authority or HTA, and (iii) MSB 

-31-

 

 

provides Grünenthal with a copy of any such updated Initial Development Plan promptly after the update has been made.  MSB shall ensure that the Initial Development Plan and each update thereto includes as a minimum:

4.3.1the clinical trial protocol for the New Phase III Clinical Trial (or, to the extent the full protocol has not yet been developed, a synopsis of the clinical trial protocol);

4.3.2details of major CMC/non-clinical studies and activities;

4.3.3scope and timelines for the conduct of the new Phase III Clinical Trial; and

4.3.4regulatory and reimbursement matters including Regulatory Materials to be filed with Regulatory Authorities, including estimated timing of meetings with Regulatory Authorities in support of Development activities during the Initial Period.

The Parties shall discuss the Initial Development Plan and the progress of MSB’s Development activities in relation to the Initial Development Plan at the meetings of the JSC during the Initial Period.  At such JSC meetings, Grünenthal shall be permitted to (i) comment on the Initial Development Plan and MSB shall reasonably consider whether the Initial Development Plan should be updated to reflect such comments and (ii) raise questions in relation to the Initial Development Plan and MSB’s Development activities thereunder which MSB shall answer in good faith.

4.4.Inclusion of European Patients.  MSB shall ensure that the number of patients included in the New Phase III Clinical Trial whose place of residence and place of treatment is within Europe is at least the greater of [***] (“Required European Patients”).  MSB shall provide Grünenthal with any evidence that Grünenthal may reasonably request from time to time to demonstrate that the Required European Patients have been or will be included in the New Phase III Clinical Trial.  If MSB fails to include the Required European Patients in the New Phase III Clinical Trial, then as MSB’s sole liability and Grünenthal’s sole remedy:

4.4.1MSB shall, on written demand from Grünenthal, pay Grünenthal[***], in which case, MSB shall pay that amount to Grünenthal within [***]of receipt of Grünenthal’s written notice demanding such payment; and

4.4.2Grünenthal may terminate this Agreement in accordance with Section 13.2.3.

The Parties agree that the payment payable under Section 4.4.1 is (a) proportionate to Grünenthal’s legitimate interests and (b) not a penalty and represent a genuine pre-estimate of the minimum level of loss that Grünenthal is likely to suffer as a result of the events giving rise to the repayment.

4.5.Grünenthal Assistance.  During the Initial Period, MSB may consult Grünenthal with respect to any Europe-specific regulatory and market access matters relevant to the New Phase III Clinical Trial and Grünenthal shall (at its 

-32-

 

 

own cost) provide Mesoblast with its expertise in relation to any such matters as may be reasonably requested by MSB from time to time.  If MSB does elect to consult Grünenthal on any such matters, MSB shall (i) give Grünenthal a reasonable period of time to provide the requested expertise and (ii) have due regard to any advice or guidance provided by Grünenthal in response to such consultation.  [***]  

4.6.Development Data, Regulatory Materials and Other Reporting Obligations.  MSB shall, during the Initial Period and through the JSC, (i) keep Grünenthal appropriately and routinely informed regarding progress with respect to the activities under the Initial Development Plan including all the study results and conclusions generated therefrom, (ii) provide Grünenthal with details of any material changes to the proposed activities under the Initial Development Plan (including changes in comparability approach, changes of major vendors (i.e. for master cell banks, finished product, QC testing) and changes in potency assay strategy), (iii) provide Grünenthal access to all data tables and listings generated from the performance of such activities, including clinical, non-clinical and CMC reports (including all clinical patient data such as pools and anonymized data, programs, data and program description)and (iv) provide Grünenthal with copies of all Regulatory Materials (including minutes from any relevant FDA meetings).  Without limiting the generality of the foregoing, (a) MSB shall also provide Grünenthal with such reports of the progress of the Development activities as Grünenthal may request from time to time, (b) MSB shall promptly inform Grünenthal in writing of any serious incident impacting patient health or safety that may arise during the conduct of its Development activities hereunder and (c) MSB shall promptly notify Grünenthal upon becoming aware of any actual or likely delay to Development activities, deviation from the Initial Development Plan or failure of any clinical trial in relation to the Product in the Field.  For clarity, nothing in this Section 4.6 shall require MSB to generate any additional data or results which would not otherwise be included in the Results Package.

4.7.Conduct.

4.7.1MSB shall use Commercially Reasonable Efforts to conduct the Development activities under the Initial Development Plan and shall conduct such activities in a good scientific manner, in compliance with Applicable Laws and the applicable cGxP and in accordance with the timelines therein; and unless the Parties otherwise agree all clinical Development activities with respect to the Product in the Field for the Territory shall be set forth in the Development Plan.  

4.7.2MSB agrees that it will not knowingly infringe, misappropriate or otherwise violate any Patents, Know-How or other intellectual property of any Third Party in the conduct of the activities under the Initial Development Plan.  

-33-

 

 

4.7.3MSB shall (a) keep records of its activities under the Initial Development Plan in compliance Applicable Laws and cGxP and (b) provide quarterly written reports regarding the progress of such activities to MSB through the JSC.

4.7.4MSB in exercising its obligation to use Commercially Reasonable Efforts to conduct Development activities with respect to the Product in the Field for the Territory in accordance with this Article 4 shall consider all relevant factors including relating to (i) the Product outside the Territory or (ii) the Product outside the Field in the Territory.  Without limitation to the generality of the foregoing, MSB shall notify Grünenthal (through the JSC) of any decision by MSB to cease or limit Development of the Product for any purpose other than Development for the Field for the Territory, including the relevant basis for any such determination.

4.8.Development Costs

4.9. [***]Continuation.  

4.9.1MSB shall provide Grünenthal with the data within the Results Package as soon as reasonably practicable after receipt of all data and materials comprising such package, and in any event within [***]of MSB confirming accuracy and completeness such data and materials (with MSB using Commercially Reasonable Efforts to do so promptly).  MSB shall ensure that the Results Package contains the information in Section 1.76 to enable Grünenthal to determine whether or not the[***].  If Grünenthal, acting reasonably and in good faith, considers that it has not been provided with all information which MSB is required to provide in accordance with this Section 4.9.1, it shall notify MSB in writing (specifying the information which is missing) and, for the purposes of Section 4.9.2, Grünenthal shall not be deemed to have received the Results Package until the missing information has been provided.

4.9.2Within [***]of receipt by Grünenthal of the Results Package, Grünenthal shall have the right to either:

(a)participate in the continued Development of the Product in the Field for the Territory as provided in Article 5 (the “Continuation”); or

(b)forego all rights it has hereunder to Develop and Commercialize the Product in the Field for the Territory.

Grünenthal may exercise the Continuation by notice in writing to MSB (“Continuation Notice”).  If, by expiry of the [***]period following receipt by Grünenthal of the Results Package, MSB has not received an Continuation Notice from Grünenthal, Grünenthal shall be deemed to have elected to forego all rights it has hereunder to Develop and Commercialize the Product in the Field for the Territory.

4.9.3If, in accordance with Section 4.9.2, Grünenthal elects (or is deemed to have elected) to forego all rights it has hereunder to Develop and Commercialize the Product in the Field for the Territory, either Party may terminate this Agreement immediately on written notice to the other Party in accordance with Section 13.3.

-34-

 

 

4.9.4If, in accordance with Section 4.9.2, Grünenthal elects to participate in the continued Development of the Product in the Field for the Territory, then:

(a)the date on which MSB receives the Continuation Notice shall be the “Continuation Date”; 

(b)Grünenthal shall, within [***]of the Election Date, pay to MSB [***](the “Continuation Trigger Fee”); and

(c)the provisions of Article 5 shall apply to all Development activities after [***].

4.9.5For the avoidance of doubt, Grünenthal shall be under no obligation to provide the Continuation Notice and any decision in relation to provision of the Continuation Notice shall be taken by Grünenthal in its sole discretion.

Article 5
DEVELOPMENT after the continuation date

5.1.Continuation Development Right.  Subject to the oversight of the JSC, following the Continuation Date, Grünenthal shall have the sole right and be responsible to Develop the Product to the extent required for filing MAAs and obtaining and maintaining Regulatory Approvals for Product (including, for the avoidance of doubt, the [***]) within the Field throughout the Territory, with Grünenthal (itself or through its Affiliates or authorized Third Parties) using Commercially Reasonable Efforts to conduct the Development of Product within the Field for the Territory in accordance with this Article 5 and the Continuation Development Plan.  For clarity, following the Continuation Date, neither Party shall conduct any Development with respect to the Product within the Field for the Territory except pursuant to the Continuation Development Plan.

5.2.Grünenthal Development. Following the Continuation Date, Grünenthal will have responsibility (itself or through its Affiliates or authorized Third Parties) for the following Development activities to support the granting or maintaining of Marketing Approvals and Pricing Approvals for the Product for the Field in the Territory: 

5.2.1the conduct of any further clinical trials with respect to the Product in the Field for the Territory (including any Europe-specific phase III Clinical Trial or phase IV Clinical Trial (each a “European Clinical Trial”)) as Grünenthal may in its sole discretion consider necessary to obtain Regulatory Approvals for Product for the Field in the Territory;

5.2.2the conduct of any[***]), in each case with respect to the Product in the Field for the Territory;

5.2.3obtaining [***]for the Product in the Field in the Territory;

-35-

 

 

5.2.4the conduct of any [***]with respect to the Product for the Territory (without limiting Section 3.5.3); and

5.2.5any Development activities that are specific to [***] 

5.3.Continuation Development Plan.  

5.3.1If Grünenthal, in its sole discretion, determines that further Development is required for the Product for the Field in the Territory, it shall as soon as reasonably practicable following the Continuation Date, provide MSB with a copy of a plan for the Development of the Product within the Field for the Territory following the Continuation Date (including, where Grünenthal considers it necessary, the conduct of any European Clinical Trial) (“Continuation Development Plan”).

5.3.2If Grünenthal considers that it requires any support or assistance from MSB with respect to any Development of the Product within the Field for the Territory, it may request such assistance in writing from MSB and MSB shall not unreasonably withhold, condition or delay its agreement to provide such assistance.  If MSB agrees to provide any such assistance, the Continuation Development Plan shall be updated accordingly by Grünenthal.

5.3.3The Continuation Development Plan will be updated from time to time by Grünenthal, but not less than annually, to incorporate any activities that Grünenthal considers are required in order to achieve the purpose of the Development collaboration described in this Agreement. By [***](or the first Business Day thereafter if such day is not a Business Day) of each calendar year, Grünenthal shall submit to the JSC any proposed updates to the Development Plan for the JSC’s review and comment.  Grünenthal may also submit proposed updates to the Continuation Development Plan to the JSC for review and comment more frequently than the annual submission described in this Section 5.3.3 if circumstances require any significant changes to the Development Plan.

5.4.Regulatory Meetings and HTA Meetings.

5.4.1Following the Continuation Date, Grünenthal may submit requests for one or more initial meetings with each of (i) the Paul-Ehrlich Institute, (ii) the EMA and (iii) any other Regulatory Authorities in the Territory which Grünenthal considers necessary to discuss the Continuation Development Plan for the Product within the Field for the Territory and solicit feedback with respect thereto (such meeting(s), “Initial Regulatory Meetings”).  MSB shall have the right to be present at and participate in each Initial Regulatory Meeting as provided in Section 8.2.1 and, where requested by Grünenthal or where required by Applicable Law, MSB shall take the lead in the relevant Initial Regulatory Meeting.  For the avoidance of doubt, nothing in this Section 5.4.1 shall limit the number of meetings Grünenthal shall be permitted to have with any Regulatory Authority in the Territory for the purposes described in this Section 5.4.1.

5.4.2Grünenthal may schedule meetings with any HTAs in the Territory to discuss matters relating to the pricing of the Product in the Field in the Territory (“HTA Meeting”).  MSB shall have the right to be present at and participate in any HTA Meeting with the relevant HTAs in each Major European Market.

-36-

 

 

5.4.3MSB shall provide Grünenthal with any assistance reasonably requested by Grünenthal that is necessary or useful in order to enable Grünenthal to adequately prepare for any Initial Regulatory Meeting or HTA Meeting.

5.4.4Each Party shall bear its own costs and expenses in relation to its participation in the Initial Regulatory Meetings and HTA Meetings. To the extent any fees are payable to any Regulatory Authorities or HTAs in connection with any Initial Regulatory Meeting or HTA Meeting, Grünenthal shall be responsible for paying such fees.

5.5.Label Extensions and Lifecycle Management. If either Party wishes to extend the scope of the Development Plan to include label extension or lifecycle management activities in the Field for the Territory beyond activities required to achieve the purpose of the Development collaboration described in Section 5.1 (“Additional LE/LCM Activities”), it may propose such updates to the other Party and the Parties shall discuss in good faith whether or not to include such Additional LE/LCM Activities in the Continuation Development Plan and, if such activities are to be included, the responsibility for conducting such Additional LE/LCM Activities[***]  Neither Party shall unreasonably withhold, condition or delay its consent to a request from the other Party to include Additional LE/LCM Activities in the Development Plan.  If the Parties cannot agree on the inclusion of any Additional LE/LCM Activities in the Continuation Development Plan, Grünenthal shall have the right to conduct such Additional LE/LCM Activities itself unless doing so would have a material adverse effect (including any safety implications) on the MSB MPC Platform and, upon Grünenthal’s request, MSB shall provide Grünenthal with such reasonable assistance as Grünenthal may require in relation to the conduct of such Additional LE/LCM Activities.

5.6.Regulatory Meetings Outside the Territory.  In the event that, following the Continuation Date, MSB schedules any meetings with the FDA or any other Regulatory Authority outside the Territory for purposes of supporting or otherwise obtaining Marketing Approval for the Product within the Field outside the Territory or any BLA or other MAA with respect thereto, then MSB shall (i) provide Grünenthal with reasonable advance notice of such meeting, (ii) provide Grünenthal with copies of any materials prepared for, or to be discussed at, any such meeting as soon as reasonably practicable in advance of the meeting date, and (iii) permit Grünenthal to (when practicable) be present at and participate in such meeting(s). However, in the event that MSB enters into an agreement with a Third Party with respect to Commercialization of the Product in any country outside the Territory, then Grünenthal’s right to be present at and participate in such meetings with Regulatory Authorities in that country will be subject to that Third Party’s sole discretion, provided that if such Third Party objects to Grünenthal’s presence and participation, MSB shall provide Grünenthal with copies of any minutes or summaries of such meetings promptly after the date of the meetings.  In any event, MSB shall keep Grünenthal informed as to all material interactions with the FDA and other Regulatory 

-37-

 

 

Authorities outside the Territory in relation to the Product in the Field.

5.7.European Clinical Trials.  If the clinical data generated by the New Phase III Clinical Trial is insufficient for the EMA to grant a Marketing Approval for the Product in the Field, Grünenthal may, in its sole discretion and at its cost and expense, elect to conduct European Clinical Trials in order to generate further clinical data to support a revised application to the EMA for Marketing Approval for the Product in the Field.  If Grünenthal elects to generate further clinical data from European Clinical Trials, Grünenthal shall determine and finalize the protocols for each European Clinical Trial.  Prior to finalizing any such protocols, Grünenthal shall submit any protocols for any European Clinical Trial to the JSC (or any Sub-Committee to whom the JSC has delegated such responsibility) for its review or comment.  Grünenthal shall have due regard to any comments made by the JSC in relation to such protocols.  Following finalization of any such protocols, Grünenthal shall ensure that the relevant European Clinical Trial is conducted in a manner that strictly adheres to Applicable Law (including cGxP), such protocols, as such protocols may be amended by Grünenthal from time to time (subject to review of such amendments by the JSC (or any Sub-Committee to whom the JSC has delegated such responsibility) and the terms of approvals of the applicable institutional review board, ethics committee and any other competent authority involved in the clinical research or drug approval process); provided, however, that if Grünenthal determines that a modification to such protocols is reasonably necessary due to circumstances related to patient safety and that notice to MSB and review of such modification by the JSC (or any Sub-Committee to whom the JSC has delegated such responsibility) cannot be accomplished in a reasonable timeframe without risk to patient safety, Grünenthal may change such protocols without having to provide them beforehand to MSB for its review and comment hereunder; however, Grünenthal shall promptly provide such changes to MSB along with the rationale for such change. 

5.8.Development Data, Regulatory Materials and Other Reporting Obligations.  Each Party shall, through the JSC (or any Sub-Committee to whom the JSC has delegated such responsibility), keep the other Party appropriately and routinely informed regarding progress with respect to the activities assigned to it under the Continuation Development Plan, including all the study results and conclusions generated therefrom, provide the other Party access to all data tables and listings generated from the performance of such activities, including clinical, non-clinical and CMC reports (including all clinical patient data such as pools and anonymized data, programs, data and program description) and Regulatory Materials, and permit a reasonable number of representatives (based on the circumstances) of the other Party to monitor such Development activities upon such other Party’s reasonable request and at reasonable times mutually agreed upon by the Parties to the extent such Party has the right to permit the other Party to so monitor.  Without limiting the generality of the foregoing, following the Continuation Date (i) each Party shall also provide such reports of 

-38-

 

 

the progress of the Development activities it controls as the other Party may request from time to time, (ii) each Party shall promptly inform the other Party in writing of any serious incident impacting patient health or safety that may arise during the conduct of its Development activities hereunder and (iii) each Party shall promptly notify the other Party upon becoming aware of any actual or likely material delay to Development activities, material deviation from the Development Plan.

5.9.Conduct.

5.9.1Each Party shall use Commercially Reasonable Efforts to conduct those activities assigned to it under the Continuation Development Plan and shall conduct such activities in a good scientific manner, in compliance with Applicable Laws and the applicable, cGxP and in accordance with the timelines therein; and unless the Parties otherwise agree all clinical Development activities with respect to the Product for the Territory shall be set forth in the Continuation Development Plan.  

5.9.2Each Party agrees that it will not knowingly infringe, misappropriate or otherwise violate any Patents, Know-How or other intellectual property of any Third Party in the conduct of the activities assigned to it under the Continuation Development Plan.  

5.9.3The Party conducting activities under the Continuation Development Plan shall (a) keep records of such activities in compliance Applicable Laws and cGxP and (b) provide quarterly written reports regarding the progress of activities to the other Party through the JSC (or any Sub-Committee to whom the JSC has delegated such responsibility); provided, that the JSC may, in its discretion, require more frequent reporting.  At the reasonable request and expense of the Party conducting activities under the Continuation Development Plan, the other Party shall provide the requesting Party with reasonable cooperation and assistance in connection therewith, provided that any such cooperation and assistance provided by the other Party shall not relieve the requesting Party from its primary obligation to conduct the relevant activities.

5.10.Development Costs. [***] 

Article 6
COMMERCIALIZATION AND MEDICAL AFFAIRS

6.1.General.  Subject to the terms and conditions of this Agreement, Grünenthal shall have the exclusive right to Commercialize Product within the Field in the Territory and conduct Medical Affairs Activities for the Product within the Field for the Territory (such exclusive rights to be to the exclusion of MSB and all Third Parties).  Grünenthal shall be responsible for all Commercialization efforts for the Product within the Field in the Territory and Medical Affairs Activities for the Product within the Field for the Territory, in each case in accordance with the Commercialization Plan.

6.2.Commercialization Plan.  By no later than[***], Grünenthal shall propose and submit to MSB for review and comment an initial draft plan for the 

-39-

 

 

Commercialization of Product within the Field in the Territory and the conduct of Medical Affairs Activities for the Product within the Field for the Territory.  After review of such draft plan by MSB, Grünenthal shall finalize such plan, as appropriate, taking into consideration in good faith any reasonable comments of MSB with respect thereto (each, as updated from time to time, a “Commercialization Plan”).  The Commercialization Plan shall be updated at least annually. The Commercialization Plan shall set forth in a level of detail consistent with practice in the biopharmaceutical industry.  Without limiting the foregoing, the Commercialization Plan shall include activities and resources consistent with Grünenthal’s obligations under Section 6.4 and will set forth certain objective Commercialization criteria, including call point identification and tier strategy.  At least [***]prior to the annual CRB meeting, Grünenthal shall provide each such Commercialization Plan and any material modification or addition thereto to MSB for its review and comment.

6.3.Pricing.  To the extent allowable under Applicable Law, Grünenthal shall keep MSB reasonably informed and permit MSB to review and comment on pricing and reimbursement in relation to the Product in the Field in the Territory and Grünenthal shall consider in good faith any such reasonable comments provided by MSB (through the CRB).

6.4.Diligence Obligations.  Subject to Section 9.1.8, Grünenthal agrees to use Commercially Reasonable Efforts to Commercialize the Product within the Field in the Territory. For the avoidance of doubt, whether or not Grünenthal has satisfied its obligation under this Section 6.4 to use Commercially Reasonable Efforts shall be measured by reference to Grünenthal’s Commercialization activities across the Territory taken as a whole and nothing in this Agreement shall require Grünenthal to file an MAA or launch the Product in the Field in every country in the Territory.  Grünenthal shall remain solely responsible, at its sole discretion, for determining the launch strategy for the Product in the Field in the Territory consistent with the use of Commercially Reasonable Efforts.

6.5.Conflicts of Interest.  During the Term, if Grünenthal or its Affiliate (i) sells the Product to a Third Party to whom it also sells or otherwise provides other products or services (ii) shifts, allocates, prices, discounts, weighs or bundles payments received in any transaction or any combination of transactions, so as to reduce or disadvantage the Net Sales of the Product, including in favor of any other product, services or consideration provided by Grünenthal or its Affiliate (“Discounts”), then the Net Sales of the Product for such sale shall be the arm’s length fair market value that would have been invoiced by Grünenthal or its Affiliates had it not applied the Discounts, which generally will mean the average sales price for the Product in the relevant country where the sale occurs for the Relevant Period. 

6.6.Medical Affairs Activities.  Grünenthal shall be solely responsible (at Grünenthal’s discretion) for conducting any Medical Affairs Activities with 

-40-

 

 

respect to the Product in the Field for the Territory.  Grünenthal shall keep MSB reasonably informed of its Medical Affairs Activities with respect to the Product in the Field for the Territory via the annual meeting of the CRB.

6.7.Reporting. 

6.7.1Without limiting any other provisions of this Agreement, at least [***]prior to the date of any annual meeting of the CRB:

(a)Grünenthal shall provide MSB with a written report summarising the Commercialization activities for the Product in the Field in the Territory and Medical Affairs Activities for the Product in the Field for the Territory hereunder, such report to include (i) an update as to the progress of its activities with respect to the Commercialization of the Product against the Commercialization Plan and (ii) any other information in relation to such Commercialization and Medical Affairs Activities that has been reasonably requested by MSB in advance of the submission of the report; and

(b)MSB shall provide Grünenthal with a written report summarising its Commercialization and Medical Affairs Activities for the Product in the Field outside the Territory, such report to include any information in relation to such Commercialization and Medical Affairs Activities that has been reasonably requested by Grünenthal in advance of the submission of the report.

6.7.2In addition to the report to be provided by Grünenthal in accordance with Section 6.7.1(a), Grünenthal shall promptly notify MSB if it anticipates or there are material deviations from any then-current Commercialization Plan and shall discuss in good faith and keep MSB informed as to any corrective actions that it intends or is taking to address such deviations.  For the avoidance of doubt, Grünenthal shall not be in breach of this Agreement if it deviates from the Commercialization Plan provided it has complied with its diligence obligations with respect to Commercialization of the Product in the Field in the Territory at Section 6.4.

6.8.Commercialization Review Board.  Promptly following Grünenthal’s finalization of the Commercialization Plan in accordance with Section 6.2, the Parties shall establish a commercialization review board (“CRB”) for the purpose of discussing, reviewing and, to the extent agreed between the Parties, harmonizing (i) Grünenthal's Commercialization and Medical Affairs Activities for the Product hereunder and (ii) MSB’s Commercialization and Medical Affairs Activities for the Product in the Field outside the Territory and for the Product outside the Field in the Territory. The CRB shall consist of up to [***]suitably senior and experienced representatives of each of MSB and Grünenthal (with [***]of such representatives appointed by each of MSB and Grünenthal being the Alliance Manager appointed by each of MSB and Grünenthal).  Either Party may replace its respective representative(s) to the CRB at any time with prior notice to the other Party, provided that such replacement is of comparable authority and scope of responsibility within that Party’s organization as the individual he or she is replacing.  The CRB shall meet (either in person or by teleconference) at least once in each [***]period 

-41-

 

 

following its establishment.  For the avoidance of doubt, the CRB shall be for discussion and review purposes only and as such (a) the CRB shall have no decision making authority and (b) the CRB’s consent is not required for the conduct of any Commercialization or Medical Affairs Activities.

6.9.Commercialization Costs.  [***]  

6.10.Territorial Considerations.

6.10.1Grünenthal shall use reasonable endeavours to ensure that its Commercialization activities for the Product in the Field in the Territory and its Medical Affairs Activities for the Product in the Field for the Territory do not have any material adverse effect on MSB’s Commercialization and Medical Affairs Activities (i) for the Product in the Field outside the Territory or (ii) for the Product outside the Field in the Territory, provided that, in each case, nothing in this Section 6.10.1 shall prevent Grünenthal or any licensee or partner of Grünenthal from determining the strategy with respect to pricing of the Product in the Field in the Territory.

6.10.2MSB shall use reasonable endeavours to ensure that its  Commercialization and Medical Affairs Activities (i) for the Product outside the Territory and (ii) for the Product outside the Field in the Territory (in each case, whether conducted by MSB or by any licensee or partner of MSB) do not have any material adverse effect on Grünenthal’s Commercialization activities for the Product in the Field in the Territory or Medical Affairs Activities for the Product in the Field for the Territory, provided that, in each case, nothing in this Section 6.10.2 shall prevent MSB or any licensee or partner of MSB from determining the strategy with respect to pricing of the Product outside the Territory or outside the Field in the Territory.

6.10.3Between meetings of the CRB, upon the reasonable request of either Party, the Parties shall schedule additional meetings or conference calls to discuss (a) the harmonization and co-ordination of (i) Grünenthal’s Commercialization and Medical Affairs Activities for the Product hereunder and (ii) MSB’s Commercialization and Medical Affairs Activities for the Product in the Field outside the Territory and for the Product outside the Field in the Territory (in each case, whether conducted by MSB or by any licensee or partner of MSB), and (b) any other steps as may be reasonably required to ensure that the territorial considerations described in Sections 6.10.1 and 6.10.2 are achieved.

Article 7
MANUFACTURE / SUPPLY

7.1.Development Supply.  MSB shall be responsible for the supply of all requirements of Product for the Development activities to be conducted pursuant to this Agreement.  MSB shall use all reasonable endeavours to ensure that supplies of the Product are available in such quantities, at such quality and at such times as is reasonably required to support all activities covered by the Development Plan.  [***].

7.2.Specifications.  Except as expressly permitted by this Agreement, MSB shall not make any changes to the Specifications without Grünenthal’s 

-42-

 

 

prior written approval, such approval not to be unreasonably withheld, conditioned or delayed.  If either Party believes a change to the Specifications is necessary or appropriate, such Party shall propose such change to the JSC (or any Sub-Committee to whom the JSC has delegated such responsibility) for review and discussion.  

7.3.Regulatory Approvals for Manufacture.  For the avoidance of doubt, in accordance with Section 8.1, with respect to Product supplied by MSB hereunder MSB shall be responsible, at its expense, for filing, obtaining and maintaining any Regulatory Approvals required for the supply of the Product (including any tissue bank licences for the Manufacture of the Product).

7.4.Direct Supply From Third Party Manufacturers.  

7.4.1At Grünenthal’s request, MSB will use reasonable efforts to facilitate the negotiation among Grünenthal and any Third Party Manufacturer of a direct supply agreement between Grünenthal and such Third Party Manufacturer, including pursuant to that manufacturing side letter agreement between the Parties and [***]dated on or about the Effective Date (each a “Direct Supply Agreement”) pursuant to which Grünenthal would have a right to obtain commercial supply of the Product or any materials used in the Manufacture of the Product directly from the Third Party Manufacturer.  Grünenthal shall keep MSB reasonably informed as to its commencement and finalization of negotiations for any Direct Supply Agreement and shall give MSB the right to review and comment on such agreement prior to the execution thereof (provided that (i) MSB shall provide its comments within[***] of receipt of the draft from Grünenthal and (ii) nothing in this Section 7.4.1 shall require Grünenthal to breach any obligation of confidentiality owed to the Third Party Manufacturer).  Any such Direct Supply Agreement will be subject to the terms and conditions of Exhibit 7.4.1.

7.4.2Grünenthal shall procure that each Direct Supply Agreement which it enters into with a Third Party Manufacturer shall include confidentiality provisions at least as protective of MSB’s Confidential Information as the provisions of Section 11.1 and provides for (a) use of such Confidential Information by the relevant Third Party Manufacturer solely for the purpose of supplying Product to Grünenthal for the purposes of this Agreement and (b) the right for a Third Party to which such Third Party Manufacturer acting in good faith has no reasonable objection to audit such uses on terms consistent with Section 8.4.1 mutatis mutandis.  Grünenthal shall also use all reasonable efforts to include a provision in each Direct Supply Agreement that requires the Third Party Manufacturer to assign to MSB any improvements or modifications to MSB’s proprietary Manufacturing process (including intellectual property rights with respect thereto, any an “Process Improvement”) which relate to the Product, including customary further assurances to effect such assignment. To the extent that Grünenthal is unable to secure a provision in any Direct Supply Agreement in accordance with the foregoing sentence, MSB shall be permitted to negotiate such provision directly with the Third Party Manufacturer, provided that MSB shall cooperate with Grünenthal to avoid any unreasonable delay in executing such Direct Supply Agreement, provided that MSB shall not be obligated to accept less than an unconditional assignment of Process Improvements exclusively related to the Product and a non-exclusive, fully paid-up worldwide license (with the right of sublicense of other  Process Improvements). Grünenthal shall use all reasonable efforts to obtain the right for MSB to enforce those provisions 

-43-

 

 

referred to in this Section 7.4.2 directly against the relevant Third Party Manufacturer as a third party beneficiary.  Where the provisions required by this Section 7.4.2 cannot be negotiated into any Direct Supply Agreement, the matter shall be escalated to the JSC which shall determine an appropriate solution that does not prevent Grünenthal from being able to enter into a Direct Supply Agreement whilst offering MSB appropriate protections with respect to MSB’s Confidential Information and Process Improvements.

7.5.Maintenance of Master Cell Banks.  MSB shall retain and maintain those master cell banks identified in Exhibit 7.5 for exclusive use by or on behalf of Grünenthal with respect to Product in the Field for the Territory until the earliest of: (a) the [***]of the First Commercial Sale of the Product in the Field in the Territory, (b) the date on which the EMA approves the use of master cell banks produced by [***]for the use in Manufacture of the Product in the Field for Europe, and (c) the date on which the EMA determines that master cell banks produced by [***]cannot be used for Manufacture of the Product in the Field for Europe, provided that if Grünenthal or its designee receives Marketing Approval [***]in the Field from the EMA, MSB’s obligation to retain and maintain master cell banks pursuant to this Section 7.5 shall be reduced by an amount proportional to the increase in Product yield for[***] compared with other Product previously Manufactured hereunder.  MSB shall not change the storage location of such master cell banks from the site of [***]at which such master cell banks are located as at the Effective Date.  At the request of Grünenthal from time to time during the Term, MSB shall make such master cell banks available for use by or on behalf of Grünenthal for the Manufacture of Product in the Field for the Territory.

7.6.Manufacturing Technology Transfer.  If Grünenthal has entered into a Direct Supply Agreement for the Manufacture of the Product then, in order to enable Grünenthal or the relevant Third Party Manufacturer to commence Manufacture of the Product for the Field for the Territory, MSB shall on Grünenthal's reasonable written request provide Grünenthal and/or the relevant Third Party Manufacturer with technology transfer assistance regarding the Manufacture of the Product in accordance with the terms of the Manufacturing Technology Transfer Plan (such assistance to be provided in accordance with all Applicable Law, including the applicable guidelines of the ICH and the World Health Organization).  [***]

Article 8
REGULATORY AND RELATED MATTERS

8.1.Regulatory Matters.

8.1.1Responsibility for Regulatory Filings.  Except as otherwise expressly provided herein, each Party shall be responsible, at its expense, for filing, obtaining and maintaining Regulatory Approvals for those activities assigned to such Party hereunder in connection with the Development, Manufacture and Commercialization of and conduct of Medical Affairs Activities for Product within the Field in the Territory.  All final and other material reports 

-44-

 

 

from non-clinical studies and clinical trials relating to the Product for the Field, as well all technical reports, shall be shared between the Parties as a basis for any such filing. All such final and other material reports and data analyses shall be prepared and delivered in the form in which they are available to the providing Party. The Parties acknowledge that unless the JSC designates otherwise, Grünenthal shall have the right and responsibility for preparing, filing and defending MAAs for Product within the Field in the Territory, provided that at Grünenthal’s reasonable request, MSB shall provide full support to Grünenthal with respect to such filings (including, if requested, assistance with analysing and understanding the Data Package and assistance with dossier preparation, including the provision of the integrated summaries of efficacy, the integrated summaries of safety, or other pooled analyses of the clinical data, as needed, and full access at any time (both before and after MAA) to the clinical database and data pooled therefrom and related metadata (e.g. CDISC compliant and assistance with preparing answers to questions from Regulatory Authorities, HTAs and/or national academic bodies).  Where the Parties make any simultaneous filings in both the Territory and the United States, the Parties shall consult and coordinate in preparing such filings in order to avoid unnecessary duplication of efforts.  All activities under this Section 8.1.1 shall be done subject to the oversight and in full consultation with the JSC (or such Sub-Committee to whom the JSC may delegate such oversight responsibility). Without limiting the foregoing, prior to the filing any MAA for Product within the Field in the Territory, Grünenthal shall provide a copy thereof to MSB for its review and comment (including any associated proposed labeling) and MSB shall provide any comments in relation thereto within [***]of receipt.  MSB shall provide Grünenthal with a copy of the Data Package and Dossier as soon as the same are available.  Upon request, MSB shall use Commercially Reasonable Efforts to provide Grünenthal with a copy of a BLA or regulatory dossier submitted to any Regulatory Authority outside the Territory other than the FDA with respect to the Product in the Field.

8.1.2Rights of Reference:  

(a)Grünenthal hereby grants MSB (and its designees) a right of reference and full use and access to Regulatory Materials of Grünenthal and its Affiliates with respect to the Product (including MAAs in the Territory) for purposes of obtaining and maintaining Regulatory Approvals for the Product outside the Territory.  Grünenthal shall, at MSB’s request and expense, take actions reasonably necessary to effect such grant of right of reference and use to MSB, including by making such filings as may be required with Regulatory Authorities in the Territory that may be necessary to record such grant.

(b)MSB hereby grants Grünenthal (and its designees) a right of reference and full use and access to Regulatory Materials of MSB and its Affiliates with respect to the Product (including MAAs outside the Territory) for purposes of obtaining and maintaining Regulatory Approvals for the Product in the Field in the Territory.  MSB shall, at Grünenthal’s request and expense, take actions reasonably necessary to effect such grant of right of reference and use to Grünenthal, including by making such filings as may be required with Regulatory Authorities outside the Territory that may be necessary to record such grant.

-45-

 

 

8.1.3CCDS Responsibility.

(a)Grünenthal shall be responsible for generating and maintaining its own company core data sheet (“CCDS”) for the Product in the Field in the Territory at its own cost and expense.

(b)MSB shall be responsible for generating and maintaining its own CCDS for the Product in the Field outside the Territory at its own cost and expense.

8.2.Regulatory Cooperation.  Following the Continuation Date, subject to the oversight of the JSC and unless otherwise required by Applicable Law, Grünenthal shall be responsible for liaising with and managing all interactions with applicable Regulatory Authorities with respect to Product within the Field in the Territory and MSB shall provide Grünenthal with any assistance requested by Grünenthal in order to facilitate such interactions with the Regulatory Authorities.  MSB shall be entitled to participate in such interactions as provided in this Section 8.2.

8.2.1Involvement of MSB.  Following the Continuation Date, to the extent relating to the Product within the Field in the Territory, Grünenthal shall provide MSB with:

(a)reasonable advance notice (and in no event less than twenty (20) Business Days’ advance notice whenever feasible) of substantive meetings (including any Initial Regulatory Meeting) with any Regulatory Authority within the Territory that are either scheduled with, or initiated by or on behalf of, Grünenthal or its Affiliates, and an opportunity to have a reasonable number (but at least two (2)) representatives participate in all substantive meetings with any Regulatory Authority, and in any case shall keep MSB informed as to all material interactions with Regulatory Authorities in relation to the Product in the Field in the Territory; and

(b)a copy of any material documents, information and correspondence submitted to any Regulatory Authority in relation to the Product in the Field in the Territory as soon as reasonably practicable.

8.2.2Other Regulatory Matters.  During the Term, each Party shall, provide the other Party with copies of all material documents, information and correspondence received from any Regulatory Authority (including a written summary of any material communications in which such other Party did not participate). Such documents, information and correspondence shall be provided (i) within twenty-four (24) hours of receipt thereof if they relate to any matter relating to the Product’s risk or cost profile or if it relates to the Regulatory Approval process, or (ii) within three (3) Business Days of receipt thereof if it relates to any other matter. Without limitation to the foregoing, each Party shall, upon reasonable request, provide the other Party with copies of any other material documents, reports and communications from or to any Regulatory Authority relevant to Product within the Field in the Territory.

8.3.Exchange of Data.  During the Term, each Party shall provide to the other Party all such Party’s Data (i.e., in case of MSB, Data comprising Product Know-How, and in the case of Grünenthal, Data comprising GRT Know-How) 

-46-

 

 

in each case with respect to Product that has not previously been provided hereunder, in each case promptly upon request by the other Party and necessary or useful for the other Party to conduct its activities under this Agreement.  The Party providing such Party’s Data shall provide the same in accordance with any applicable guidelines of the ICH, in electronic form to the extent the same exists in electronic form (and in case of BLA-related data in eCTD format including SAS (full version) data of each clinical trial), and shall provide copies as reasonably requested and an opportunity for the other Party or its designee to inspect (and copy) all other materials comprising such Data (including for example, original patient report forms and other original source data, to the extent access is allowed under Applicable Law).  The Parties will cooperate and reasonably agree upon formats and procedures to facilitate the orderly and efficient exchange of such Data, including the agreement of any data transfer agreements that are reasonably required to ensure that the transfer of any personal data required by this Agreement is in compliance with applicable data protection laws.

8.4.Audit Rights.

8.4.1Audit by Grünenthal.  During the Term, MSB shall permit Grünenthal, during normal business hours and upon reasonable advance notice, reasonable access to all relevant facilities of MSB and its Affiliates and Third Party Manufacturers appointed by MSB or its Affiliates, in each case at which Development and Manufacturing activities for the Product are conducted to audit and verify compliance with (i) applicable regulatory requirements with respect to matters relating to the Manufacture (including quality matters) of Product within the Field for the Territory, (ii) all Data to be provided to Grünenthal pursuant to Section 8.3 and (iii) the activities with respect to the Development and Manufacture of the Product.  Grünenthal may conduct any such audit itself or using a suitably qualified Third Party consultant selected by Grünenthal and acceptable to MSB (such acceptance not to be unreasonably withheld, conditioned or delayed).  Where Grünenthal uses such Third Party consultant to conduct the audit, Grünenthal shall have the right to attend the audit alongside the Third Party consultant.  In connection with any such audit, MSB shall have the right to put in place reasonable precautionary measures to prevent any confidential information of any Third Party being disclosed to Grünenthal, provided that such measures do not frustrate the purpose of the audit.  MSB shall give Grünenthal and any selected Third Party consultant reasonably necessary assistance for a full and correct conduct of the audit.  Grünenthal shall only be permitted to conduct such audits with respect to each applicable facility at a reasonable frequency during the term of this Agreement, unless (i) it has reason to believe (acting reasonably and in good faith) that MSB is in material breach of its obligations under this Agreement, (ii) a serious incident impacting patient health or safety occurs in the conduct of Development activities hereunder or (iii) required by a Regulatory Authority in the Territory, in which case additional audits shall be permitted. Where required by a Regulatory Authority in the Territory, MSB shall allow the Regulatory Authority access to its premises for the purposes of conducting any such audit. Any audit conducted pursuant to this Section 8.4.1 shall not relieve MSB of any of its obligations under this Agreement.

-47-

 

 

8.4.2Third Parties.  MSB shall procure for Grünenthal the rights set forth in Section 8.4.1 from Third Parties acting on MSB’s behalf, including study sites and other contractors with respect to the Product within the Field.  

8.5. Safety Data Exchange Agreement. On the Effective Date, the Parties shall enter into a safety data exchange agreement in the form agreed upon by the Parties (“SDE Agreement”).

Article 9
PAYMENTS

9.1.Fees and Royalty.

9.1.1Signature Fee.  By no later than the date which is the later of (a) ten (10) Business Days after the Effective Date and (b) October 1, 2019, Grünenthal shall pay to MSB $15,000,000 (fifteen million Dollars) (the “Signature Fee”).  As at the Amendment and Restatement Date, MSB hereby confirms that it received payment of the Signature Fee in accordance with this Section 9.1.1.

9.1.2Milestones.  Grünenthal shall pay to MSB the amounts set forth in Exhibit 9.1.2 (each, a “Milestone Payment”) upon the achievement of the corresponding milestone event for Product (each, a “Milestone Event”). The Milestone Payments shall each be due and payable to MSB within [***]of Grünenthal becoming aware of the achievement of the corresponding Milestone Event set forth in Exhibit 9.1.2.  The Party responsible for the activity to which a Milestone Event relates shall promptly notify the other Party in writing of its achievement of the relevant Milestone Event. Each Milestone Payment shall be payable only once in respect of each Milestone Event.  If, prior to the date on which a Milestone Payment for any Milestone Event is due, Grünenthal notifies MSB of a bona fide  Milestone Dispute with respect to that Milestone Event (such notification of dispute to be made within[***] of Grünenthal receiving notice from MSB that the Milestone Event has occurred), (i) Grünenthal’s obligation to pay the Milestone Payment shall be suspended pending resolution of that Milestone Dispute and (ii) if the outcome of the Milestone Dispute (either through agreement of the Senior Executives in accordance with Section 2.5.2 or by expert determination in accordance with Part A of Exhibit 2.9) is that the Milestone Event has occurred, Grünenthal shall pay the applicable Milestone Payment within [***]of the date on which the Milestone Dispute is resolved or determined.

9.1.3Royalty.  Subject to Sections 9.1.4 to 9.1.8 below and Exhibit 7.4.1 with respect to the Royalty Period, Grünenthal shall pay to MSB that percentage of Annual Net Sales set forth in Exhibit 9.1.3 (the “Royalty”). Within [***]after the end of each Quarter, Grünenthal shall deliver to MSB a report setting out in detail the following information: (a) units of Product sold during the Quarter; (b) Net Sales of Product sold during the Quarter; (c) all relevant exchange rate conversions in accordance with Section 9.6; (d) any Supply Price Offset with respect to that Quarter; and (e) the Royalty due to MSB with respect to such Net Sales. The calculation in the report shall be made in, and the Royalty shall be payable in, Dollars.  Following receipt of such report, MSB shall provide Grünenthal with an invoice for the Royalties for that Quarter, as specified in the report.

-48-

 

 

9.1.4Royalty Period.  On a country-by-country basis, sales of the Product by Grünenthal shall be royalty free both (a) prior to the Royalty Start Date for that country and (b) following expiring of the Royalty Period for that country.

9.1.5Royalty Offset.  If a Party is unable to resolve a Third Party’s claim or assertion of infringement of a Patent or other intellectual property right with respect to the manufacture, use, sale, offer for sale or importation of Product within the Field in the Territory in accordance with Section 10.3 and the claim or assertion of infringement remains outstanding, then Grünenthal, acting in a commercially reasonable manner, may obtain a licence from such Third Party allowing Grünenthal to Commercialize the Products in accordance with this Agreement without infringing such Third Party’s Patent or other intellectual property right.

In such event, Grünenthal shall be entitled to offset an amount equal to the payments made to such Third Party in any Quarter against the Royalty payments that would otherwise be payable to MSB in respect of that Quarter, provided that in no event shall such offset otherwise reduce the Royalty otherwise payable by more than [***].  

9.1.6Royalty Reduction for Competition.  If any Third Party Commercializes any Third Party Competitive Product in any country in the Territory after the First Commercial Sale of the Product in the Territory, the Royalties payable by Grünenthal with respect to that country pursuant to Section 9.1.3 shall be reduced as follows:

(a)if the aggregate market share of all Third Party Competitive Products in that country during any Annual Period is less than [***], there will be no reduction in Royalties owed for Annual Net Sales in that country;

(b)if the aggregate market share of all Third Party Competitive Products in that country during any Annual Period is greater than or equal to [***]but less than[***], then the Royalties owed for Annual Net Sales in that country for each Annual Period thereafter will be reduced to an amount equal to [***]of the royalty rates set out in Exhibit 9.1.3; 

(c)if the aggregate market share of all Third Party Competitive Products in that country is [***]or more during any Annual Period, then the Royalties owed for Annual Net Sales in that country for each Annual Period thereafter will be reduced to an amount equal to [***]of the royalty rates set out in Exhibit 9.1.3; and 

(d)if the aggregate market share of all Third Party Competitive Products in that country is [***]or more during any [***]Annual Periods, then (i) the Royalties owed for Annual Net Sales in that country for each Annual Period thereafter will be reduced to a royalty rate of [***]of Net Sales and (ii) such royalty rate shall apply to all Annual Net Sales in that country such that the royalty tiers described in Exhibit 9.1.3 shall no longer apply to that country.

The aggregate market share of Third Party Competitive Products in the Territory in any Annual Period shall be calculated by reference to (i) aggregate unit sales of all [***]Products in the Field in the relevant country in the Territory in that Annual Period, divided by (ii) aggregate unit sales of all [***]Products and the Product in the Field in the relevant country in the Territory 

-49-

 

 

in that Annual Period.  Unless otherwise agreed by the Parties, the unit sales of each such Competing Product sold during a half calendar year will be as reported by IQVIA, formerly known as IMS America Ltd. of Plymouth Meeting, Pennsylvania (“IMS”) or any successor to IMS or any other independent sales auditing firm reasonably agreed upon in writing by the Parties as being an appropriate source of information in the Territory.

9.1.7European Royalty Reduction Based on Gross Margin. If, in any Quarter, Grünenthal’s Gross Margin for the Product in any country within Europe is less than [***], then for so long as Grünenthal’s Gross Margin for the Product in any country within Europe remains less than [***], each applicable Royalty Rate for Annual Net Sales in that country will be reduced to a rate equal to [***]of the royalty rates set out in Exhibit 9.1.3. Net Sales from the so affected country(ies) within Europe shall be attributed on a pro-rata basis to each royalty tier under which Royalties are paid during the applicable Annual Period.  For the avoidance of doubt, Gross Margin shall always be calculated disregarding any reduction of the royalty rate that would be made pursuant to this Section 9.1.7.

9.1.8Royalty Reduction for Material Breach.  If (a) MSB commits any material breach of this Agreement in relation to which MSB becomes liable to pay any damages to Grünenthal (whether by way of any settlement agreed between the Parties or by way of arbitral award made pursuant to any arbitration under Section 14.4) and (b) MSB fails to pay such damages in accordance with the terms of the relevant settlement or arbitral award and fails to remedy such failure within [***]of receipt of written notice from Grünenthal requiring it to do so, then [***]

9.1.9Within [***]following the end of each Annual Period, the Parties shall collaborate (acting reasonably and in good faith) in the conduct of a Royalty true-up to ensure that the Royalties paid with respect to that Annual Period accurately reflect the requirements of Sections 9.1.3 to 9.1.8 having regard to the various reductions, adjustments and set-offs referenced in those Sections. 

9.2.Payment Method.  All payments due under this Agreement to a Party from another Party shall be made by bank wire transfer in immediately available funds to the relevant account outlined below (or such alternative account as may be notified by the receiving Party to the paying Party from time to time on written notice) and shall be non-refundable and non-creditable, (except for the [***]).  All payments hereunder shall be made in Dollars.  Except as otherwise provided herein, all payments due under this Agreement shall be due and payable within [***]of the date of invoice.  If the receiving Party notifies the paying Party of an alternative account for payment, (a) its notice to the paying Party of the new account shall identify the details of the account including the name of the account holder (which must be the receiving Party or an Affiliate of the receiving Party) and (b) the change in account shall only take effect with respect to payments due after the date that is [***]following the paying Party’s receipt of notice of the change.

MSB account details as the Amendment and Restatement Date: 

[***]

-50-

 

 

Grünenthal account details as the Amendment and Restatement Date:

[***]

9.3.Taxes.

9.3.1The Parties agree that for income tax purposes in any jurisdiction they will treat the transaction under this Agreement, unless otherwise required by Applicable Law, as a collaboration agreement that does not constitute a partnership or a joint venture, and agree to not take (or cause any Person to take), any position on any Tax return or in the course of any audit, examination or other proceeding inconsistent with such treatment, unless otherwise required by Applicable Law and except upon a final determination of the applicable Taxing Authority.

9.3.2All payments made under this Agreement shall be net prices and free and clear of any and all taxes (like sales and use taxes, consumption taxes, goods- and sale taxes or value added taxes or comparable taxes), duties, levies, fees or other charges, except for withholding taxes. Where any sum due to be paid to a Party hereunder is subject to any withholding tax, the Parties shall use Commercially Reasonable Efforts to do all such acts and things and to sign all such documents as will enable them to take advantage of any applicable double taxation agreement or treaty. In the event there is no applicable double taxation agreement or treaty, or if an applicable double taxation agreement or treaty reduces but does not eliminate such withholding or similar tax, the paying Party shall deduct any withholding taxes from payment and pay such withholding or similar tax to the appropriate government authority. In any case the entitled Party (to be defined by the contract) will apply for issuing the tax certificate of paid withholding tax at the tax authority and send this certificate in the original version to the partner.

9.4.Inspection of Records.

9.4.1Grünenthal shall, and shall cause its Affiliates to, keep full and accurate books and records setting forth (a) gross amounts invoiced of Product, Net Sales of Product, itemized deductions from gross amounts invoiced taken to calculate Net Sales and (b) other particulars necessary to calculate amounts payable to MSB under this Article 9.  Grünenthal shall permit MSB, by independent qualified public accountants engaged by MSB and reasonably acceptable to Grünenthal (provided that the firms described on Exhibit 9.4.1 shall be deemed acceptable), to examine such books and records at any reasonable time during normal working hours on reasonable (at least [***]) prior notice, but not later than [***]following the rendering of any corresponding reports, accountings and payments pursuant to this Article 9.  The foregoing right of review may be exercised only once during each Annual Period, unless there is a reasonable basis for exercise of such right of review more frequently.

9.4.2If, as a result of any such examination, MSB reasonably concludes that Grünenthal has underreported the Royalty or other amounts payable hereunder to MSB under this Article 9, MSB shall inform Grünenthal of its disagreement with the calculation of Royalty or other amounts payable to MSB in a written notice setting forth MSB’s calculation of Royalty or other amounts payable to MSB in reasonable detail.  If the Grünenthal does not dispute the calculations set forth in MSB’s notice within [***]after receipt of such notice from MSB, the 

-51-

 

 

calculations in MSB’s notice shall be deemed the final Royalty or other amounts payable to MSB hereunder for such period.

9.4.3In the event Grünenthal disputes MSB’s calculation of Royalty or other amounts payable to MSB as set forth in such notice, Grünenthal shall within [***]after receipt of such notice from MSB, provide written notice to MSB of its disagreement with MSB’s notice and the Parties will attempt thereafter to resolve such dispute amicably.  If after [***]the Parties are unable to resolve such dispute, the Parties agree to submit the dispute for resolution to an independent Third Party accounting firm jointly selected by the Parties and the decision of such independent accounting firm as to as to the amount of Royalty or other amount for such audited period shall be final (absent clear error).

9.4.4MSB shall bear its cost of any such examination and review (including the fees of the independent accounting firm jointly selected by the Parties); provided that if the inspection and audit shows an underpayment of more than the lesser of [***], then Grünenthal shall promptly reimburse MSB for all reasonable costs incurred in connection with such examination and review.  Grünenthal shall promptly pay to MSB the amount of any underpayment revealed by an examination and review.  At Grünenthal’s election, Grünenthal may either require MSB to promptly pay to Grünenthal the amount of overpayment by Grünenthal revealed by such examination and review or make the amount of such overpayment fully creditable against future payment owed by Grünenthal to MSB under this Article 9.

9.5.Late Payment.  Any payments or portions thereof due hereunder which are not paid when due shall bear interest equal to the lesser of (a) the rate equal to [***], effective for the date that payment was due, plus an additional [***], or (b) the maximum rate permitted by Applicable Law, calculated on the number of days such payment is delinquent.  This Section 9.5 shall in no way limit any other remedies available to either Party.  For the purposes of this Section 9.5, [***]

9.6.Currency Conversion.  If any currency conversion shall be required in connection with the calculation of amounts payable hereunder, such conversion shall be made using the same exchange rates used by Grünenthal for its own public financial reporting purposes, or if none is used, then the average of the buying and selling rates on the last Business Day of the Relevant Period to which the amount applies as published by the European Central Bank.

9.7.Acknowledgement.  The Parties acknowledge that the economic terms and conditions set forth herein were negotiated and agreed to and represent a fair and equitable allocation of the value from Product within the Field in the Territory.  The Parties further acknowledge that there is considerable value in the Product Technology (including the Product Know-How) that is consistent with the economic terms and conditions herein.

-52-

 

 

Article 10
INTELLECTUAL PROPERTY

10.1.Ownership of Inventions.  As between the Parties, all right, title and interest to inventions and other subject matter made (a) solely by or on behalf of MSB in the course of conducting activities under this Agreement (“MSB Sole Inventions”) and all intellectual property rights therein (including Patents claiming the same, the “MSB Sole Patents”) shall be solely owned by MSB, (b) solely by or on behalf of Grünenthal in the course of conducting activities under this Agreement (“GRT Sole Inventions”) and all intellectual property rights therein (including Patents claiming the same, the “GRT Sole Patents”) shall be solely owned by Grünenthal, and (c) made jointly by or on behalf of each Party in the course of conducting activities under this Agreement (“Joint Inventions”) and all intellectual property rights therein (including Patents claiming the same, the “Joint Patents”) shall be jointly owned by Grünenthal and MSB.  For the avoidance of doubt, (i) MSB reserves the right to use, practice or otherwise exploit any and all MSB Sole Inventions, MSB Improvements and Joint Inventions for any and all purposes subject to the rights granted under Section 3.1 and (ii) Grünenthal reserves the right to use, practice or otherwise exploit any and all GRT Sole Inventions and Joint Inventions for any and all purposes. Subject to any exclusive rights granted under this Agreement, each Party shall have the rights to license, assign or otherwise exploit Joint Inventions or the intellectual property therein (including Joint Patents) without the obligation to obtain any approval or accounting and each Party waives any such approval or accounting right.

10.2.Patent Prosecution.

10.2.1Prosecution by MSB.  Subject to Section 10.2.2, MSB (or its designee) shall control the Prosecution and Maintenance of Product Patents (including Joint Patents).

10.2.2Back-Up Rights for Grünenthal. In the event MSB determines to abandon any Product-Specific Patent or Joint Patent in any jurisdiction in the Territory (without initiation of the Prosecution and Maintenance of a substitute therefor), MSB shall provide Grünenthal with prompt written notice (at least [***]prior to the date such abandonment would become effective), in which event Grünenthal shall have the right, at its option, to require the assignment of all right, title and interest in and to such Patent, without further consideration, to Grünenthal (or its designee) and assume the Prosecution and Maintenance of such Patent in its own name.  In the event MSB determines to abandon any Non-Product-Specific Patent in any jurisdiction in the Territory (without initiation of the Prosecution and Maintenance of a substitute therefor), (a) MSB shall provide Grünenthal with at least [***]notice prior to the date such abandonment would become effective, (b) within [***]after such notice, by written notice to MSB, Grünenthal shall have the right to require MSB to continue Prosecuting and Maintaining such Patent or assign such Patent to Grünenthal (or its designee) and (c) within [***]after MSB’s receipt of such notice, MSB shall provide notice to Grünenthal if MSB elects to continue to Prosecute and Maintain such Patent and if no such notice is provided by MSB, Grünenthal shall have the right, at its option, to require the assignment of all right, title and interest in and to such Patent, without further consideration, to 

-53-

 

 

Grünenthal (or its designee) and assume the Prosecution and Maintenance of such Patent in its own name.

10.2.3Cooperation.  With respect to any Product Patent (including Joint Patents), the Party controlling the Prosecution and Maintenance shall (a) keep the other Party reasonably informed on such activities (including notifying the other Party of all material developments with respect to such activities in the Territory in a timely manner and providing the other Party copies of all material documents received and filed in connection with the Prosecution and Maintenance of such Product Patent), and (b) provide the other Party an opportunity to review and comment on material submissions and correspondence with any patent office and shall: (i) with respect to Non-Product-Specific Patents, in good faith, take into consideration the other Party’s input with respect thereto; and (ii) with respect to Product-Specific Patents, incorporate such comments unless it has a reasonable basis not to do so, which basis is communicated to and discussed in good faith with  the other Party.

10.2.4Product-Specific Claims.  MSB shall consider in good faith any reasonable request by Grünenthal to separate Product-Specific Claims into a Product-Specific Patent, by filing appropriate divisional(s) or otherwise, to the extent it would not interfere with any other claims in or otherwise be detrimental to any Patent in which MSB has an interest.

10.2.5Patent Costs.  The Prosecution and Maintenance of Product Patents by MSB (or its designee) shall be at MSB’s expense, except that Grünenthal shall be responsible for reimbursing MSB for [***]of the Third Party costs and expenses incurred by MSB or its Affiliate for the Prosecution and Maintenance of Joint Patents within [***]after receipt of an invoice from MSB therefor.  If Grünenthal provides MSB with [***]written notice specifying that it no longer desires to bear such costs and expenses with respect to a particular Joint Patent, then [***]after MSB’s receipt of such notice, Grünenthal shall not be responsible for any further costs or expenses under this Section 10.2.5 related to any such Joint Patent; provided however that Grünenthal shall be responsible for any costs and expenses incurred up to and as of the date that is [***]after MSB receives such notice, and all right, title and interest in and to such Joint Patent (together with any Patents issuing thereon or therefrom) shall be assigned, without further consideration, to MSB (subject to the rights granted under Section 3.1).

10.3.Defense of Third Party Infringement Claims.  If Product becomes the subject of a Third Party’s claim or assertion of infringement of a Patent or other intellectual property right with respect to the manufacture, use, sale, offer for sale or importation of Product within the Field in the Territory, the Party first having notice of the claim or assertion shall promptly notify the other Party, and the Parties shall promptly confer to consider the claim or assertion and the appropriate course of action.  Unless the Parties otherwise agree in writing, each Party shall have the right to defend itself against a suit that names it as a defendant (the “Defending Party”).  Neither Party shall enter into any settlement of any claim described in this Section 10.3 that adversely affects the other Party’s rights or interests without such other Party’s written consent, which consent shall not be unreasonably withheld, conditioned or delayed.  In any event, the other Party shall reasonably assist the Defending Party and cooperate in any such litigation at the Defending Party’s request and expense.

-54-

 

 

10.4.Enforcement.

10.4.1Notice.  Subject to the provisions of this Section 10.4, in the event that either Party reasonably believes that any Product Patent is being infringed by a Third Party within the Field in the Territory or is subject to a declaratory judgment action arising from such infringement, such Party shall promptly notify the other Party.  In addition, each Party shall promptly notify the other Party in the event it receives any written claim contesting the validity, ownership or enforceability (as applicable) of any of the Product Technology.

10.4.2By Grünenthal within the Field. As between the Parties, Grünenthal shall have the initial right (but not the obligation) to initiate and control at its expense any enforcement action with respect to any infringement of any  Product Patent solely within the Field in the Territory, to defend any declaratory judgment action with respect to any Product-Specific Patent in the Territory, and to defend any claim contesting the validity, ownership or enforceability (as applicable) of any Product-Specific Patent in the Territory (each, an “Enforcement Action”) provided that (a) such right to initiate or defend an Enforcement Action with respect to Non-Product-Specific Patents is subject to MSB’s approval, not to be unreasonably withheld, conditioned or delayed and (b) MSB, at its option, shall have the right, within [***]after commencement of a declaratory judgment action with respect to a Product-Specific Patent, to intervene and participate in the defense of the action at its own expense.  In the event that Grünenthal or its designee fails to commence an Enforcement Action with respect to any infringement of any Product Patent within [***](or such shorter period necessary to initiate and maintain full rights of enforcement under such action) of a request by MSB to do so, MSB or its designee may commence an Enforcement Action with respect to such infringement at its own expense.  With respect to any Enforcement Action controlled by Grünenthal under this Section 10.4.2, MSB agrees to join such Enforcement Action as a party, or to permit Grünenthal to add MSB as a party, upon Grünenthal’s request and expense, in the event and to the extent Grünenthal reasonably believes such joinder is necessary to fully enforce rights under, and obtain remedies in respect of, any Product Patent.

10.4.3Other Enforcement Actions.  As between the Parties, MSB or its designee shall have the sole right (but not the obligation) to initiate and control at its expense any enforcement action with respect to infringement of any Product Patent in the Territory not solely within the Field, to defend any declaratory judgment action with respect to any Non-Product-Specific Patent, and to defend any claim contesting the validity, ownership or enforceability (as applicable) of any Product Technology other than Product-Specific Patents in the Territory.  In the event that (a) MSB or its designee fails to commence an enforcement action or defense pursuant to this Section 10.4.3 with respect to any such matters within the Field in the Territory (which actions or defense shall also be considered an Enforcement Action) within ninety (90) days of its receipt of Grünenthal’s written request for initiation of such an action (or within such shorter period as may be necessary to initiate and maintain full enforcement rights under such an action), (b) there is a reasonable likelihood of success on the merits for such an action or defense; provided that in the event the Parties do not agree on whether there is a reasonable likelihood of success on the merits, such matter shall be referred to an independent patent attorney(s) mutually agreed by the Parties (which attorney shall have at least twenty five (25) years of biopharmaceutical patent litigation experience in the Territory) for resolution, (c) MSB is not enforcing any other Product Patent against such Third Party infringer in respect of infringement of such Product Patent in the 

-55-

 

 

Territory and within the Field, and (d) there is not a Product-Specific Patent that Grünenthal could enforce against such Third Party infringer; then after consulting with MSB regarding Grünenthal’s reasons for believing that failure to commence or defend such action may have a material adverse impact on any of the Grünenthal Rights or the Grünenthal’s exercise or enjoyment thereof and considering in good faith any concerns that MSB may have regarding commencement or defense of such action, Grünenthal or its designee may commence an enforcement action or defense with respect to such infringement within the Field or defense of such Non-Product-Specific Patent, and shall have the sole right to control any such action at its own expense; provided that MSB, at its option, shall have the right at any time to participate in such action at its own expense. MSB agrees to join any such enforcement action as a party, or to permit Grünenthal to add MSB as a party, upon Grünenthal’s request, in the event and to the extent Grünenthal reasonably believes such joinder is necessary to fully enforce rights under, and obtain remedies in respect of, such infringement.

10.4.4Cooperation.  The Party commencing, controlling or defending any Enforcement Action under this Section 10.4 (the “Enforcing Party”) shall keep the other Party reasonably informed of the progress of any such Enforcement Action, and such other Party shall have the right to participate with counsel of its own choice at its own expense.  In any event, the other Party shall reasonably cooperate with the Enforcing Party, including providing information and materials, at the Enforcing Party’s request and expense.  The Enforcing Party shall also have the right to control settlement of such Enforcement Action; provided, however, no settlement shall be entered into without the prior written consent of the other Party if such settlement would materially and adversely affect the interests of the other Party, such consent not to be unreasonably withheld, conditioned or delayed.  The Enforcing Party shall carefully and duly consider any comments the other Party provides regarding such Enforcement Action.

10.4.5Recoveries.  Any recovery received as a result of any Enforcement Action to enforce any Product Patent pursuant to this Section 10.4 shall be used first to reimburse each Party for the costs and expenses (including court, attorneys’ and professional fees) incurred in connection with such Enforcement Action, and the remainder of the recovery shall be shared between MSB and Grünenthal [***]

10.4.6Enforcement Outside the Territory. If MSB initiates any enforcement action with respect to the infringement of any Product-Specific Patent outside the Territory, MSB shall (a) keep Grünenthal reasonably informed of the progress of such Enforcement Action, (b) to the extent the outcome of such Enforcement Action could affect Grünenthal’s interests in the Territory, carefully and duly consider any comments the other Party provides regarding such Enforcement Action and (c) not settle such Enforcement Action without the prior written consent of Grünenthal if such settlement would materially and adversely affect the interests of Grünenthal, such consent not to be unreasonably withheld, conditioned or delayed.

10.4.7Entity.  In this Section 10.4, a reference to MSB shall mean (a) Mesoblast Limited to the extent the relevant Patent is Controlled by Mesoblast Limited, and (b) Mesoblast Sàrl to the extent the relevant Patent is Controlled by Mesoblast Sàrl.

10.5.Regulatory Exclusivity.  In the event that either Party reasonably believes that exclusivity rights under any Marketing Approval for the Product within the Field in the Territory are being violated (whether by making, 

-56-

 

 

using, offering, for sale or selling any biosimilar equivalent of Product, or otherwise) by a Third Party, such Party shall promptly notify the other Party.  For clarity, as holder of the Marketing Approval for a Product, Grünenthal shall have the first right to bring any action to enforce such exclusivity rights arising from a Marketing Approval for the Product within the Field in the Territory.

10.6.Patent Marking.  To the extent required by Applicable Law, Grünenthal shall mark (or cause to be marked) Product Commercialized hereunder, in those countries in which such notices impact recoveries of damages or remedies available with respect to infringements of Patents, with appropriate Product Patent numbers or indicia consistent with Applicable Law.

10.7.Data.  All Data generated by or on behalf of a Party through the performance of activities under this Agreement shall be owned by that Party unless expressly stated otherwise hereunder.

10.8.Trademarks.  Grünenthal shall be solely responsible for the selection (in good faith consultation with MSB), registration, prosecution, maintenance, enforcement and defense of, and will solely own all right, title and interest in, all Trademarks for use in connection with the Commercialization of the Product within the Field in the Territory (collectively, the “Product Marks”), as well as all expenses associated therewith.  Grünenthal will have the right to implement a branding strategy for Product, as outlined in the Commercialization Plan using such Product Marks.

10.9.Recordal of Licence.  Grünenthal shall have the right to record any licence granted to it by MSB under this Agreement at any relevant intellectual property registry.  Upon Grünenthal’s request, MSB shall ([***]) provide Grünenthal with any assistance reasonably requested by Grünenthal to enable Grünenthal to exercise its right under this Section 10.9.

Article 11
CONFIDENTIALITY

11.1.Confidentiality; Exceptions.  Except to the extent expressly authorized by this Agreement or otherwise agreed by the Parties in writing, the Parties agree that the receiving Party shall keep confidential and shall not publish or otherwise disclose or use for any purpose other than as provided for in this Agreement any confidential or proprietary information or materials furnished to it by the other Party pursuant to this Agreement (collectively, “Confidential Information”).  The terms and conditions of this Agreement shall be deemed to be the Confidential Information of each Party.  Notwithstanding the foregoing, Confidential Information shall not be deemed to include information or materials to the extent that it can be established by written documentation by the receiving 

-57-

 

 

Party that such information or material:

11.1.1was already known to or possessed by the receiving Party without any obligation of confidentiality, at the time of its disclosure to the receiving Party hereunder;

11.1.2was generally available to the public or otherwise part of the public domain at the time of its disclosure to the receiving Party hereunder;

11.1.3became generally available to the public or otherwise part of the public domain after its disclosure hereunder other than through any act or omission of the receiving Party in breach of this Agreement;

11.1.4was independently developed by the receiving Party without use of or reference to the other Party’s Confidential Information as demonstrated by documented evidence prepared by the receiving Party contemporaneously with such independent development; or

11.1.5was disclosed to the receiving Party, other than under an obligation of confidentiality, by a Third Party not known by the receiving Party to have an obligation to the disclosing Party not to disclose such information to others.

11.2.Authorized Use and Disclosure.  Each Party may disclose Confidential Information of the other Party to the extent such disclosure is reasonably necessary in the following situations:

11.2.1Prosecuting and Maintaining Product Patents in accordance with Section 10.2  provided that the receiving Party has provided reasonable prior notice of such disclosure to the disclosing Party (unless prohibited by Applicable Law) and had due regard to any representation made by the disclosing Party in relation to such disclosure;

11.2.2complying with the requirement of Regulatory Authorities with respect to filing for, obtaining and maintaining Regulatory Approvals for Product in accordance with this Agreement (including conducting Development of Product provided that the receiving Party has provided prior reasonable notice of such disclosure to the disclosing Party (unless prohibited by Applicable Law) and had due regard to any representation made by the disclosing Party in relation to such disclosure;

11.2.3complying with Applicable Laws and regulations promulgated by security exchanges, court order or administrative subpoenas or orders or otherwise submitting information to tax authorities and other governmental authorities; provided that the receiving Party has provided prior notice of such disclosure to the disclosing Party (unless prohibited by Applicable Law) and afforded the disclosing Party the opportunity to resist or obtain protections in respect of such disclosure;

11.2.4disclosure to its or its Affiliates’ employees, consultants, advisors (including financial advisors, lawyers and accountants), permitted sublicensees and subcontractors,  and others on a need to know basis, for the sole purpose of performing its or its Affiliates’ obligations or exercising its or its Affiliates’ rights under this Agreement, provided that in each case the recipient of such Confidential Information are bound by written or otherwise 

-58-

 

 

legally enforceable obligations of confidentiality and non-use at least as equivalent in scope as those set forth in this Article 11 prior to any such disclosure; and

11.2.5disclosure to existing and potential merger partners, investors, acquirers or licensees, including their respective consultants and professional advisors (including financial advisors, lawyers and accounts), solely on a need-to-know basis in order to evaluate an actual or potential investment, acquisition or business transactions; and provided that in connection with such disclosure, the disclosing Party shall inform each disclosee of the confidential nature of such information and cause each disclosee to treat such information as confidential consistent with the nature of the Confidential Information so disclosed and provided further that the receiving Party has provided prior notice of such disclosure to the disclosing Party (excluding details of the recipient) and had due regard to any representation made by the disclosing Party in relation to such disclosure.

11.3.Prior Agreements.  This Agreement supersedes (a) the mutual non-disclosure agreement between Mesoblast Limited and Grünenthal dated [***] (as extended by such Persons) and (b) that certain term sheet between Mesoblast Limited and Grünenthal dated [***]with respect to Part iv (Confidentiality) thereof (the “Prior Understandings”).   All such information or materials disclosed or provided by MSB or its Affiliates to Grünenthal or its Affiliates (or their representatives) under the Prior Understandings shall be deemed Confidential Information of MSB (subject to the exceptions set forth herein) and shall be subject to Grünenthal’s confidentiality obligations under this Article 11.  All such information disclosed by Grünenthal or its Affiliates to MSB or its Affiliates (or their representatives) under the Prior Understandings shall be deemed Confidential Information of Grünenthal (subject to the exceptions set forth herein) and shall be subject to MSB’s confidentiality obligations under this Article 11.

11.4.Scientific Publications. 

11.4.1The Parties, through the JSC or CRB (as applicable) shall (a) determine the strategy for, (b) develop a publication plan in relation to, and (c) coordinate, the publication and presentation of results of clinical trials of the Product and other Data generated in the conduct of the Development activities hereunder.  

11.4.2Each Party recognises that the publication of papers regarding results of and other information regarding activities under this Agreement, including oral presentations and abstracts, may be beneficial to both Parties, provided such publications are subject to reasonable controls to protect Confidential Information.  In particular, it is the intent of the Parties to maintain the confidentiality of any Confidential Information included in any patent application until such patent application has been published.  Accordingly each Party shall submit to the other Party any proposed publication or public disclosure containing clinical or scientific results relating directly to Product within the Field at least [***]in advance (subject to a Party’s right to make disclosures described in Section 11.2.3) to allow the other Party to review such proposed publication or disclosure.  The reviewing Party shall notify the requesting Party in writing during such [***]reviewing period if the reviewing Party wishes to (a) remove its Confidential Information 

-59-

 

 

from such proposed publication or presentation, in which event the requesting Party shall remove such Confidential Information from its proposed publication or presentation; or (b) request a reasonable delay in publication or presentation in order to protect patentable information, in which event the requesting Party shall delay the publication or presentation for a period of no more than [***] to enable patent applications to be filed in accordance with Section 10.2 protecting inventions disclosed in such publication or presentation.  If, during the [***] reviewing period, the reviewing Party notifies the requesting Party that it does not consent to the publication due to any good faith concerns that the publication would be contrary to Applicable Laws, detrimental to the Product in the Field or detrimental to the interests of the reviewing Party, the requesting Party shall not make the publication and the matter shall be referred to the JSC for resolution.  For clarity, if the reviewing Party fails to notify the requesting Party during the [***]reviewing period as provided under this Section 11.4, the requesting Party shall be free to proceed with the proposed publication or presentation.

11.5.Publicity.

11.5.1Press Release.  

(a)The Parties issued a press release upon the Effective Date; MSB and Grünenthal agree each may disclose to Third Parties the information contained in such press release without the need for further approval by the other.  

(b)Subject to Section 11.5.1(a) and 11.5.1(c), neither Party shall make any further public announcements or issue any further press releases referencing this Agreement, the subject matter of this Agreement or the other Party (“Public Announcement”) without the prior written consent of the other Party, which shall not be unreasonably withheld, conditioned or delayed, however, to the extent such Public Announcement is required by Applicable Law or any recognized stock exchange on which the Announcing Party’s stock trades as determined by the Announcing Party in consultation with its outside legal counsel, such Public Announcement shall be deemed consented to by the other Party.  The Parties agree to consult with each other reasonably and in good faith with respect to the text and timing of any Public Announcements prior to its issuance.

(c)In addition to the requirements of Section11.5.1(b), where either Party (the “Announcing Party”) wishes to make any further Public Announcement:

(i)the Announcing Party shall provide the other Party with a written draft of the Public Announcement at least 48 hours prior to the proposed publication of the Public Announcement (unless the rules of any recognized stock exchange on which the Announcing Party’s stock trades require publication sooner, in which case the Announcing Party shall be permitted to publish the Public Announcement provided that it indemnifies the other Party’s Indemnitees (i.e., Grünenthal Indemnitees, if MSB is the Announcing Party, and MSB Indemnitee, if Grünenthal is the Announcing Party) from and against any Losses incurred by the other Party’s Indemnitees as a result of such sooner publication) in accordance with Section 12.5; 

 (ii)if the other Party’s consent to the publication of the Public Announcement is conditional on the incorporation of any reasonable comments raised by the other 

-60-

 

 

Party, the Announcing Party shall incorporate such reasonable comments into the Public Announcement prior to publication (however, to the extent such Public Announcement is required by Applicable Law or any recognized stock exchange on which the Announcing Party’s stock trades as determined by the Announcing Party in consultation with its outside legal counsel, such condition shall only apply if consistent therewith as determined by the Announcing Party in consultation with its outside legal counsel); and

(iii)if the Announcing Party is found to be in breach of either Section 11.5.1(b) or Section 11.5.1(c)(ii), in accordance with Section 14.4, then the arbitrators shall determine the applicable damages, if any, payable to the other Party as a result of such breach.

11.5.2Publicity Review.  The Parties acknowledge the importance of supporting each other’s efforts to publicly disclose results and significant developments regarding Product within the Field in the Territory and other activities in connection with this Agreement, beyond what may be strictly required by Applicable Law and the rules of recognized stock exchanges.  If, from time to time, a Party wishes to make any such disclosure which is not strictly required by Applicable Law or the rules of recognized stock exchanges it shall provide the other Party with written details of the proposed disclosure and shall only make such disclosure if it has received the other Party’s prior written consent (not to be unreasonably withheld, conditioned or delayed).  Such disclosures may include disclosures relating to achievement of significant events in the Development (including regulatory process and occurrence of Marketing Approval for Product within the Field in the Territory) or Commercialization of Product within the Field in the Territory hereunder.  Unless otherwise requested by MSB, Grünenthal shall indicate that MSB is the owner and innovator of Product and the Product Technology in each public disclosure regarding Product issued by Grünenthal pursuant to this Section 11.5.2.  The principles to be observed by each Party in such disclosures shall be accuracy, compliance with Applicable Law and regulatory guidance documents, reasonable sensitivity to potential negative reactions of applicable Regulatory Authorities and the need to keep investors and others informed regarding the requesting Party’s business, including as required by the rules of recognized stock exchanges.  

For the avoidance of doubt, nothing in this Section 11.5 shall prevent a Party from making any disclosure required by Applicable Law or the rules of recognized stock exchanges.

11.6.Common Interest.  The Parties acknowledge that as a result of their activities under this Agreement they may desire to share information or materials for which attorney-client privilege or similar privileges or doctrines may apply, including pursuant to Article 10, and in such case at the request of either Party, the Parties shall agree on and enter into a “common interest agreement” on standard and customary terms and conditions wherein the Parties will document such common interest and the appropriate protections for such information and materials.

-61-

 

 

Article 12
REPRESENTATIONS, WARRANTIES AND COVENANTS; INDEMNIFICATION

12.1.Grünenthal Representations and Warranties.  Grünenthal represents and warrants to MSB that as of the Effective Date and as of the Amendment and Restatement Date:

12.1.1it is duly organized and validly existing under the Applicable Law of the jurisdiction of its incorporation, and has full corporate power and authority to enter into this Agreement and to carry out the provisions hereof;

12.1.2it is duly authorized to execute and deliver this Agreement and to perform its obligations hereunder, and the individual executing this Agreement on its behalf has been duly authorized to do so by all requisite corporate action;

12.1.3this Agreement is legally binding upon it and enforceable in accordance with its terms and the execution, delivery and performance of this Agreement by it does not conflict with any agreement, instrument or understanding, oral or written, to which it is a party or by which it may be bound, nor violate any material Applicable Law, except to the extent that the enforceability thereof may be limited by (a) applicable bankruptcy, insolvency, fraudulent conveyance, reorganization, moratorium or similar laws from time to time in effect affecting generally the enforcement of creditors’ rights and (b) general principles of equity;

12.1.4it has not granted, and shall not grant during the Term, any right to any Third Party which would conflict with the rights granted to MSB hereunder;

12.1.5to Grünenthal’s Knowledge there is no action, suit or inquiry or investigation instituted by any Person which questions or threatens the validity of this Agreement or Grünenthal’s ability to perform its obligations under this Agreement; and

12.1.6neither Grünenthal nor any of its Affiliates, nor, to Grünenthal’s Knowledge, any of its subcontractors, employees or agents has ever been, is currently, or is the subject of a debarment proceeding that could lead to that party becoming, as applicable, a Debarred Entity or Debarred Individual.

12.2.MSB’s Warranties.  Each of Mesoblast Limited and Mesoblast Sàrl represents and warrants to Grünenthal that as of the Effective Date and as of the Amendment and Restatement Date:  

12.2.1it is duly organized and validly existing under the Applicable Law of the jurisdiction of its incorporation, and has full corporate power and authority to enter into this Agreement and to carry out the provisions hereof;

12.2.2it is in good standing, has the power to carry on its business as now conducted and, as at the Relevant Date, has not suffered any MSB Insolvency Event;

-62-

 

 

12.2.3it is duly authorized to execute and deliver this Agreement and to perform its obligations hereunder, and the individual executing this Agreement on its behalf has been duly authorized to do so by all requisite corporate action;

12.2.4this Agreement is legally binding upon it and enforceable in accordance with its terms and the execution, delivery and performance of this Agreement by it does not conflict with any agreement, instrument or understanding, oral or written, to which it is a party or by which it may be bound, nor violate any material Applicable Law, except to the extent that the enforceability thereof may be limited by (a) applicable bankruptcy, insolvency, fraudulent conveyance, reorganization, moratorium or similar laws from time to time in effect affecting generally the enforcement of creditors’ rights and (b) general principles of equity;

12.2.5MSB has not granted, and will not grant during the Term, rights to any Third Party under the Product Technology that conflict with the rights granted to Grünenthal hereunder;

12.2.6to MSB’s Knowledge there is no action, suit or inquiry or investigation instituted by any Person which questions or threatens the validity of this Agreement or ability to perform its obligations under this Agreement; 

12.2.7to MSB’s Knowledge, all Development activity conducted by or on behalf of MSB or its Affiliates prior to the Relevant Date in relation to the Product have been conducted in compliance with Applicable Laws;

12.2.8neither MSB nor any of its Affiliates has been in material breach of any Applicable Laws relating to the conduct of its business in the twenty-four month period prior to Relevant Date;

12.2.9neither MSB nor any of its Affiliates is in breach of the MSB Loan Agreement;

12.2.10the Product Technology is not subject to any security interest or other encumbrance other than the security interests granted pursuant to the MSB Loan Agreement;

12.2.11neither MSB nor any of its Affiliates, nor, to MSB’s Knowledge, any of its subcontractors, employees or agents has ever been, is currently, or is the subject of a debarment proceeding that could lead to that party becoming, as applicable, a Debarred Entity or Debarred Individual;

12.2.12neither MSB or any of its Affiliates has intentionally withheld from Grünenthal any information (a) that is material to the Development, Commercialization and/or Manufacturing activities with respect to the Product contemplated by this Agreement and (b) that would have affected Grünenthal’s decision to enter into this Agreement; and 

12.2.13all information disclosed to Grünenthal by MSB in relation to the Product prior to the Relevant Date (including all information included in the “Mesoblast” electronic data room relating to the transaction contemplated hereunder hosted by Donnelley Financial Solutions Venue) was accurate in all material respects. Promptly following the Effective 

-63-

 

 

Date, MSB will provide a copy of the contents of such data room to Grünenthal in electronic form, all of which shall be deemed the Confidential Information of MSB. 

12.3.MSB Product Technology Warranties and Covenants.  In addition to its other obligations under this Agreement in respect of Product Technology each of Mesoblast Limited and Mesoblast Sàrl represents, warrants and covenants to Grünenthal as of the Effective Date and as of the Amendment and Restatement Date, as follows:

12.3.1MSB has prior to the Relevant Date disclosed to Grünenthal a complete and accurate copy of all agreements between MSB or any of its Affiliates with any Third Party pursuant to which MSB or its Affiliate has acquired rights (whether by license, assignment or other transfer) to any Product Technology from any Third Party and pursuant to which MSB or its Affiliate has any continuing obligations, financial or otherwise, to such Third Party in respect of such Product Technology (such agreements the “Third Party Project Technology Agreements”).  During the Term, MSB shall comply, and shall cause its Affiliates to comply with their respective obligations under any Third Party Project Technology Agreement.

12.3.2(a) MSB (either Mesoblast Limited, Mesoblast Sàrl or an Affiliate) Controls the Product Patents described on Exhibit 1.65 and the Product-Specific Patents described on Exhibit 1.67, (b) no Product Patent has been invalidated or held unenforceable and, to MSB’s Knowledge there are no facts that will cause any Product Patent to be invalid or unenforceable, and (c) to its Knowledge, MSB has not misrepresented or failed to disclose any facts or circumstances in any application for any Product Patent that it or its Affiliate owns, prosecutes or maintains or has the authority to prosecute or maintain that would constitute fraud or a material misrepresentation with respect to such application and that would affect the enforceability of any granted or subsequently granted patent of such Product Patent.

12.3.3to MSB’s Knowledge there are no Third Party Patents or Know-How that MSB would need to acquire rights (whether by license, assignment or other transfer) under to Develop and Manufacture Product as currently contemplated by MSB or to Commercialize the Product, in each case within the Field in the Territory, and all such rights that are Controlled by MSB are included in the Product Technology.

12.3.4MSB has not received any written claim by any Person contesting the validity, ownership or enforceability (as applicable) of any Product Technology or alleging that any Development activities in respect of Product conducted by or on behalf of MSB or its Affiliates infringes, misappropriates or otherwise violates any Patents, Know-How or other Third Party intellectual property and MSB is not aware of any such claim having been threatened.

12.3.5to MSB’s Knowledge, none of the Development activities in respect of Product conducted by or on behalf of MSB or its Affiliates has infringed, misappropriated or otherwise violated any Patents, Know-How or other intellectual property of any Third Party, whether directly, as a contributory infringer, through inducement or otherwise.

12.3.6to MSB’s Knowledge, none of the Development, Manufacture or Commercialization of Product (including, for the avoidance of doubt, methods of isolating, 

-64-

 

 

preparing, culturing, purifying, proliferating, and enhancing MPCs and MPC preparations and populations) within the Field, as currently contemplated by MSB (including pursuant to the Development Plan) will infringe, misappropriate or otherwise violate, any Patents, Know-How or other the intellectual property of any Third Party, whether directly, as a contributory infringer, through inducement or otherwise.

12.3.7to MSB’s Knowledge no Third Party is infringing, misappropriating or otherwise violating any Product Technology in the Territory within the Field.

12.3.8MSB and its Affiliates have taken, and during the Term shall continue to take Commercially Reasonable Efforts to maintain and protect Product Technology, including taking reasonable steps, to maintain and protect the confidentiality of the Product Know-How consistent with its past practice.

12.4.Disclaimer of Warranties.  EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT AND THE EXPRESS WARRANTIES OF ANY OTHER TRANSACTION AGREEMENT (ONCE EXECUTED), MSB AND GRÜNENTHAL EXPRESSLY DISCLAIM ANY WARRANTIES OR CONDITIONS, EXPRESS, IMPLIED, STATUTORY OR OTHERWISE, WITH RESPECT TO THE SUBJECT MATTER OF THIS AGREEMENT (INCLUDING THE PRODUCT AND PRODUCT TECHNOLOGY), INCLUDING ANY WARRANTY OF MERCHANTABILITY, NONINFRINGEMENT, OR FITNESS FOR A PARTICULAR PURPOSE.

12.5.Indemnification.

12.5.1Indemnification by MSB. MSB hereby agrees to defend, hold harmless and indemnify (collectively, “Indemnify”) Grünenthal and its Affiliates, and its and their agents, directors, officers and employees (the “Grünenthal Indemnitees”) from and against any liability or expense (including reasonable legal expenses, fines and attorneys’ fees) (collectively, “Losses”) resulting from suits, claims, actions and demands, in each case brought by a Third Party (each, a “Third Party Claim”) against any Grünenthal Indemnitee arising out of (a) MSB’s breach of this Agreement including any of MSB’s respective representations and warranties under Section 12.2 or Section 12.3, (b) the gross negligence, intentional misconduct or noncompliance with Applicable Law of MSB, any of its Affiliates or any of its subcontractors or sublicensees, or (c) the conduct of activities under this Agreement by MSB, any of its Affiliates or any of its subcontractors or sublicensees.  MSB’s obligation to Indemnify the Grünenthal Indemnitees pursuant to this Section 12.5.1 shall not apply to the extent that any such Losses are Losses for which Grünenthal is obligated to Indemnify MSB Indemnitees pursuant to Section 12.5.2.

12.5.2Indemnification by Grünenthal.  Grünenthal hereby agrees to Indemnify MSB and its Affiliates, and its and their agents, directors, officers and employees (the “MSB Indemnitees”) from and against any and all Losses resulting from Third Party Claims arising out of: (a) Grünenthal’s breach of this Agreement, including any of Grünenthal’s representations and warranties under Section 12.1, (b) Grünenthal’s gross negligence, intentional misconduct or noncompliance with Applicable Law of Grünenthal, any of its Affiliates or any of its subcontractors or sublicensees or (c) the conduct of activities under this Agreement by Grünenthal, 

-65-

 

 

any of its Affiliates or any of its subcontractors or sublicensees.  Grünenthal’s obligation to Indemnify MSB Indemnitees pursuant to the foregoing sentence shall not apply to the extent that any such Losses are Losses for which MSB is obligated to Indemnify the Grünenthal Indemnitees pursuant to Section 12.5.1.

12.5.3Procedure. To be eligible to be indemnified hereunder, the indemnified Party shall provide the indemnifying Party with prompt notice of the Third Party Claim giving rise to the indemnification obligation pursuant to this Section 12.5 and, except as provided below, the exclusive ability to defend (with the reasonable cooperation of the indemnified Party) or settle any such claim; provided, however, that the indemnifying Party shall not enter into any settlement that admits fault, wrongdoing or damages without the indemnified Party’s written consent, such consent not to be unreasonably withheld, conditioned or delayed. The indemnified Party shall have the right to participate, at its own expense and with counsel of its choice, in the defense of any claim or suit that has been assumed by the indemnifying Party, provided that the indemnifying Party shall have no obligations with respect to any Losses resulting from the indemnified Party’s admission, settlement or other communication without the prior written consent of the indemnifying Party, such consent not to be unreasonably withheld, conditioned or delayed.  If: (a) the indemnifying Party does not assume the defense of any such claim or legal proceeding in accordance with the terms hereof within [***]after the first to occur of its receipt of notice thereof from the indemnified Party, (b) a good faith and diligent defense is not being or ceases to be conducted by the indemnifying Party, or (c) if Grünenthal is the indemnified Party, if the claim or legal proceeding involves allegations that the Product or its manufacture, use, sale, offer for sale or importation within the Field in the Territory infringes a Patent and for this clause (c) Grünenthal notifies MSB that it will control the defense of such Third Party Claim at the time it provides notice of such Third Party Claim, the indemnified Party shall have the right (but not the obligation) to defend or settle (and control the defense of) such claim or legal proceeding, and in such event, the indemnifying Party shall cooperate, at its own expense, with the indemnified Party in the defense and/or settlement of such claim or legal proceeding and shall pay, as they become due, all reasonable costs, expenses and fees incurred by either Party in connection with such defense and settlement (in addition to any indemnification obligations hereunder); provided that if Grünenthal elects to control the defense of a Third Party Claim as described in clause (c), Grünenthal shall not enter into any settlement that admits fault, wrongdoing or damages without MSB’s written consent, such consent not to be unreasonably withheld, conditioned or delayed and Grünenthal shall use Commercially Reasonable Efforts to limit the costs, expenses and fees incurred by it in connection with such defense and settlement in a manner consistent with the defense and settlement of similar claims in which Grünenthal bears such costs, expenses and fees.

12.6.Limitation of Liability.  EXCEPT TO THE EXTENT ARISING AS A RESULT OF A PARTY’S BREACH OF ITS OBLIGATIONS UNDER ARTICLE 10 OR TO THE EXTENT AWARDED TO A THIRD PARTY BY A COURT OF COMPETENT JURISDICTION IN A THIRD PARTY CLAIM FOR WHICH SUCH PARTY IS RESPONSIBLE TO INDEMNIFY THE OTHER PARTY, NEITHER PARTY SHALL BE LIABLE TO THE OTHER FOR ANY SPECIAL, CONSEQUENTIAL, INCIDENTAL, PUNITIVE, OR INDIRECT DAMAGES ARISING FROM OR RELATING TO THIS AGREEMENT, REGARDLESS OF ANY NOTICE OF THE 

-66-

 

 

POSSIBILITY OF SUCH DAMAGES.  NOTWITHSTANDING THE FOREGOING, NOTHING IN THIS SECTION 12.6 IS INTENDED TO OR SHALL LIMIT OR RESTRICT THE INDEMNIFICATION RIGHTS OR OBLIGATIONS OF ANY PARTY UNDER SECTION 11.5.1(c)(i) OR SECTION 12.5.

12.7.Insurance. Each of Mesoblast Limited and Mesoblast Sàrl hereby represents, warrants and covenants to Grünenthal that (i) it is insured at its own expense against liability and other risks associated with its Development and Manufacturing activities and obligations under this Agreement (including product liability and clinical trial liability) in such amounts and on such terms as are customary for prudent practices for biopharmaceutical companies in the life sciences industry for the activities to be conducted by it under this Agreement, provided that the minimum amount of such insurance coverage shall be [***]and the policies shall have a minimum run-off extended reporting period of [***], (ii) it shall maintain such insurance for as long as it is conducting Development or Manufacturing activities under this Agreement and for a period of at least [***] thereafter and (iii) all insurance policies required in order to satisfy its obligations under this Section 12.7 shall be written by insurance companies with an A.M. Best’s rating of A:VIII or higher.  MSB shall provide Grünenthal with copies of such insurance policies within [***]of the Effective Date and at any time thereafter during the Term upon Grünenthal’s written request (such request to be made no more than once in each calendar year).

Article 13
TERM AND TERMINATION

13.1.Term.  

13.1.1Agreement Term.  This Agreement shall become effective as of the Effective Date and shall continue in full force thereafter for an indefinite term until terminated pursuant to the other provisions of this Article 13 (the “Term”).  

13.1.2Country-by-country Termination. Notwithstanding Section 13.1.1, following expiration of the Royalty Period in a country in the Territory, all rights and obligations of the Parties hereunder with respect to that country shall immediately terminate (without need for notice from either Party), save that the licences granted under Sections 3.1 and 3.2.3 shall survive such termination and remain in force in that country until expiry of the Term.

13.2.Grünenthal Termination Rights. Grünenthal may terminate this Agreement by providing the applicable written notice to MSB and referencing the applicable Section by which it is so terminating and the reason (if any) for such termination:

13.2.1on [***]written notice to MSB, without reason at any time during the Term; 

13.2.2[***]

-67-

 

 

 

13.2.3on [***]written notice to MSB, if MSB fails to include the Required European Patients in the New Phase III Clinical Trial, provided that Grünenthal has not provided the Continuation Notice;

13.2.4on [***]written notice to MSB (such notice to be provided within [***]of the conclusion of any relevant [***]with any [***] in any [***]), if Grünenthal reasonably determines in good faith based on HTA requirements for the Continuation Development Plan that the Reimbursement Net Price on the estimated Net Price Determination Date is likely to be less than [***] for a patient population in line with the inclusion criteria of any of [***];

13.2.5on [***]written notice to MSB, if Grünenthal (acting reasonably and in good faith) determines based on [***]that the likelihood of obtaining [***]and/or [***]for the Product within the Field in the Territory would be increased by the conduct of the [***]using [***]rather than [***];

13.2.6on [***]written notice to MSB if Grünenthal receives written notice from the [***]that:

(a)it will not, or is unlikely to, [***]the Product based on [***]from the [***], in its sole discretion, elects not to generate any further clinical data to support a filing of a [***] for the Product with the [***]; or

(b)it will not, or is unlikely to, grant[***]based on the filing of any [***]for the Product, 

provided in each case that such termination notice is provided within [***]of Grünenthal’s receipt of the written notice from the [***];

13.2.7on [***]written notice to MSB if Grünenthal receives written notice from any [***]that it will not, or is unlikely to, grant [***], provided that such termination notice is provided within [***]of Grünenthal’s receipt of the written notice from the relevant [***];

13.2.8on [***]written notice to MSB if MSB fails to complete the activities set forth in and in accordance with the [***], provided (i) such notice may not be given prior to the [***]and (ii) that such right to terminate will be stayed if, within such [***], MSB provides Grünenthal with a reasonable plan for curing the specified failure and for so long as MSB is actively executing such plan until cured;

13.2.9on[***]written notice to MSB, if any [***]has received Regulatory Approval and the first commercial sale of such product has been made in the Territory prior to the First Commercial Sale of the Product in the Territory, provided that such termination notice is provided within [***] of the date on which Grünenthal  becomes aware of the launch of the relevant [***};

13.2.10on [***]written notice to MSB, if [***]has received Regulatory Approval and the first commercial sale of such product has been made in the Territory and such [***]has a material adverse effect on the Net Sales of the Product in the Field in the Territory, 

-68-

 

 

provided that such termination notice is provided by no later than [***]anniversary of the date on which Grünenthal becomes aware of the launch of the relevant [***]; 

13.2.11on [***] written notice to MSB, if the Reimbursement Net Price is less than [***]for a patient population in line with the inclusion criteria of the [***]Clinical Trial or, if conducted, a [***] Clinical Trial, provided that such termination notice is provided within [***]of the Net Price Determination Date; 

13.2.12[***]on written notice to MSB if, in accordance with Section 2.5.1, the Parties fail to agree the governance structure that shall be applicable to the Parties’ relationship under this Agreement following the Continuation Date by the date that is [***]after the Continuation Date, provided that such termination notice is provided within [***]; or

13.2.13On [***] written notice to MSB, if any failure by MSB to obtain any [***]results in a delay to the conduct of any [***]Clinical Trial of [***]or more by comparison to the estimated timelines for the conduct of such [***]Clinical Trial set out in the Continuation Development Plan, provided that such termination notice is provided within [***]of notice of such delay.

13.3.Termination for Failure to Provide Continuation Notice.  Either Party may terminate this Agreement in accordance with Section 4.9.3, provided that such notice of termination is provided within the later of [***]of the date of Grünenthal’s election or deemed election under Section 4.9.2(b) and [***].

13.4.Termination for Breach.  

13.4.1Either Party may terminate this Agreement in the event the other Party materially breaches this Agreement, and, if such breach is capable of being cured such breach shall have continued for [***]after notice thereof was provided to the breaching Party by the non-breaching Party.  Any such termination shall become effective upon notice thereof to the extent such breach is not capable of being cured or otherwise at the end of such [***]period unless the breaching Party has cured any such breach prior to the expiration of the [***]period.  Notwithstanding the foregoing, this Section 13.4.1 shall not apply to any material breach of a Party’s payment obligations hereunder and any such breaches shall instead be subject to Section 13.4.2 below.  

13.4.2If a Party (the “Paying Party”) has failed to make any payment in excess of [***]or more due hereunder to the other Party (the “Receiving Party”) by the date that is [***]after the relevant due date for payment, the Receiving Party may provide the Paying Party with a written notice (“Reminder Notice”) requiring that payment is made within [***]and notifying the Paying Party of its intent to terminate this Agreement if such payment is not made by that date.  If the Paying Party has not paid such outstanding amount within [***]of receipt of the Reminder Notice, the Receiving Party may immediately terminate this Agreement on written notice to the Paying Party.

-69-

 

 

13.5.Termination by Mesoblast.  

13.5.1Patent Challenge.  If, without the prior consent of MSB (such consent not to be unreasonably withheld, conditioned or delayed) and except as provided below, Grünenthal or any of its Affiliates challenges under any court action or proceeding, or before any patent office, the validity, patentability, enforceability, scope or non-infringement of any Product Patent, or initiates a reexamination of any Product Patent, or assists any Third Party to conduct any of the foregoing activities (each, a “Challenge”), MSB will have the right to immediately terminate this Agreement.  In any event, Grünenthal shall notify MSB at least [***]prior to initiating any such Challenge.  However the foregoing shall not apply to: (i) any such action or proceeding brought in response to an action brought against Grünenthal, its Affiliate for infringement of any Product Patent or (ii) any ordinary course Prosecution and Maintenance matters (i.e., those intended to cause a Product Patent to issue or strengthen an already issued Product Patent or that are approved by MSB) controlled by Grünenthal in accordance with Section 10.2.

13.5.2For Patient Safety or Impracticability.  If during the conduct of the [***]and after consultation with the JSC, MSB determines (acting reasonably and in good faith) that (a) based on clinical evidence of adverse event(s), continued conduct of the [***]poses a significant risk to patients or (b) despite using Commercially Reasonable Efforts continued Development is not likely to [***]for the Product for the Field in the Territory, then MSB shall provide written [***]to Grünenthal setting forth the proposed basis for such termination and available documentation and information in support of the same.  Such termination shall become effective [***]after such termination; provided that if requested by Grünenthal, the JSC shall meet and discuss other possibilities to go forward.  

13.6.Termination for Insolvency. 

13.6.1MSB shall have the right to terminate this Agreement upon delivery of written notice to Grünenthal in the event that (a) Grünenthal such other Party files in any court or agency pursuant to Applicable Law a petition in bankruptcy or insolvency or for reorganization or similar arrangement for the benefit of creditors or for the appointment of a receiver or trustee of Grünenthal or its assets, (b) Grünenthal is served with an involuntary petition against it in any insolvency proceeding and such involuntary petition has not been stayed or dismissed within [***]of its filing, (c) Grünenthal makes an assignment of substantially all of its assets for the benefit of its creditors or (d) any event occurs that corresponds to any of those in paragraphs (a) to (c) in relation to Grünenthal or any of its assets in any country or territory in which it is incorporated or carries on business or to the jurisdiction of whose courts it or any of its assets is subject.

13.6.2Grünenthal shall have the right to terminate this Agreement upon delivery of written notice to MSB in the event that (a) either Mesoblast Limited or Mesoblast Sàrl files in any court or agency pursuant to Applicable Law a petition in bankruptcy or insolvency or for reorganization or similar arrangement for the benefit of creditors or for the appointment of a receiver or trustee of Mesoblast Limited or Mesoblast Sàrl (as applicable) or its assets, (b) either Mesoblast Limited or Mesoblast Sàrl is served with an insolvency petition against it in any insolvency proceeding and such involuntary petition has not been stayed or dismissed within [***]of its filing, (c) either Mesoblast Limited or Mesoblast Sàrl makes an assignment of 

-70-

 

 

substantially all of its assets for the benefit of its creditors, or (d) any event occurs that corresponds to any of those in paragraphs (a) to (c) in relation to either Mesoblast Limited or Mesoblast Sàrl or any of their assets in any country or territory in which it is incorporated or carries on business or to the jurisdiction of whose courts it or any of its assets is subject (an “MSB Insolvency Event”).

13.7.[***].

13.8.General Effects of Expiration or Termination.

13.8.1Accrued Obligations.  Expiration or termination of this Agreement for any reason shall not release either Party of any obligation or liability which, at the time of such expiration or termination, has already accrued to the other Party or which is attributable to a period prior to such expiration or termination.

13.8.2General Survival.    Upon termination of this Agreement, the following Sections of this Agreement shall survive: [***]any other provisions which are expressed to survive termination or which are required to give effect to such termination.

13.9.Additional Effects of Certain Terminations.  If this Agreement is terminated pursuant to this Article 13:

13.9.1Ongoing Trials.  Other than where this Agreement is terminated by [***]if there are any ongoing clinical trials with respect to the Product being conducted [***]If this Agreement is terminated by [***]shall be responsible for the costs of such transition; in all other events,[***] shall be responsible for the costs of such transition and any ongoing activities.  

13.9.2Regulatory Materials.  Other than where this Agreement is terminated[***]:

(a)Grünenthal shall promptly assign and transfer to MSB all Regulatory Materials for the Product that are held or controlled by or under authority of Grünenthal or its Affiliates, and shall take such actions and execute such other instruments, assignments and documents as may be necessary to effect the transfer of rights under the Regulatory Materials to MSB;

(b)Grünenthal shall cause each of its Affiliates to transfer any such Regulatory Materials to MSB if this Agreement terminates;

(c)if Applicable Law prevents or delays the transfer of ownership of a Regulatory Material to MSB, Grünenthal shall grant, and does hereby grant, to MSB an exclusive and irrevocable right of access and reference to such Regulatory Material for the Product, and shall cooperate fully to make the benefits of such Regulatory Materials available to MSB or its designee(s);

(d)within [***]after notice of such termination, Grünenthal shall provide to MSB copies of all such Regulatory Materials, and of all preclinical, non-clinical and clinical data (including raw data, original records, investigator reports, both preliminary and final, 

-71-

 

 

statistical analyses, expert opinions and reports, safety and other electronic databases) that is then in existence and in Grünenthal’s Control; and

(e)MSB shall be free to use and disclose such Regulatory Materials and other items in connection with the exercise of its rights and licenses under this Section 13.9.

13.9.3Technology Licenses. In the event of termination for any reason other than termination by [***]due to a breach caused by MSB’s willful misconduct or gross negligence, (i) [***] .  The process for agreeing [***]. 

13.9.4Trademarks.  Other than where this Agreement is terminated by [***]:

(a)upon the effective date of termination under [***], MSB may purchase from Grünenthal all worldwide rights in and to any and all (i) Product Marks and (ii) any domain names which include such Product Marks relating exclusively to the Product (including all content and copyright associated therewith) at the [***]; and

(b)upon receipt of the full payment price [***]. It is understood that such assignment shall not include the Grünenthal’s name or trademark for the Grünenthal’s company itself or any trademarks used in relation to campaigns, product bundles and/or Grünenthal and/or its Affiliates divisions.

13.9.5Provision of Product.

(a)Upon termination of this Agreement [***]all quantities of the Product in its or its Affiliates’ Control that are suitable for commercial sale with more than [***]of shelf-life remaining, within [***]after the termination of this Agreement [***].

(b)[***], then upon request by MSB or its designee, [***]some or all quantities of the Product in its or its Affiliates’ Control (as requested by MSB), within [***]after the termination of this Agreement [***].

(c)[***], if, at the date of termination, the Product was Manufactured by any Third Party for Grünenthal, or Grünenthal had contracts with vendors which contracts are necessary or useful for MSB to take over responsibility for the Product in the Territory, then Grünenthal shall to the extent permitted by the terms of the contract and requested in writing by MSB, assign all of the relevant Third Party contracts  to MSB, and in any case, Grünenthal agrees to cooperate with MSB with a view to ensuring uninterrupted supply of the Product, including by using reasonable efforts to obtain agreement from such Third Party to assign such Third Party contracts as requested by MSB.  

(d)[***]if, at the date of termination, Grünenthal or its Affiliate is Manufacturing the Product or component thereof, then Grünenthal (or its Affiliate) shall continue to provide for Manufacturing of such Product or component thereof for MSB, at a price equal to COGS from the effective date of termination until such time as MSB is able, using Commercially Reasonable Efforts to do so but no longer than [***]after the date of termination , to secure an acceptable alternative commercial Manufacturing source from which sufficient quantities of the Product may be procured and legally sold in the Territory.  [***].

-72-

 

 

13.9.6General Assistance.  Each Party agrees to fully cooperate with the other Party and its designee(s) to facilitate a smooth, orderly and prompt transition of any Development, Manufacture and Commercialization activities and Medical Affairs Activities for the Product to the other Party or its designee(s), in each case to the extent that the other Party will be responsible for such activities following termination.  Without limiting the foregoing, other than where this Agreement is terminated by Grünenthal pursuant to Section 13.2.8, Section 13.3, or Section 13.4.1, Grünenthal shall promptly provide MSB (a) copies of customer lists, customer data and other customer information and contracts relating to the Product, (b) pricing methodologies and supporting documentation and assumptions relating to the Product and (c) Manufacturing Data and other information (including protocols for the production, packaging, testing and other Manufacturing activities) relating to the Product in Grünenthal’s Control, which in each case MSB shall have the right to use and disclose for the sole purpose of furthering the Development and Commercialization of the Product.

13.9.7Costs and Expenses. 

(a)[***].

(b)[***].

(c)[***].

13.9.8Continuation of Grünenthal’s Rights.(i) [***]:

(a)Grünenthal shall retain its rights hereunder with respect to the Development, Manufacture and Commercialization of Product for the Field in the Territory; and

(b)the licences granted to Grünenthal pursuant to Section 3.1.1(a) [***]; and

(c)if the termination takes effect prior to completion of the Development activities under the Development Plan, [***], 

.

13.10.Termination Press Releases.  In the event of termination of this Agreement for any reason, the Parties shall cooperate in good faith to coordinate public disclosure of such termination and the reasons therefor, and shall not, except to the extent required by Applicable Law or the rules of a recognized stock exchange, disclose such information without the prior approval of the other Party, such approval not to be unreasonably withheld, conditioned or delayed.  To the extent possible under the situation, the terminating Party shall provide the non-terminating Party with a draft of any such public disclosure it intends to issue [***]in advance and with the opportunity to review and comment on such statement, it being understood that if the non-terminating Party does not notify the terminating Party in writing within such [***]period (or such shorter period if required by Applicable Law or the rules of a recognized stock exchange) of any reasonable objections, such disclosure shall be deemed 

-73-

 

 

approved, and in any event the Parties shall work diligently and reasonably to agree on the text of any such proposed disclosure in an expeditious manner.  The principles to be observed in such disclosures shall be accuracy, compliance with Applicable Law and regulatory guidance documents, reasonable sensitivity to potential negative reactions to such news and the need to keep investors and others informed regarding the Parties’ business and other activities.  Accordingly, in such situation, the non-terminating Party shall not withhold, condition or delay its approval of a proposed disclosure that complies with such principles.

13.11.No Prejudice.  All termination rights that a Party has under this Article 13 shall be without prejudice to that Party’s other rights and remedies.

Article 14
DISPUTE RESOLUTION

14.1.Dispute Resolution.  The Parties agree that any dispute arising with respect to the interpretation, enforcement, termination or invalidity of this Agreement, or the failure of the JSC or any Sub-Committee to reach unanimous agreement on any issue within its respective authority under this Agreement, any alleged failure to perform, or breach of, this Agreement, or any issue relating to the interpretation or application of this Agreement (each, a “Dispute”), shall be resolved through the procedures set forth in this Article 14.

14.2.Committee Disputes.  Disputes as to matters within the authority of the JSC or any Sub-Committee will, in the first instance, be referred for resolution in accordance with Section 2.5; provided that any dispute as to the application of such Section 2.5 shall be subject to the provisions of this Article 14.

14.3.Other Disputes.  All Disputes other than those Disputes resolved as described in Section 14.2 (each, an “Other Dispute”) shall be subject to the provisions of this Section 14.3 and all Other Disputes other than those described in Section 14.5 shall be subject to the provisions of Section 14.4, if applicable.  With respect to all Other Disputes, if the Parties are unable to resolve any such Other Dispute within [***]after such Other Dispute is first identified by either Party in writing to the other, either Party shall have the right to refer such Other Dispute to the Senior Executives for attempted resolution by written notice to the other Party referencing the particular Other Dispute and this Section 14.3.  In such case, the Senior Executives shall conduct good faith negotiations and seek to resolve the Other Dispute within [***]after such notice is received, including having at [***]meeting of the Senior Executive within [***]after such notice is received.  If the Senior Executives resolve such Other Dispute, a memorandum setting forth their agreement to resolve the Other Dispute will be prepared and signed by both Parties if requested by either Party.  In all events, the Parties shall cooperate in an effort to limit the issues for 

-74-

 

 

consideration in such manner as narrowly as reasonably practicable in order to resolve the Other Dispute.

14.4.Binding Arbitration.  If the Senior Executives are not able to resolve (a) any Other Dispute referred to them under Section 14.3 within the time period set forth in Section 14.3 or (b) any matter referred to them under Section 2.5.2 (other than a matter (i) for which a Party has final decision making authority under Section 2.5.3 or (ii) to be referred to expert determination in accordance with Section 2.9) within the time period set forth in Section 2.5.2, then unless such dispute or matter is described in Section 14.5, such dispute or matter shall be resolved through binding arbitration, which arbitration may be initiated by either Party by written notice to the other Party referencing the particular dispute or matter and this Section 14.4 at any time after the conclusion of such period, on the following basis:

14.4.1The place of arbitration shall be [***]and all proceedings and communications shall be in English.

14.4.2The arbitration shall be administered and finally settled under the Rules of Arbitration of the International Chamber of Commerce 2017 (the “ICC Rules”).

14.4.3The arbitration shall be conducted by three arbitrators appointed in accordance with the ICC Rules, upon the written request of either Party.  In each case, the arbitrators shall be neutral, independent individuals with experience in the biopharmaceutical business related to the subject matter of the dispute or matter.  Within thirty (30) days after the notice initiating the arbitration, each Party shall appoint one arbitrator meeting the foregoing criteria by written notice to the other Party and the two Party-appointed arbitrators shall select the third arbitrator within [***]of their appointment in accordance with the ICC Rules.  

14.4.4Judgment upon the award rendered by such arbitrators shall be binding on the Parties and may be entered by any court or forum having jurisdiction.

14.4.5Either Party may apply to the arbitrators for interim injunctive relief until the arbitration award is rendered or the controversy is otherwise resolved.  Further, either Party also may, without waiving any remedy under this Agreement, seek from any court having jurisdiction any injunctive or provisional relief necessary to protect the rights or property of such Party pending the arbitration award.

14.4.6The arbitrators shall have no authority to award punitive or any other type of damages not measured by a Party’s compensatory damages; except as allowed under Section 12.6.

14.4.7Each Party shall bear its own costs and expenses and attorneys’ fees and an equal share of the arbitrators’ and any administrative fees of arbitration, unless the arbitrators determine that a Party has incurred unreasonable expenses due to vexatious or bad faith position taken by the other Party, in which event, the arbitrator may make an award of all or any portion of such expense so incurred.

-75-

 

 

14.4.8Reasons for the arbitrators’ decision should be complete and explicit, including determinations of law and fact.  The written reasons should also include the basis for any damages awarded and a statement of how the damages were calculated.  Such written decision should be rendered by the arbitrators following a full comprehensive hearing, as soon as practicable but in no event later than [***]following the selection of the arbitrator(s) under Section 14.4.3.

14.4.9Except to the extent necessary to confirm an award or as may be required by law, neither Party nor any arbitrator may disclose the existence, content, or results of an arbitration without the prior written consent of both Parties, such consent not to be unreasonably withheld, conditioned or delayed. Any documents submitted to or issued by the arbitrators shall be kept confidential and shall not be disclosed, except that any such documents may be disclosed (i) as reasonably necessary in connection with any action to enforce or collect the award, (ii) to the extent discoverable or admissible in any action arising out of or in connection with this Agreement, or (iii) as required by Applicable Law.

14.4.10In no event shall an arbitration be initiated after the date when commencement of a legal or equitable proceeding based on the dispute, controversy or claim would be barred by the applicable statute of limitations; provided that such limitation shall be tolled as of the date a Party notifies the other Party of such dispute or matter pursuant to this Agreement.

14.5.Patent Dispute Resolution.  Other than disputes described in Section 10.4.3, any dispute, controversy or claim between the Parties relating to the ownership, scope, validity, enforceability or infringement of any Patent rights covering the manufacture, use or sale of the Product rights relating to the Product shall be submitted to a court of competent jurisdiction in which such Patent rights were granted or arose.

14.6.Interim Relief.  Notwithstanding anything in this Article 14 to the contrary, Grünenthal and MSB shall each have the right to apply to any court of competent jurisdiction for appropriate interim or provisional relief, as necessary to protect the rights or property of that Party, pending the selection of the arbitrator or arbitrator’s determination of the merits of any Dispute.

Article 15
MISCELLANEOUS

15.1.Governing Law.  This Agreement and any dispute arising from the performance or breach hereof shall be governed by and construed and enforced in accordance with the laws of the State of Victoria, Australia without reference to conflicts of laws principles.

15.2.Assignment.  This Agreement shall not be assignable by either Party to any Third Party without the written consent of the other Party (such consent not to be unreasonably withheld, conditioned or delayed) and any such attempted assignment shall be void.  Notwithstanding the foregoing, either 

-76-

 

 

Party may assign this Agreement, without the written consent of the other Party, (a) to an Affiliate of such Party (in whole or in part), provided that such Party shall remain responsible for such Affiliate’s conduct or (b) to an entity that acquires all or substantially all of the stock, business or assets of such Party relating to this Agreement (whether by merger, reorganization, acquisition, sale, operation of law or otherwise) or (c) to any bank or financial institution (as an assignment by way of security and on enforcement of any such security) provided that the assignment shall not in any way operate so as to increase the liability of the other Party under this Agreement or impose any more onerous or additional obligations on the other Party or any of its Affiliates.  No assignment or transfer of this Agreement shall be valid and effective unless and until the Assignee agrees in writing to be bound by the provisions of this Agreement.  The terms and conditions of this Agreement shall be binding on and inure to the benefit of the permitted successors and assigns of each Party.  Except as expressly provided in this Section 15.2, any attempted assignment or transfer of this Agreement shall be null and void. 

15.3.Notices.  Any notice, request, delivery, approval or consent required or permitted to be given under this Agreement shall be in writing and shall be deemed to have been sufficiently given if delivered in person, transmitted by email (receipt verified) or by express courier service (signature required) or [***] after it was sent by registered letter, return receipt requested (or its equivalent), provided that no postal strike or other disruption is then in effect or comes into effect within [***]after such mailing, in the case of MSB, to the address of Mesoblast Limited shown below, and in the case of Grünenthal, to the address of Grünenthal shown below. This Section 15.3 shall not apply in relation to the service of any claim form, notice, order, judgment or other document relating to or in connection with any proceedings, suit or action arising out of or in connection with this Agreement.

	
 
	
If to MSB, addressed to:
	

	
 
	

	
Mesoblast Limited
55 Collins Street, Level 38
Melbourne 3000
Victoria Australia

Attention: [***]

Telephone: [***]

Email: [***]

With a copy to:  Wilson Sonsini Goodrich & Rosati

	
 
	

	
Professional Corporation

650 Page Mill Road

Palo Alto, CA  94304-1050

United States

Attention: [***]

Telephone: [***]

Email: [***]

-77-

 

 

If to Grünenthal, addressed to:

Grünenthal GmbH

Zieglerstraße 6

52078 Aachen

Germany

Attention: [***]

Telephone: [***]

 

Email: [***]

 

	
 
	
With a copy to:
	
Allen & Overy LLP

One Bishops Square

London E1 6AD

United Kingdom

Attention:  [***]

Telephone:  [***]

 

Email: [***]     

15.4.English Language.  This Agreement is written and executed in the English language.  Any translation into any other language shall not be an official version hereof, and in the event of any conflict in interpretation between the English version and such translation, the English version shall control.  All notices, correspondence, minutes by either Party and other interactions between the Parties under or in connection with this Agreement shall be in English and to the extent that any document provided is in another language a translation thereof into English shall be provided.

15.5.Waiver.  Neither Party may waive or release any of its rights or interests in this Agreement except in writing.  The failure of either Party to assert a right hereunder or to insist upon compliance with any term or condition of this Agreement shall not constitute a waiver of that right or excuse a similar subsequent failure to perform any such term or condition.  No waiver by either Party of any condition or term in any one or more instances shall be construed as a continuing waiver of such condition or term or of another condition or term.

15.6.Severability.  If any provision hereof should be held invalid, illegal or unenforceable in any jurisdiction, the Parties shall negotiate in good faith a valid, legal and enforceable substitute provision that most nearly reflects the original intent of the Parties and all other provisions hereof shall remain in full force and effect in such jurisdiction and shall be liberally construed in order to carry out the intentions of the Parties as nearly as may be possible.  Such invalidity, illegality or unenforceability shall not affect the validity, legality or enforceability of such provision in any other jurisdiction.  

15.7.Joint and Several Liability. Mesoblast Limited and Mesoblast Sàrl shall be jointly and severally liable for their obligations under 

-78-

 

 

this Agreement. Grünenthal may take action against, or release or compromise in whole or in part the liability of one of Mesoblast Limited or Mesoblast Sàrl under this Agreement, without affecting the liability of the other.

15.8.No Third Party Beneficiaries.  Except for the rights to indemnification provided for certain Third Parties as specified in Section 12.5, all rights, benefits and remedies under this Agreement are solely intended for the benefit of Grünenthal and its Affiliates and MSB and its Affiliates, and except for such rights to indemnification expressly provided pursuant to Section 12.5, no Third Party shall have any rights whatsoever to (a) enforce any obligation contained in this Agreement (b) seek a benefit or remedy for any breach of this Agreement, or (c) take any other action relating to this Agreement under any legal theory, including, actions in contract, tort (including but not limited to, negligence, gross negligence and strict liability), or as a defense, setoff or counterclaim to any action or claim brought or made by either Party.

15.9.Entire Agreement/Modification.  This Agreement, including its Exhibits, sets forth all the covenants, promises, agreements, warranties, representations, conditions and understandings between the Parties and supersedes and terminates all prior agreements and understandings between the Parties including the Prior Understandings.  No subsequent alteration, amendment, change or addition to this Agreement shall be binding upon the Parties unless reduced to writing and signed by the respective authorized officers of each Party.  

15.10.Relationship of the Parties.  The Parties agree that the relationship of MSB and Grünenthal established by this Agreement is that of independent contractors.  Furthermore, the Parties agree that this Agreement does not, is not intended to, and shall not be construed to, establish a partnership or any other fiduciary relationship.  Except as may be specifically provided herein, neither Party shall have any right, power or authority, nor shall they represent themselves as having any authority to assume, create or incur any expense, liability or obligation, express or implied, on behalf of the other Party, or otherwise act as an agent for the other Party for any purpose.

15.11.Force Majeure.  Except with respect to payment of money, neither Party shall be liable to the other for failure or delay in the performance of any of its obligations under this Agreement for the time and to the extent such failure or delay is caused by earthquake, riot, civil commotion, war, terrorist acts, flood, or governmental acts or restriction, or other cause that is beyond the reasonable control of the respective Party.  The Party affected by such force majeure will provide the other Party with full particulars thereof as soon as it becomes aware of the same (including its best estimate of the reasonably expected extent and duration of the interference with its activities), and will use Commercially Reasonable Efforts to overcome the difficulties created thereby and to resume performance of its obligations as soon as practicable.  If the performance of any such obligation under this Agreement is delayed owing to 

-79-

 

 

such a force majeure for any continuous period of more than [***]the Parties will consult with respect to an equitable solution, including the possibility of the mutual termination of this Agreement.

15.12.Compliance with Applicable Law; Anti-Corruption; Grünenthal Business Partner Code of Conduct.

15.12.1General.  Notwithstanding anything to the contrary contained herein, all rights and obligations of MSB and Grünenthal are subject to prior compliance with, and each Party shall comply with, all Applicable Law.  In addition, each Party shall conduct, and shall require Persons acting on its behalf or under its authority to conduct, activities under this Agreement in accordance with good scientific and business practices and Applicable Law.

15.12.2Anti-Corruption.  Each Party represents, warrants and covenants that (a) it has complied and will comply with Anti-Corruption Laws, in all material respects, including taking all reasonable actions with respect thereto and putting into place reasonable and customary infrastructure to manage and ensure such compliance; (b) it has not permitted and will not knowingly permit any Person acting on its behalf to violate any Anti-Corruption Law; and (c) its and its Affiliates and their employees, agents and contractors will not make any payments or transfer of value which have the purpose or effect of public or commercial bribery, acceptance of or acquiescence in extortion, kickbacks, or other unlawful or improper means of obtaining or retaining business or any other improper advantage.  Each Party will promptly report to the other Party if there is a government or judicial determination of a violation of Anti-Corruption Laws by such Party.

15.12.3Grünenthal Business Partner Code of Conduct. MSB shall at all times during the Term comply with the Grünenthal Business Partner Code of Conduct as set forth in Exhibit 15.12.3. MSB shall maintain complete and accurate records of, and supporting documentation for, MSB’s compliance with the Grünenthal Business Partner Code of Conduct for the Term and three (3) years from its effective date of termination.

15.12.4MSB Compliance System. MSB hereby confirms that, as at the Effective Date, it is in the process of developing a formalised compliance system consistent with good industry practice and undertakes to (i) finalise that compliance system as soon as reasonably practicable after the Effective Date and (ii) implement and maintain that compliance system throughout the Term. Upon Grünenthal’s written request, MSB shall provide Grünenthal with written updates with respect to its implementation and maintenance of such compliance system and shall provide Grünenthal with any other information and assistance as Grünenthal may reasonably require in order to verify MSB’s compliance with this Section 15.12.4.

15.13.Further Assurance. Each Party shall and shall procure that each of its Affiliates shall upon request, at its own cost and expense, at all times from the Effective Date do or procure the doing of all things as may be required to give full effect to this Agreement, including the execution of all deeds and documents.

-80-

 

 

15.14.Costs. Save as expressly stated herein, each Party shall pay the costs and expenses incurred by it in connection with the entering into of this Agreement.

15.15.Counterparts.  This Agreement may be executed in any number of counterparts, each of which shall be deemed an original, and all of which together, shall constitute one and the same instrument.

[The remainder of this page intentionally left blank; the signature page follows.]

 

 

-81-

 

 

 

IN WITNESS WHEREOF, the Parties have executed this Agreement in duplicate originals by their duly authorized representatives.

 

	
MESOBLAST LIMITED
	
 
	
MESOBLAST INTERNATIONAL SÀRL

	
 
	
 
	
 
	
  
	
 
	
 
	
 

	
By:
	
  
	
/s/ Silviu Itescu
	
 
	
By:
	
  
	
/s/ Ralph Challancin

	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
Name:
	
 
	
Silviu Itescu
	
 
	
Name:
	
 
	
Ralph Challancin

	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
Title:
	
 
	
Chief Executive Officer
	
 
	
Title:
	
 
	
Director

 

	
GRÜNENTHAL GMBH
	
 
	
 

	
 
	
 
	
 
	
  
	
 
	
 
	
 

	
By:
	
  
	
/s/ Gabriel Baertschi
	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
Name:
	
 
	
Gabriel Baertschi
	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
Title:
	
 
	
Chief Executive Officer
	
 
	
 
	
 
	
 

 

 

	
GRÜNENTHAL GMBH
	
 
	
 

	
 
	
 
	
 
	
  
	
 
	
 
	
 

	
By:
	
  
	
/s/ Ralf Radermacher
	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
Name:
	
 
	
Ralf Radermacher
	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
Title:
	
 
	
Senior Vice President, Corporate Development and Licensing
	
 
	
 
	
 
	
 

 

 

[Signature Page to Development and Commercialization Agreement]

 

 

List of Exhibits: 

	
 
	
•
	
Exhibit 1.11 – Approved CMOs

	
 
	
•
	
Exhibit 1.62 – Product Formulations (MPC-06-ID)

	
 
	
•
	
Exhibit 1.65 –Product Patents (Excluding Product-Specific Patents)

	
 
	
•
	
Exhibit 1.67 –Product-Specific Patents

	
 
	
•
	
Exhibit 1.79 – Product Specifications

	
 
	
•
	
Exhibit 1.86 – TPP

	
 
	
•
	
Exhibit 2.9 – Expert Determination for Certain Disputes

	
 
	
•
	
Exhibit 2.10 – Key Personnel

	
 
	
•
	
Exhibit 7.4.1 – [***]

	
 
	
•
	
Exhibit 7.5 – Master Cell Banks

	
 
	
•
	
Exhibit 9.1.2 – Milestone Events and Payments 

	
 
	
•
	
Exhibit 9.1.3 – Royalties 

	
 
	
•
	
Exhibit 9.4.1 – Acceptable Accounting Firms

	
 
	
•
	
Exhibit 15.12.3 – The Grünenthal Business Partner Code of Conduct 

 

 

 

 

 

 

 

EXHIBIT 1.11
APPROVED CMOS

 

[***]

 

 

 

 

EXHIBIT 1.62
PRODUCT FORMULATIONS (MPC-06-ID)

[***]

 

 

 

 

 

 

EXHIBIT 1.65
PRODUCT PATENTS (EXCLUDING PRODUCT-SPECIFIC PATENTS)

Part 1- Platform Product Patents

		
	
[***]
	
 

	
 
	
 

	
 
	
 

	
 
	
 

	
 
	
 

	
 
	
 

 

 

		
	
 
	
 

	
 
	
 

	
 
	
 

	
 
	
 

	
 
	
 

	
 
	
 

	
 
	
 

 

 

 

 

Part 2 – Manufacturing

		
	
[***]
	
 

	
 
	
 

 

 

 

 

 

Part 3 – Therapeutic Indications

 

 

		
	
[***]
	
 

	
 
	
 

	
 
	
 

 

 

EXHIBIT 1.67
PRODUCT-SPECIFIC PATENTS

		
	
[***]
	
 

	
 
	
 

	
 
	
 

 

 

 

 

EXHIBIT 1.79

PRODUCT SPECIFICATIONS

[***] 

 

 

 

 

 

EXHIBIT 1.86
TPPs

[***]

 

 

 

 

EXHIBIT 2.9

EXPERT DETERMINATION FOR CERTAIN DISPUTES

 

Part A - Milestone Disputes

 

1.[***]. 

 

 

 

 

Part B – Improvement Compensation Disputes

1.[***]

 

 

 

 

 

 

 

EXHIBIT 2.10.1

KEY PERSONNEL

[***]

 

 

 

 

 

EXHIBIT 7.4.1

[***].

 

 

 

 

 

 

EXHIBIT 7.5

MASTER CELL BANKS

 

					
	
P3 Clinical Lots 

[***]

 

 

 
	
 
	
 
	
 
	
 

 

 

 

 

 

EXHIBIT 9.1.2
MILESTONE EVENTS AND PAYMENTS 

Grünenthal shall pay to MSB the amount set forth in the tables below upon the occurrence of the corresponding event in accordance with Section 9.1.2 of the Agreement.

a.Approval Milestone.

[***]

 

b.Pricing and Reimbursement Milestones.

[***]

 

For the avoidance of doubt, the Milestone Events and Milestone Payments in this paragraph (b) are mutually exclusive such that Grünenthal shall only pay one of these Milestone Payments.

c.Commercial Milestones. 

[***]

For clarity if more than one Milestone Event described in this paragraph (c) occurs during any Annual Period, the Milestone Payments for all such Milestone Events shall be payable.

 

EXHIBIT 9.1.3
ROYALTIES

Grünenthal shall pay to MSB that portion of Annual Net Sales set forth in the tables below in accordance with Section 9.1.3 of the Agreement.

[***]

 

 

 

 

EXHIBIT 9.4.1
ACCEPTABLE ACCOUNTING FIRMS

 

	
•
	
[***],

or any other independent certified accounting firm as may be agreed between MSB and Grünenthal from time to time

 

 

 

 

EXHIBIT 15.12.3
THE GRÜNENTHAL BUSINESS PARTNER CODE OF CONDUCT

 

 

 

 

 

 

 

 

Code of conduct for grunenthal's business partners so,i understand that we should act lawfully and respectfully? yes AI,and our business partners should too maximise business.Minimum risk.GRUNENTHAL

 

 

 

 

 

 

Code of Conduct for Grunenthals Business Partners Our business partners are expected to act in the same manner. This Code of Conduct (“Code”) does not constitute an exhaustive list of the applicable legal frameworks our business partners need to adhere to, but is intended to emphasise the most important topics for the Grunenthal Group.2

 

 

 

 

 

 

Grunenthal firmly demands from all of its worldwide suppliers, distributors, resellers, sales agents,

 

 

 

 

 

 

Respect and fairness Grunenthel expects all of its Bussiness Partners to treat its employees and all  persons acting on its behalf in line with the highest ethical standards. All international and national conventions and laws in the area of fundamental rights must be adhered to. Bussiness Partners must provide a workplace free of harassament and discrimination for reasons such as gender, race nationality, age, religion, sexual orientation, gender identity, physical appearance, social origin, disability, union membership, family status or political opinions. They declare that they are not employing under-aged persons in their workforce in accordance with local and international regulations and international treaties regarding child labour. 4

 

 

 

 

 

 

Protection of assets and confidentiality All Business Partners and all subcontractors and/or individuals acting on their behalf must respect Grunenthal’s assets, business-related information and intellectual property rights. They must treat all information received in the course of the business relationship as strictly confidential to the extent that such information is not already publicly known or legally available to third parties. Also, Business Partners are expected to protect confidential information against unauthorised access and use and destroy or return it to Grunenthal once it is no longer needed in the business relationship. Anti-Corruption and compliance All forms of corruption are strictly prohibited; i.e. the direct or indirect offer, granting or acceptance of illegitimate advantage to generate, maintain or accelerate business, including facilitation payments. All Business Partners must ensure that no advantage are exchanged in the course of their business relationships. Business Partners may only provide lawful, adequate, documented and transparent remuneration, gifts, hospitality, sponsoring and donations. Special diligence and stricter internal controls must be undertaken when interacting with public officials. Grunenthal expects its Business Partners to install adequate internal measures for the prevention of business-related crimes and administrative offences, depending on the Business Partner’s risk exposure, size and financial resource.

 

 

 

 

 

 

Costoms duites and export controls/sanctions All business partners must ensure that they have their customs affairs handled by competent personnel and comply with all applicable customs duties. Business partners must constantly monitor the most recent developments to ensure that current export controls and sanction regulation are strictly followed. Environment business partners must comply with all applicable environment regulation. All required environmental permits, licenses, information registration and restriction must be obtained, maintained and their operational reporting requirements followed. Business partners must have systems in place to ensure a responsible and sustainable use of the natural resources and the safe handling, movement, storage, recycling, reuse, or management of waste, air emissions and wastewater discharges. Any waste, wastewater or emissions with the potential to adversely impact human or environmental health shall be appropriately managed, controlled and treated prior to relesing it into the environment. Employees must be protected from overexposure to chemical, biological and physical hazards. Data protection all business partners must strictly adhere to all applicable data protection laws when collecting, processing, storing or otherwise handling personal data of their own employees of their customers, suppliers, business partners and other data subjects.

 

 

 

 

 

 

Code of Conduct for Grunenthal’s Business Partners We hereby acknowledge on behalf of the Business Partner that it recognises all obligations arising out of or in connection with this Code of Conduct and that it will comply with it as long as the business relationship lasts. Place, date Authorised signatory and company stamp Authorised signatory (if applicable) and company stamp Page-7

 

 

 

 

 

 

Grunenthal GmbH, 52099 Aachen, Germany

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00333-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00333-of-00352.parquet"}]]